Becton, Dickinson and (BDX) 10-K 27 Nov 24 2024 FY Annual report Financial data

Cover Page

Cover Page - USD ($)	12 Months Ended
	Sep. 30, 2024	Oct. 31, 2024	Mar. 31, 2024
Entity Information [Line Items]
Document type	10-K
Document Annual Report	true
Document period end date	Sep. 30, 2024
Current fiscal year end date	--09-30
Document Transition Report	false
Entity File Number	001-4802
Entity registrant name	BECTON, DICKINSON AND COMPANY
Entity Incorporation, State or Country Code	NJ
Entity Tax Identification Number	22-0760120
Entity Address, Address Line One	1 Becton Drive,
Entity Address, City or Town	Franklin Lakes,
Entity Address, State or Province	NJ
Entity Address, Postal Zip Code	07417-1880
City Area Code	201
Local Phone Number	847-6800
Entity well-known seasoned issuer	Yes
Entity voluntary filers	No
Entity Current Reporting Status	Yes
Entity current reporting status	Yes
Entity filer category	Large Accelerated Filer
Entity small business	false
Entity emerging growth company	false
ICFR Auditor Attestation Flag	true
Document Financial Statement Error Correction [Flag]	false
Entity shell company	false
Entity public float			$ 71,455,056,628
Entity common stock, shares outstanding (shares)		289,122,120
Entity central index key	0000010795
Document fiscal year focus	2024
Document fiscal period focus	FY
Amendment flag	false
Common Stock  Issued at Par Value | NEW YORK STOCK EXCHANGE, INC. [Member]
Entity Information [Line Items]
Title of 12(b) Security	Common stock, par value $1.00
Trading Symbol	BDX
Security Exchange Name	NYSE
1.900% Notes due December 15, 2026 | NEW YORK STOCK EXCHANGE, INC. [Member]
Entity Information [Line Items]
Title of 12(b) Security	1.900% Notes due December 15, 2026
Trading Symbol	BDX26
Security Exchange Name	NYSE
3.020% Notes due May 24, 2025 | NEW YORK STOCK EXCHANGE, INC. [Member]
Entity Information [Line Items]
Title of 12(b) Security	3.020% Notes due May 24, 2025
Trading Symbol	BDX25
Security Exchange Name	NYSE
1.208% Notes due June 4, 2026 | NEW YORK STOCK EXCHANGE, INC. [Member]
Entity Information [Line Items]
Title of 12(b) Security	1.208% Notes due June 4, 2026
Trading Symbol	BDX/26A
Security Exchange Name	NYSE
1.213% Notes due February 12, 2036 | NEW YORK STOCK EXCHANGE, INC. [Member]
Entity Information [Line Items]
Title of 12(b) Security	1.213% Notes due February 12, 2036
Trading Symbol	BDX/36
Security Exchange Name	NYSE
0.034% Notes due August 13, 2025 | NEW YORK STOCK EXCHANGE, INC. [Member]
Entity Information [Line Items]
Title of 12(b) Security	0.034% Notes due August 13, 2025
Trading Symbol	BDX25A
Security Exchange Name	NYSE
3.519% Notes due February 8, 2031 | NEW YORK STOCK EXCHANGE, INC. [Member]
Entity Information [Line Items]
Title of 12(b) Security	3.519% Notes due February 8, 2031
Trading Symbol	BDX31
Security Exchange Name	NYSE
3.828% Notes due June 7, 2032 | NEW YORK STOCK EXCHANGE, INC. [Member]
Entity Information [Line Items]
Title of 12(b) Security	3.828% Notes due June 7, 2032
Trading Symbol	BDX32A
Security Exchange Name	NYSE

Audit Information

Audit Information	12 Months Ended
	Sep. 30, 2024
Audit Information [Abstract]
Auditor Name	ERNST & YOUNG LLP
Auditor Location	New York, New York
Auditor Firm ID	42

Consolidated Statements of Inco

Consolidated Statements of Income - USD ($) $ in Millions	12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2022
Income Statement [Abstract]
Revenues	$ 20,178	$ 19,372	$ 18,870
Cost of products sold	11,053	11,202	10,393
Selling and administrative expense	4,857	4,719	4,709
Research and development expense	1,190	1,237	1,256
Integration, restructuring and transaction expense	458	313	192
Other operating expense (income), net	222	(210)	37
Total Operating Costs and Expenses	17,780	17,261	16,588
Operating Income	2,397	2,111	2,282
Interest expense	(528)	(452)	(398)
Interest income	163	49	16
Other expense, net	(28)	(46)	(117)
Income from Continuing Operations Before Income Taxes	2,005	1,662	1,783
Income tax provision	300	132	148
Net Income from Continuing Operations	1,705	1,530	1,635
(Loss) Income from Discontinued Operations, Net of Tax	0	(46)	144
Net Income	1,705	1,484	1,779
Preferred stock dividends	0	(60)	(90)
Net income applicable to common shareholders	$ 1,705	$ 1,424	$ 1,689
Basic Earnings per Share
Income (Loss) from Continuing Operations, Per Basic Share (in USD per share)	$ 5.88	$ 5.14	$ 5.42
Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share (in USD per share)	0	(0.16)	0.50
Earnings Per Share, Basic	5.88	4.97	5.93
Diluted Earnings per Share
Income (Loss) from Continuing Operations, Per Diluted Share (in USD per share)	5.86	5.10	5.38
Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Diluted Share (in USD per share)	0	(0.16)	0.50
Diluted Earnings per Share (in USD per share)	$ 5.86	$ 4.94	$ 5.88

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Income - USD ($) $ in Millions	12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2022
Statement of Comprehensive Income [Abstract]
Net Income	$ 1,705	$ 1,484	$ 1,779
Other Comprehensive (Loss) Income, Net of Tax
Foreign currency translation adjustments	(166)	(91)	305
Defined benefit pension and postretirement plans	14	4	210
Cash flow hedges	(32)	27	85
Unrealized loss on available-for-sale debt securities	(1)	0	0
Other Comprehensive (Loss) Income, Net of Tax	(184)	(60)	600
Comprehensive Income	$ 1,521	$ 1,424	$ 2,379

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Millions	Sep. 30, 2024	Sep. 30, 2023
Current Assets
Cash and equivalents	$ 1,717	$ 1,416
Restricted cash	139	65
Short-term investments	445	8
Trade receivables, net	3,033	2,534
Inventories	3,843	3,273
Prepaid expenses and other	1,292	1,380
Total Current Assets	10,468	8,676
Property, Plant and Equipment, Net	6,821	6,557
Goodwill	26,465	24,522
Developed Technology, Net	7,733	8,058
Customer Relationships, Net	2,635	2,338
Other Intangibles, Net	549	552
Other Assets	2,615	2,078
Total Assets	57,286	52,780
Current Liabilities
Current debt obligations	2,170	1,141
Accounts payable	1,896	1,641
Accrued expenses	3,476	2,604
Salaries, wages and related items	1,246	1,115
Income taxes	168	139
Total Current Liabilities	8,956	6,641
Long-Term Debt	17,940	14,738
Long-Term Employee Benefit Obligations	942	1,023
Deferred Income Taxes and Other Liabilities	3,558	4,582
Commitments and Contingencies
Shareholders’ Equity
Common Stock, Value, Issued	371	371
Capital in excess of par value	19,893	19,720
Retained earnings	16,139	15,535
Deferred compensation	25	24
Treasury Stock, Value	(8,807)	(8,305)
Accumulated other comprehensive loss	(1,732)	(1,548)
Total Shareholders’ Equity	25,890	25,796
Total Liabilities and Shareholders’ Equity	$ 57,286	$ 52,780

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Sep. 30, 2024	Sep. 30, 2023
Statement of Financial Position [Abstract]
Common stock, par value (in USD per share)	$ 1	$ 1
Common stock, shares authorized (shares)	640,000,000	640,000,000
Common stock, shares issued (shares)	370,594,401	370,594,401
Treasury Stock, common, shares	81,493,082	80,202,608

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Millions	12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2022
Operating Activities
Net Income	$ 1,705	$ 1,484	$ 1,779
(Loss) Income from Discontinued Operations, Net of Tax	0	(46)	144
Net Income from Continuing Operations	1,705	1,530	1,635
Adjustments to net income from continuing operations to derive net cash provided by continuing operating activities:
Depreciation and amortization	2,286	2,288	2,229
Share-based compensation	247	259	233
Deferred income taxes	(211)	(622)	(120)
Change in operating assets and liabilities:
Trade receivables, net	(453)	(290)	32
Inventories	98	(15)	(631)
Prepaid expenses and other	23	192	(436)
Accounts payable, income taxes and other liabilities	625	(517)	(473)
Pension obligation	(70)	112	(55)
Gain on sale of business	0	(268)	0
Product remediation-related charges	38	653	72
Other, net	(445)	(332)	(16)
Net Cash Provided by Continuing Operating Activities	3,844	2,990	2,471
Investing Activities
Capital expenditures	(725)	(874)	(973)
Purchases of investments, net	(421)	0	0
Acquisitions, net of cash acquired	(3,924)	0	(2,070)
Proceeds from divestitures, net	0	540	0
Other, net	(444)	(382)	(178)
Net Cash Used for Continuing Investing Activities	(5,514)	(716)	(3,220)
Financing Activities
Change in short-term debt	400	(230)	230
Proceeds from long-term debt	4,517	1,662	497
Distribution from Embecta Corp. (see Note 2)	0	0	1,266
Net transfer of cash to Embecta upon spin-off	0	0	(265)
Payments of debt	(1,142)	(2,155)	(805)
Repurchase of common stock	(500)	0	(500)
Dividends paid	(1,100)	(1,114)	(1,082)
Other, net	(89)	(120)	(77)
Net Cash Provided by (Used for) Continuing Financing Activities	2,087	(1,956)	(736)
Net cash (used for) provided by operating activities	(46)	(1)	163
Net cash used for investing activities	0	0	(11)
Net cash provided by financing activities	0	0	145
Net Cash (Used for) Provided by Discontinued Operations	(46)	(1)	298
Effect of exchange rate changes on cash and equivalents and restricted cash	4	5	(45)
Net Increase (Decrease) in Cash and Equivalents and Restricted Cash	375	322	(1,233)
Opening Cash and Equivalents and Restricted Cash	1,481	1,159	2,392
Closing Cash and Equivalents and Restricted Cash	$ 1,856	$ 1,481	$ 1,159

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Sep. 30, 2024
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Summary of Significant Accounting Policies Basis of Presentation The accompanying Consolidated Financial Statements and Notes to Consolidated Financial Statements of Becton, Dickinson and Company (the "Company" or "BD") have been prepared in accordance with U.S. generally accepted accounting principles ("U.S. GAAP"). Within the financial statements and tables presented, certain columns and rows may not add due to the use of rounded numbers for disclosure purposes. Percentages and earnings per share amounts presented are calculated from the underlying amounts. Our fiscal year ends on September 30. On April 1, 2022, the Company completed the spin-off of its Diabetes Care business as a separate publicly traded company. The historical results of the Diabetes Care business (previously included in BD’s Medical segment) that was contributed to Embecta Corp ("Embecta") in the spin-off were reflected as discontinued operations in the Company’s consolidated financial statements. Additional disclosures regarding the spin-off are provided in Note 2. Principles of Consolidation The consolidated financial statements include the Company’s accounts and those of its majority-owned subsidiaries after the elimination of intercompany transactions. The Company has no material interests in variable interest entities. Cash Equivalents Cash equivalents consist of all highly liquid investments with a maturity of three months or less at time of purchase. Restricted Cash Restricted cash consists of cash restricted from withdrawal and usage and largely represents funds that are restricted for certain product liability matters, which are further discussed in Note 6. Trade Receivables The Company grants credit to customers in the normal course of business and the resulting trade receivables are stated at their net realizable value. The allowance for doubtful accounts represents the Company’s estimate of expected credit losses relating to trade receivables and is determined based on historical experience, current conditions, reasonable and supportable forecasts and other specific account data. Amounts are written off against the allowances for doubtful accounts when the Company determines that a customer account is not collectable. Inventories Inventories are stated at the lower of approximate cost or net realizable value determined on the first-in, first-out basis. Property, Plant and Equipment Property, plant and equipment are stated at cost, less accumulated depreciation and amortization. Depreciation and amortization are principally provided on the straight-line basis over estimated useful lives, which range from 20 to 45 years for buildings, four one years for leasehold improvements. Depreciation and amortization expense was $676 million, $696 million and $672 million in fiscal years 2024, 2023 and 2022, respectively. Goodwill and Other Intangible Assets The Company’s unamortized intangible assets include goodwill that arises from acquisitions of businesses. The Company reviews goodwill for impairment using quantitative models. Goodwill is reviewed at least annually for impairment at the reporting unit level, which is defined as an operating segment or one level below an operating segment, referred to as a component. The Company’s reporting units represent one level below reporting segments. The Company reviews goodwill for each reporting unit by comparing the fair value of the reporting unit, estimated using an income approach, with its carrying value. The annual impairment review performed on July 1, 2024 indicated that all identified reporting units’ fair values exceeded their respective carrying values. Amortized intangible assets include developed technology assets which arise from acquisitions. These assets represent acquired intellectual property that is already technologically feasible upon the acquisition date or acquired in-process research and development assets that are completed subsequent to acquisition. Developed technology assets are generally amortized over periods ranging from 15 to 20 years, using the straight-line method. Customer relationship assets are generally amortized over periods ranging from 10 to 15 years, using the straight-line method. Other intangibles with finite useful lives, which include patents, are amortized over periods principally ranging from one Foreign Currency Translation Generally, foreign subsidiaries’ functional currency is the local currency of operations and the net assets of foreign operations are translated into U.S. dollars using current exchange rates. The U.S. dollar results that arise from such translation, as well as exchange gains and losses on intercompany balances of a long-term investment nature, are included in the foreign currency translation adjustments in Accumulated other comprehensive income (loss). Revenue Recognition The Company recognizes revenue from product sales when the customer obtains control of the product, which is generally upon shipment or delivery, depending on the delivery terms specified in the sales agreement. Revenues associated with certain instruments and equipment for which installation is complex, and therefore significantly affects the customer’s ability to use and benefit from the product, are recognized upon customer acceptance of these installed products. Revenue for certain service arrangements, including extended warranty and software maintenance contracts, is recognized ratably over the contract term. When arrangements include multiple performance obligations, the total transaction price of the contract is allocated to each performance obligation based on the estimated relative standalone selling prices of the promised goods or services underlying each performance obligation. Variable consideration such as rebates, sales discounts and sales returns are estimated and treated as a reduction of revenue in the same period the related revenue is recognized. These estimates are based on contractual terms, historical practices, and current trends, and are adjusted as new information becomes available. Revenues exclude any taxes that the Company collects from customers and remits to tax authorities. Equipment lease transactions with customers are evaluated and classified as either operating or sales-type leases. Generally, these arrangements are accounted for as operating leases and therefore, revenue is recognized at the contracted rate over the rental period defined within the customer agreement. Additional disclosures regarding the Company's accounting for revenue recognition are provided in Note 7. Shipping and Handling Costs The Company considers its shipping and handling costs to be contract fulfillment costs and records them within Selling and administrative expense. Shipping expense was $702 million, $733 million and $751 million in 2024, 2023 and 2022, respectively. Contingencies The Company establishes accruals for future losses which are both probable and can be reasonably estimated. Additional disclosures regarding the Company's accounting for contingencies are provided in Note 6. Derivative Financial Instruments All derivatives are recorded in the balance sheet at fair value and changes in fair value are recognized currently in earnings unless specific hedge accounting criteria are met. Any deferred gains or losses associated with derivative instruments are recognized in income in the period in which the underlying hedged transaction is recognized. The cash flows related to the Company's derivative instruments designated as net investment hedges are reported as investing activities in the consolidated statements of cash flows. Cash flows for all other derivatives, including undesignated hedges, are classified in the same line item as the cash flows of the related hedged item, which is generally within operating or financing activities. Additional disclosures regarding the Company's accounting for derivative instruments are provided in Note 14. Income Taxes The Company has reviewed its needs in the United States for possible repatriation of undistributed earnings of its foreign subsidiaries and continues to invest foreign subsidiaries earnings outside of the United States to fund foreign investments or meet foreign working capital and property, plant and equipment expenditure needs. As a result, the Company is permanently reinvested with respect to all of its historical foreign earnings as of September 30, 2024. Deferred taxes are not provided on undistributed earnings of foreign subsidiaries that are indefinitely reinvested. The determination of the amount of the unrecognized deferred tax liability related to the undistributed earnings is not practicable because of the complexities associated with its hypothetical calculation. The Company conducts business and files tax returns in numerous countries and currently has tax audits in progress in a number of tax jurisdictions. In evaluating the exposure associated with various tax filing positions, the Company records accruals for uncertain tax positions based on the technical support for the positions, past audit experience with similar situations, and the potential interest and penalties related to the matters. The Company maintains valuation allowances where it is more likely than not that all or a portion of a deferred tax asset will not be realized. Changes in valuation allowances are included in the tax provision in the period of change. In determining whether a valuation allowance is warranted, management evaluates factors such as prior earnings history, expected future earnings, carryback and carryforward periods and tax strategies that could potentially enhance the likelihood of the realization of a deferred tax asset. Additional disclosures regarding the Company's accounting for income taxes are provided in Note 17. The Tax Cuts and Jobs Act was enacted on December 22, 2017 and subjects a U.S. shareholder to tax on global intangible low-taxed income ("GILTI") earned by certain foreign subsidiaries. The Company has elected to account for its GILTI tax due as a period expense in the year the tax is incurred. Earnings per Share Basic earnings per share are computed by dividing income available to common stockholders by the weighted average number of common shares outstanding. Diluted earnings per share reflect the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock. In computing diluted earnings per share, only potential common shares that are dilutive (i.e., those that reduce earnings per share or increase loss per share) are included in the calculation. Fair Value Measurements A fair value hierarchy is applied to prioritize inputs used in measuring fair value. The three levels of inputs used to measure fair value are detailed below. Additional disclosures regarding the Company’s fair value measurements are provided in Notes 10 and 15. Level 1 — Inputs to the valuation methodology which represent unadjusted quoted prices in active markets for identical assets and liabilities. Level 2 — Inputs to the valuation methodology which include: quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; inputs other than quoted prices that are observable for the asset or liability. Level 3 — Inputs to the valuation methodology which are unobservable and significant to the fair value measurement. Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions. These estimates or assumptions affect reported assets, liabilities, revenues and expenses as reflected in the consolidated financial statements. Actual results could differ from these estimates.

Divestitures

Divestitures	12 Months Ended
	Sep. 30, 2024
Discontinued Operations and Disposal Groups [Abstract]
Divestitures	Divestitures Surgical Instrumentation Platform The Company completed the sale of its Interventional segment's Surgical Instrumentation platform in August 2023. The Company recognized a pre-tax gain on the sale of approximately $268 million, which was recorded as a component of Other operating expense (income), net in fiscal year 2023. The historical financial results for the Surgical Instrumentation platform have not been classified as a discontinued operation. Spin-Off of Embecta Corp. On April 1, 2022, the Company completed the spin-off of its former Diabetes Care business as a separate publicly traded company named Embecta through a distribution of Embecta’s publicly traded common stock (listed on NASDAQ under the ticker symbol "EMBC") to BD’s shareholders of record as of the close of business on March 22, 2022 (the “record date”). The Company distributed one share of Embecta common stock for every five common shares of BD outstanding as of the record date and shareholders received cash in lieu of fractional shares of Embecta common stock. BD retained no ownership interest in Embecta subsequent to the spin-off. The distribution is expected to qualify and has been treated as tax-free to the Company and its shareholders for U.S. federal income tax purposes. On March 31, 2022, Embecta used a portion of the proceeds from financing transactions to make a cash distribution of approximately $1.266 billion to the Company. The Company and Embecta entered into various agreements to effect the spin-off and provide a framework for the relationship between the Company and Embecta after the spin-off. Such agreements include the separation and distribution agreement, as well as the following ongoing agreements: a cannula supply agreement, an intellectual property matters agreement, a transition services agreement, manufacturing and supply agreements, a lease agreement, a distribution agreement to support commercial operations, a logistics services agreement and other agreements including an employee matters agreement and a tax matters agreement. Under these agreements, the Company has continued to provide certain products and services to Embecta following the spin-off. The agreements do not provide the Company with the ability to influence the operating or financial policies of Embecta subsequent to the spin-off date. Amounts included in the Company’s consolidated statements of income during the fiscal years ended September 30, 2024, 2023 and 2022 as a result of these agreements are detailed in Note 19. Details of (Loss) Income from Discontinued Operations, Net of Tax , which represent the historical results of the Diabetes Care business prior to the spin-off date of April 1, 2022, are as follows: Millions of dollars 2022 Revenues $ 538 Cost of products sold 143 Selling and administrative expense 78 Research and development expense 32 Other operating expense, net 95 Total Operating Costs and Expenses 348 Operating Income 190 Interest expense (4) Income from Discontinued Operations Before Income Taxes 186 Income tax provision 42 Income from Discontinued Operations, Net of Tax $ 144 In fiscal year 2023, the Company recorded expenses of $46 million within (Loss) Income from Discontinued Operations, Net of Tax related to a foreign tax associated with the spin-off. For fiscal year 2022, in the table above, Other operating expense, net, includes $30 million of costs incurred by the Company to execute the spin-off and other costs for related residual activities, as well as $78 million of separation costs incurred by the Company prior to the spin-off date, including those for consulting, legal, tax and other advisory services associated with the spin-off. The amounts of Revenues and Cost of products sold

Accounting Changes

Accounting Changes	12 Months Ended
	Sep. 30, 2024
Accounting Changes and Error Corrections [Abstract]
Accounting Changes	Accounting Changes New Accounting Principles Adopted In September 2022, the Financial Accounting Standards Board ("FASB") issued an accounting standard update that requires additional qualitative and quantitative disclosures regarding supplier finance programs. The new disclosure requirements are intended to help investors better consider the effect of these programs on a company's working capital, liquidity, and cash flows. The Company adopted this accounting standard on October 1, 2023, and disclosures regarding the Company’s supplier finance programs are provided in Note 15. On July 1, 2022, the Company early-adopted an accounting standard update issued by the FASB, which requires an entity to apply the provisions of Accounting Standard Codification Topic 606, "Revenue from Contracts with Customers," ("ASC 606") when recognizing and measuring contract assets and contract liabilities acquired in a business combination. The Company’s adoption of this accounting standard update for business combinations that occurred during fiscal year 2022 did not have a material impact on its consolidated financial statements. New Accounting Principles Not Yet Adopted In November 2024, the FASB issued an accounting standard update that requires the Company to disclose more detailed information about the types of expenses (including purchases of inventory, employee compensation, depreciation, amortization, and depletion) included in each relevant income statement expense caption. The update is effective for the Company beginning with its fiscal year 2028 reporting and for interim reporting beginning with its fiscal year 2029. Early adoption is permitted. The Company is currently evaluating the impact that this update will have on its disclosures. In December 2023, the FASB issued an accounting standard update that requires more disaggregated information to be included in the income tax rate reconciliation and income taxes paid annual disclosures. This update is effective for the Company beginning in its fiscal year 2026 and the Company is currently evaluating the impact that this update will have on its disclosures.

Shareholders' Equity

Shareholders' Equity	12 Months Ended
	Sep. 30, 2024
Stockholders' Equity Note [Abstract]
Shareholders' Equity	Shareholders’ Equity Changes in certain components of shareholders’ equity were as follows: Common Capital in Retained Deferred Treasury Stock (Millions of dollars) Shares (in Amount Balance at September 30, 2021 $ 365 $ 19,272 $ 13,826 $ 23 (80,164) $ (7,723) Net income — — 1,779 — — — Cash dividends: Common ($3.48 per share) — — (992) — — — Preferred — — (90) — — — Issuance of shares under employee and other plans, net — (108) (1) — 1,271 44 Share-based compensation — 239 — — — — Common stock held in trusts, net (a) — — — — 25 — Repurchase of common stock — 150 — — (2,415) (650) Spin-off of Embecta (See Note 2) — — 634 — — — Balance at September 30, 2022 $ 365 $ 19,553 $ 15,157 $ 23 (81,283) $ (8,330) Net income — — 1,484 — — — Cash dividends: Common ($3.64 per share) — — (1,046) — — — Preferred — — (60) — — — Issuance of shares for preferred shares converted to common shares (b) 6 (4) — — — — Issuance of shares under employee and other plans, net — (88) — 1 1,056 24 Share-based compensation — 259 — — — — Common stock held in trusts, net (a) — — — — 24 — Balance at September 30, 2023 $ 371 $ 19,720 $ 15,535 $ 24 (80,203) $ (8,305) Net income — — 1,705 — — — Cash dividends: Common ($3.80 per share) — — (1,100) — — — Issuance of shares under employee and other plans, net — (73) — 1 801 2 Share-based compensation — 247 — — — — Common stock held in trusts, net (a) — — — — 27 — Repurchase of common stock — — — — (2,118) (503) Balance at September 30, 2024 $ 371 $ 19,893 $ 16,139 $ 25 (81,493) $ (8,807) (a) Common stock held in trusts consists of the Company’s shares held in rabbi trusts in connection with deferred compensation under the Company’s employee salary and bonus deferral plan and directors’ deferral plan. (b) Represents the conversion, in accordance with their terms, of 1.500 million mandatory convertible preferred shares that were issued in May 2020 were converted into 5.955 million shares of BD common stock on the mandatory conversion date of June 1, 2023. Share Repurchases In fiscal year 2024, the Company executed and settled accelerated share repurchase (“ASR”) agreements for the repurchase of 2.118 million shares of its common stock for total consideration of $500 million, excluding a 1% excise tax on share repurchases of $3 million, which was recorded as an increase to Treasury stock. In fiscal year 2022, the Company executed an ASR agreement in which 1.953 million common shares were repurchased and delivered in fiscal year 2022 for $500 million, and were recorded as an increase to Treasury stock. Also in fiscal year 2022, $150 million was recorded as an increase to Treasury stock , with an offsetting increase to Capital in excess of par value for the delivery of 462 thousand shares upon final settlement of a separate ASR agreement which was executed in fiscal year 2021. The share repurchases discussed above were made pursuant to the repurchase program authorized by the Board of Directors on September 24, 2013 for 10 million shares, which was fully utilized as of September 30, 2022, and a repurchas e program authorized by the Board of Directors on November 3, 2021 for up to an additional 10 million shares of BD common stock, for which there is no expiration date. The components and changes of Accumulated other comprehensive income (loss) were as follows: (Millions of dollars) Total Foreign Benefit Plans Cash Flow Available-for-Sale Debt Securities Balance at September 30, 2021 $ (2,088) $ (1,292) $ (784) $ (10) $ — Other comprehensive income before reclassifications, net of taxes 306 54 169 83 — Amounts reclassified into income, net of 43 — 41 2 — Spin-off of Embecta (See Note 2) 251 251 — — — Balance at September 30, 2022 $ (1,488) $ (987) $ (574) $ 75 $ — Other comprehensive (loss) income before reclassifications, net of taxes (106) (91) (37) 21 — Amounts reclassified into income, net of 46 — 41 6 — Balance at September 30, 2023 $ (1,548) $ (1,078) $ (571) $ 103 $ — Other comprehensive loss before reclassifications, net of taxes (227) (166) (32) (28) (1) Amounts reclassified into income, net of 42 — 46 (4) — Balance at September 30, 2024 $ (1,732) $ (1,244) $ (557) $ 70 $ (1) The amount of foreign currency translation recognized in other comprehensive income during the years ended September 30, 2024, 2023 and 2022 included net (losses) gains relating to net investment hedges, as further discussed in Note 14. The amount recognized in other comprehensive income relating to cash flow hedges in 2024 is primarily related to foreign exchange contracts and forward starting interest rate swaps, which were terminated during fiscal year 2024. The amounts recognized in other comprehensive income relating to cash flow hedges in 2023 and 2022 are primarily related to forward starting interest rate swaps. Additional disclosures regarding the Company's derivatives are provided in Note 14. The tax impacts for benefit plans and cash flow hedges recognized in other comprehensive income before reclassifications in 2024, 2023 and 2022 were immaterial to the Company's consolidated financial results. The tax impacts for reclassifications out of Accumulated other comprehensive income (loss) relating to benefit plans and cash flow hedges in 2024, 2023 and 2022 were also immaterial to the Company's consolidated financial results.

Earnings per Share

Earnings per Share	12 Months Ended
	Sep. 30, 2024
Earnings Per Share [Abstract]
Earnings per Share	Earnings per Share The weighted average common shares used in the computations of basic and diluted earnings per share (shares in thousands) for the years ended September 30 were as follows: 2024 2023 2022 Average common shares outstanding 289,763 286,282 285,005 Dilutive share equivalents from share-based plans (a) (b) 1,246 2,110 2,333 Dilutive share equivalents from Series C preferred shares (c) — — 26 Average common and common equivalent shares outstanding — assuming dilution 291,009 288,392 287,364 (a) In 2023 and 2022, dilutive share equivalents associated with mandatory convertible preferred stock of 4 million and 6 million, respectively, were excluded from the diluted shares outstanding calculation because the result would have been antidilutive. All of the mandatory convertible preferred shares outstanding were converted during fiscal year 2023, as further discussed in Note 4. (b) In 2024, 1 million of certain share-based compensation awards were excluded from the diluted earnings per share calculation as the exercise prices of these awards were greater than the average market price of the Company’s common shares. In 2023 and 2022, no such awards were excluded from the diluted earnings per share calculation. Additional disclosures regarding the Company’s share-based compensation are provided in Note 9. (c) Represents dilutive share equivalents from Series C preferred shares that temporarily replaced shares of common stock held in trusts to adhere to trust requirements until the Company’s spin-off of its Diabetes Care business on April 1, 2022 was completed.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Sep. 30, 2024
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Commitments The Company has certain future purchase commitments entered in the normal course of business to meet operational and capital requirements. As of September 30, 2024, these commitments aggregated to approximately $1.831 billion and will be expended over the next several years. Contingencies The Company is involved, both as a plaintiff and a defendant, in various legal proceedings that arise in the ordinary course of business, including, without limitation, product liability and environmental matters in certain U.S. and international locations. Given the uncertain nature of litigation generally, the Company is not able, in all cases, to reasonably estimate the amount or range of loss that could result from an unfavorable outcome of litigation in which the Company is a party. Even if the Company believes it has meritorious defenses, from time to time the Company engages in settlement discussions and mediation and considers settlements taking into account various factors including, among other things, developments in such legal proceedings and the resulting risks and uncertainties. These activities have resulted in settlements for certain matters and going forward could result in further settlements, which may be confidential and could be significant and result in charges in excess of accruals. In accordance with U.S. GAAP, the Company establishes accruals to the extent future losses are probable and reasonably estimable. With respect to putative class action lawsuits and certain tort actions in the United States and certain of the Canadian lawsuits described below or in our other SEC filings, the Company may not be able to determine if a probable loss exists for the following reasons: (i) all or certain of the proceedings are in early stages; (ii) the Company has not received and reviewed complete information regarding all or certain of the plaintiffs and their medical conditions; and/or (iii) there are significant factual issues to be resolved. In addition, there is uncertainty as to the likelihood of a class being certified or the ultimate size of any class. With respect to certain of the civil investigative demands (“CIDs”) served by the Department of Justice which are discussed below, the Company may not be able to determine if a probable loss exists, unless otherwise noted, for the following reasons: (i) all or certain of the proceedings are in early stages; and/or (ii) there are significant factual and legal issues to be resolved. Product Liability Matters As of September 30, 2024, the Company is defending approximately 6,610 product liability claims involving the Company’s line of hernia repair devices (collectively, the “Hernia Product Claims”).The Company’s outstanding Hernia Product Claims as of September 30, 2023 were approximately 34,845. The reduction in the number of outstanding claims primarily reflects a settlement agreement that was consummated in the fourth quarter of fiscal year 2024 to resolve the vast majority of the Company’s existing hernia litigation. The aggregate amount payable pursuant to this settlement is within the Company's current product liability accrual for this matter and will be paid out over a multi-year period. The majority of the outstanding claims are currently pending in a coordinated proceeding in Rhode Island State Court (“RI”) and in a federal multi-district litigation (“MDL”) established in the Southern District of Ohio, but claims are also pending in other state and/or federal court jurisdictions. In addition, outstanding claims include multiple putative class actions in Canada. Generally, the Hernia Product Claims seek damages for personal injury allegedly resulting from use of the products. The Company believes that it has meritorious defenses and is vigorously defending itself in these matters. There are no trials currently scheduled. The Company also continues to be a defendant in certain other mass tort litigation. As of September 30, 2024, the Company is defending product liability claims involving the Company’s line of pelvic mesh products, the majority of which are pending in a coordinated proceeding in New Jersey Superior Court and in various federal court jurisdictions, the Company’s line of inferior vena cava (“IVC”) filter products, which are pending in various jurisdictions, and the Company’s line of implantable ports, the majority of which are pending in an MDL in the United States District Court for the District of Arizona. The Company believes that it has meritorious defenses and is vigorously defending itself in these matters. In most product liability litigations like those described above, plaintiffs allege a wide variety of claims, ranging from allegations of serious injury caused by the products to efforts to obtain compensation notwithstanding the absence of any injury. In many of these cases, the Company has not yet received and reviewed complete information regarding the plaintiffs and their medical conditions and, consequently, is unable to fully evaluate the claims. The Company expects that it will receive and review additional information regarding any remaining unsettled product liability matters. Other Matters On November 2, 2020, a putative shareholder derivative action captioned Jankowski v. Forlenza, et al., Civ. No. 2:20-cv-15474, was filed in the U.S. District Court for the District of New Jersey by a shareholder, derivatively on behalf of the Company, against certain of the Company’s directors and officers. The complaint asserts claims for breach of fiduciary duty; violations of sections 10(b), 14(a) and 21D of the Exchange Act, and insider trading. The complaint principally alleges, that the Company made misleading statements regarding Alaris TM infusion pumps in a proxy statement and other SEC filings. A second federal derivative action was filed on January 24, 2021, and the two actions were consolidated and stayed. In March 2021, the Company received letters from two additional shareholders which, in general, mirrored the allegations in the derivative actions, and demanded, among other things, that the Board of Directors pursue claims against members of management for claimed breaches of fiduciary duties. Consistent with New Jersey law, the Board appointed a special committee to review the allegations and demands in the derivative actions and demand letters. Following an investigation, the special committee determined that no action was warranted, and rejected the shareholders’ demands, communicating its determination to counsel for the shareholders. On January 10, 2023, one of the two shareholders referenced above filed a separate derivative action that: (i) is generally consistent with the shareholder letter and the two prior actions; and (ii) purports to challenge the reasonableness of the special committee’s process and determination. That action was also stayed. Following entry of a stipulated scheduling order for an amended complaint and motion to dismiss the consolidated federal action, the case schedule was adjourned without date pending mediation. Mediation proceedings have taken place, with negotiations continuing. On September 10, 2024, the Company received an additional substantially identical shareholder demand letter and on September 26, 2024, that shareholder filed a second substantially identical state court derivative action. The Company believes that the defendants have meritorious defenses and intends to vigorously defend these matters, if ongoing negotiations are unproductive. Beginning in February 2021, the Company received subpoenas from the Enforcement Division of the SEC requesting information from the Company relating to, among other things, certain reporting issues involving BD Alaris TM infusion pumps included in SEC disclosures prior to 2021. The Company is cooperating with the SEC and is engaged in discussions with the SEC with respect to a potential resolution of this matter. Although the Company cannot predict the outcome of the discussions with the SEC, the Company expects that any resolution will likely require the Company to pay monetary penalties and/or undertake other remedial actions, any of which could potentially be material. As a result, although no agreement has been reached, the Company recorded charges of $50 million and $125 million in the third and fourth quarters of 2024, respectively, to Other operating expense (income), net to accrue an estimated $175 million liability as of September 30, 2024 based on these discussions. However, the Company cannot anticipate the timing, scope, outcome or ultimate impact of the investigation, financial or otherwise, including but not limited to what actions the SEC might pursue against the Company and/or individuals. As a result, the ultimate resolution of this matter is unknown at this time, and it is possible that the amount of the Company’s liability could significantly exceed its currently accrued amount. In July 2017, C.R. Bard, which was acquired by the Company in December 2017, received a CID from the Department of Justice seeking documents and information relating to an investigation into possible violations of the False Claims Act in connection with the sales and marketing of FloChec® and QuantaFlo TM devices. The Company has responded to these requests and met with the Department of Justice in February and July 2024; discussions are ongoing. In April 2019, the Department of Justice served the Company and CareFusion with CIDs seeking information regarding certain of CareFusion’s contracts with the Department of Veteran’s Affairs, some dating back more than 10 years, for certain products, including Alaris TM and Pyxis TM devices, in connection with a civil investigation of possible violations of the False Claims Act, and the government later expanded the investigation to include several additional contracts. The government has made several requests for documents and interviews or depositions of Company personnel. The Company is cooperating with the government and responding to these requests. In September 2021, the Company received a CID related to an inquiry initiated by the Department of Justice in the Northern District of Georgia in 2018 concerning sales and marketing practices with respect to certain aspects of the Company’s urology business. After multiple document productions and interviews, the Company and the government mediated the case in an effort to resolve this dispute; an agreement was reached to resolve this matter for an adequately accrued amount that is not material to the Company’s consolidated financial results. In April 2023, the Department of Justice served the Company with a CID seeking information regarding the Company’s Genesis TM container products in connection with an investigation of possible violations of the False Claims Act. The government has requested documents and the Company is cooperating with the government and responding to its requests. The Company was sued in state and federal courts in Georgia by plaintiffs who work or reside near Company facilities in Covington, GA, where ethylene oxide (“EtO”) sterilization activities take place. The federal cases have been dismissed and refiled in state court. The plaintiffs in the cases seek compensatory and punitive damages. Pursuant to Georgia statute, punitive damages in these cases are generally capped at $250,000 per claimant, unless the plaintiff can prove by clear and convincing evidence that the Company acted, or failed to act, with a specific intent to cause harm. The cases allege a variety of injuries, including but not limited to multiple types of cancer, allegedly attributable to exposure to EtO. As of September 30, 2024, the Company has approximately 350 of such suits involving approximately 360 plaintiffs asserting individual personal injury claims; approximately 50 of the cases also allege injury caused by exposure to a chemical of another defendant entirely unrelated to the Company. No cases have yet been tried although a trial date has been set for one such case scheduled for April 2025. The Company believes that it has meritorious defenses and is vigorously defending itself in these matters. In 2015, legislation was enacted in Italy which requires medical technology companies to make payments to the Italian government if Italy’s medical device expenditures exceed annual regional expenditure ceilings. The amount of these payments is based on the amount by which the regional ceilings for the given year were exceeded. Considerable uncertainty has existed regarding the enforceability and implementation of this payback legislation since it was enacted and the Company, as well as other medical device companies, have filed appeals which challenge the enforceability of this legislation. In July 2024, the Italian Constitutional Court issued two judgments which concluded that the medical device payback legislation is constitutional; however, litigation proceedings before Italian Courts are still pending. While the Company has recorded a preliminary estimate of the liability related to this matter, ultimate resolution is unknown at this time, and it is possible that the amount of the Company’s liability could differ from the currently accrued amount. This estimated amount, which substantially relates to years prior to the current fiscal year, was recorded for the fiscal year ended September 30, 2024 as a $62 million reduction of Revenues. In May 2024, CareFusion 303, Inc., the Company’s subsidiary that manufactures its BD Pyxis TM dispensing equipment, received a Form 483 Notice from the U.S. Food and Drug Administration (“FDA”) that contained observations of non-conformance with the FDA’s quality system and Medical Device Reporting (“MDR”) regulations. In November 2024, the Company received a Warning Letter that contained alleged violations of the quality system regulations, MDR regulation, the corrections and removals reporting regulation and law. During the fourth quarter of fiscal year 2024, the Company recorded a $28 million liability for estimated future costs associated with certain actions required to respond to the Warning Letter and to address the non-conformities. The Company is currently working to respond to this Warning Letter; however, no assurances can be given regarding further action by the FDA as a result of the noted non-conformities, or that corrective actions proposed and taken by CareFusion 303, Inc. will be adequate to address the non-conformities. Any failure to adequately address this Warning Letter may result in regulatory actions initiated by the FDA without further notice, which may include, but are not limited to, seizure, injunction and civil monetary penalties. As a result, the ultimate resolution of this Warning Letter and its impact on the Company’s operations is unknown at this time, and it is possible that the amount of the Company’s liability could exceed its currently accrued amount. The Company is also involved both as a plaintiff and a defendant in other legal proceedings and claims that arise in the ordinary course of business. The Company believes that it has meritorious defenses and is vigorously defending itself in each of these matters. Except as otherwise noted, the Company cannot predict the outcome of the other legal matters discussed above, nor can it predict whether any outcome will have a material adverse effect on the Company’s consolidated results of operations and/or consolidated cash flows. Further, the Company may not be able to determine if a probable loss exists for certain of the other legal matters discussed above, and accordingly, the Company has recorded no provisions for such matters in its consolidated results of operations. The Company is a potentially responsible party to a number of federal administrative proceedings in the United States brought under the Comprehensive Environment Response, Compensation and Liability Act, also known as “Superfund,” and similar state laws. The Company also is subject to administrative proceedings under environmental laws in jurisdictions outside the U.S. The affected sites are in varying stages of development. In some instances, the remedy has been completed, while in others, environmental studies are underway or commencing. For several sites, there are other potentially responsible parties that may be jointly or severally liable to pay all or part of cleanup costs. While it is not feasible to predict the outcome of these proceedings, based upon the Company’s experience, current information and applicable law, the Company does not expect these proceedings to have a material adverse effect on its consolidated results of operations and/or consolidated cash flows. Litigation Accruals The Company regularly monitors and evaluates the status of product liability and other litigated matters, and may, from time-to-time, engage in settlement discussions and mediation taking into consideration, among other things, developments in the litigation and the risks and uncertainties associated therewith. These activities have resulted in confidential settlements and going forward could result in further settlements, the terms of which may be confidential and could be significant and result in charges in excess of accruals. A determination of the accrual amounts for these contingencies is made after analysis of each litigation matter. When appropriate, the accrual is developed with the consultation of outside counsel and, in the case of certain mass tort litigation, actuarial specialists regarding the nature, timing, and extent of each matter. During fiscal years 2024, 2023 and 2022, the Company recorded a pre-tax (benefit) charge to Other operating expense (income), net, of approximately $(36) million, $26 million and $21 million, respectively, related to certain of the product liability matters discussed above under the heading “Product Liability Matters,” including the related legal defense costs. The benefit recorded in fiscal year 2024 primarily reflected the favorable resolution of claims during the fiscal year. The Company considers relevant information when estimating its product liability accruals, including, but not limited to: the nature, number, and quality of unfiled and filed claims; the rate of claims being filed; the status of settlement discussions with plaintiffs’ counsel; the allegations and documentation supporting or refuting such allegations; publicly available information regarding similar medical device mass tort settlements; historical information regarding other product liability settlements involving the Company; and the stage of litigation. Because currently available information regarding product liability matters is often limited, there is inherent uncertainty and volatility relating to the Company’s estimate of product liability. As additional information becomes available, the Company records adjustments to its product liability accruals as required. Accruals for the Company's product liability claims which are discussed above, as well as the related legal defense costs, amounted to approximately $1.7 billion and $1.9 billion at September 30, 2024 and 2023, respectively. These accruals are recorded within Accrued expenses and Deferred Income Taxes and Other Liabilities on the Company's consolidated balance sheets. The decrease in the Company’s product liability accrual as of September 30, 2024, as compared with September 30, 2023, largely reflected reductions to the accrual due to the payment of settlements and legal fees, as well as the adjustment of $36 million noted above. The decrease in the number of outstanding hernia repair device claims discussed above did not materially impact the Company’s product liability accrual because the aggregate amount payable pursuant to this settlement agreement will be paid out over a multi-year period. The accrual also reflects a determination that the remaining outstanding hernia repair device claims are generally of lower quality. Claim activity during the fiscal year 2024 relating to the pelvic mesh device and IVC filter matters did not materially impact the Company’s product liability accrual as of September 30, 2024. The particular outcome in any one product liability trial is typically not representative of potential outcomes of all cases or claims. Because the accrual already contemplates a wide range of possible outcomes, including those with a de minimis value, individual outcomes generally do not impact the value of other cases in the total case inventory or the overall product liability accrual. In view of the uncertainties discussed above, the Company could incur charges in excess of any currently established accruals and, to the extent available, liability insurance. In the opinion of management, any such future charges, individually or in the aggregate, could have a material adverse effect on the Company’s consolidated results of operations, financial condition, and/or consolidated cash flows.

Revenues

Revenues	12 Months Ended
	Sep. 30, 2024
Revenue from Contract with Customer [Abstract]
Revenues	Revenues The Company sells a broad range of medical supplies, devices, laboratory equipment and diagnostic products which are distributed through independent distribution channels and directly by BD through sales representatives. End-users of the Company's products include healthcare institutions, physicians, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. Timing of Revenue Recognition The Company's revenues are primarily recognized when the customer obtains control of the product sold, which is generally upon shipment or delivery, depending on the delivery terms specified in the sales agreement. Revenues associated with certain instruments and equipment for which installation is complex, and therefore significantly affects the customer’s ability to use and benefit from the product, are recognized when customer acceptance of these installed products has been confirmed. For certain service arrangements, including extended warranty and software maintenance contracts, revenue is recognized ratably over the contract term. The majority of revenues relating to extended warranty contracts associated with certain instruments and equipment is generally recognized within a few years whereas deferred revenue relating to software maintenance contracts is generally recognized over a longer period. Measurement of Revenues The Company acts as the principal in substantially all of its customer arrangements and as such, generally records revenues on a gross basis. Revenues exclude any taxes that the Company collects from customers and remits to tax authorities. The Company considers its shipping and handling costs to be costs of contract fulfillment and has made the accounting policy election to record these costs within Selling and administrative expense . Payment terms extended to the Company's customers are based upon commercially reasonable terms for the markets in which the Company's products are sold. Because the Company generally expects to receive payment within one year or less from when control of a product is transferred to the customer, the Company does not generally adjust its revenues for the effects of a financing component. The Company’s allowance for doubtful accounts reflects the current estimate of credit losses expected to be incurred over the life of its trade receivables. Such estimated credit losses are determined based on historical loss experiences, customer-specific credit risk, and reasonable and supportable forward-looking information, such as country or regional risks that are not captured in the historical loss information. Amounts are written off against the allowances for doubtful accounts when the Company determines that a customer account is uncollectable. The allowance for doubtful accounts for trade receivables is not material to the Company's consolidated financial results. The Company's gross revenues are subject to a variety of deductions which are recorded in the same period that the underlying revenues are recognized. Such variable consideration includes rebates, sales discounts and sales returns. Because these deductions represent estimates of the related obligations, judgment is required when determining the impact of these revenue deductions on gross revenues for a reporting period. Rebates provided by the Company are based upon prices determined under the Company's agreements with its end-user customers. Additional factors considered in the estimate of the Company's rebate liability include the quantification of inventory that is either in stock at or in transit to the Company's distributors, as well as the estimated lag time between the sale of product and the payment of corresponding rebates. The Company’s rebate liabilities are classified as an offset to Trade receivables, net , or as Accounts payable or Accrued expenses , depending on the form of settlement and were $749 million and $669 million at September 30, 2024 and 2023, respectively. The impact of other forms of variable consideration, including sales discounts and sales returns, is not material to the Company's revenues. Additional disclosures relating to sales discounts and sales returns are provided in Note 19. The Company's agreements with customers within certain organizational units including Medication Management Solutions, Integrated Diagnostic Solutions and Biosciences, contain multiple performance obligations including both products and certain services noted above. The transaction price for these agreements is allocated to each performance obligation based upon its relative standalone selling price. Standalone selling price is the amount at which the Company would sell a promised good or service separately to a customer. The Company generally estimates standalone selling prices using its list prices and a consideration of typical discounts offered to customers. Effects of Revenue Arrangements on Consolidated Balance Sheets Due to the nature of the majority of the Company's products and services, the Company typically does not incur costs to fulfill a contract in advance of providing the customer with goods or services. Capitalized contract costs associated with the costs to fulfill contracts for certain products in the Medication Management Solutions organizational unit are immaterial to the Company's consolidated balance sheets. The Company's costs to obtain contracts are comprised of sales commissions which are paid to the Company's employees or third party agents. The majority of the sales commissions incurred by the Company relate to revenue that is recognized over a period that is less than one year and as such, the Company has elected a practical expedient provided under ASC 606 to record the majority of its expense associated with sales commissions as it is incurred. Commissions relating to revenues recognized over a period longer than one year are recorded as assets which are amortized over the period over which the revenues underlying the commissions are recognized. Capitalized contract costs related to such commissions are immaterial to the Company's consolidated balance sheets. The Company records contract liabilities for unearned revenue that is allocated to performance obligations such as extended warranty and software maintenance contracts, which are performed over time as discussed further above. Accrued expenses on the Company’s consolidated balance sheet as of September 30, 2024 and 2023, included approximately $482 million and $412 million, respectively, of contract liabilities. The Company's liability for product warranties provided under its agreements with customers is not material to its consolidated balance sheets. Remaining Performance Obligations The Company's obligations relative to service contracts, which are further discussed above, and pending installations of equipment, primarily in the Company's Medication Management Solutions unit, represent unsatisfied performance obligations of the Company. The revenues under existing contracts with original expected durations of more than one year, which are attributable to products and/or services that have not yet been installed or provided, are estimated to be approximately $2.3 billion at September 30, 2024. The Company expects to recognize the majority of this revenue over the next three years. Within the Company's Medication Management Solutions, Medication Delivery Solutions, Integrated Diagnostic Solutions, and Biosciences units, some contracts also contain minimum purchase commitments of reagents or other consumables and the future sales of these consumables represent additional unsatisfied performance obligations of the Company. The revenue attributable to the unsatisfied minimum purchase commitment-related performance obligations, for contracts with original expected durations of more than one year, is estimated to be approximately $2.1 billion at September 30, 2024. This revenue will be recognized over the customer relationship periods. Disaggregation of Revenues A disaggregation of the Company's revenues by segment, organizational unit and geographic region is provided in Note 8.

Segment Data

Segment Data	12 Months Ended
	Sep. 30, 2024
Segment Reporting [Abstract]
Segment Data	Segment Data The Company's organizational structure is based upon three worldwide business segments: BD Medical (“Medical”), BD Life Sciences (“Life Sciences”) and BD Interventional ("Interventional"). The Company’s segments are strategic businesses that are managed separately because each one develops, manufactures and markets distinct products and services. Medical Medical produces a broad array of medical technologies and devices that are used to help improve healthcare delivery in a wide range of settings. The primary customers served by Medical are hospitals and clinics; physicians’ office practices; consumers and retail pharmacies; governmental and nonprofit public health agencies; pharmaceutical companies; and healthcare workers. Medical consists of the following organizational units: Medication Delivery Solutions; Medication Management Solutions; Pharmaceutical Systems; Advanced Patient Monitoring. Life Sciences Life Sciences provides products for the safe collection and transport of diagnostics specimens, and instruments and reagent systems to detect a broad range of infectious diseases, healthcare-associated infections and cancers. In addition, Life Sciences produces research and clinical tools that facilitate the study of cells, and the components of cells, to gain a better understanding of normal and disease processes. That information is used to aid the discovery and development of new drugs and vaccines, and to improve the diagnosis and management of diseases. The primary customers served by Life Sciences are hospitals, laboratories and clinics; blood banks; healthcare workers; physicians’ office practices; academic and government institutions; and pharmaceutical and biotechnology companies. Life Sciences consists of the following organizational units: Integrated Diagnostic Solutions and Biosciences. Interventional Interventional provides vascular, urology, oncology and surgical specialty products that are intended to be used once and then discarded or are either temporarily or permanently implanted. The primary customers served by Interventional are hospitals, ambulatory surgery centers, individual healthcare professionals, extended care facilities, alternate site facilities, and patients via the segment's Homecare business. Interventional consists of the following organizational units: Surgery; Peripheral Intervention; Urology and Critical Care. Additional Segment Information Distribution of products is primarily through independent distribution channels, and directly to end-users by BD and independent sales representatives. No customer accounted for 10% or more of revenues in any of the three years presented. Segment disclosures are on a performance basis consistent with internal management reporting. The Company evaluates performance of its business segments and allocates resources to them primarily based upon operating income, which represents revenues reduced by product costs and operating expenses. The Company’s chief operating decision maker does not receive any asset information by business segment and, as such, the Company does not report asset information by business segment. The tables below reflect the Company’s revenues and operating income from continuing operations. Revenues and operating income from the former Diabetes Care business prior to its spin-off on April 1, 2022 are included in (Loss) Income from Discontinued Operations, Net of Tax . See Note 2 for further information. Financial information for the Company’s segments is detailed below. The Company has no material intersegment revenues. (Millions of dollars) 2024 2023 2022 United States International Total United States International Total United States International Total Medical Medication Delivery Solutions $ 2,661 $ 1,768 $ 4,429 $ 2,519 $ 1,774 $ 4,293 $ 2,483 $ 1,825 $ 4,308 Medication Management Solutions 2,627 670 3,297 2,303 677 2,980 1,935 598 2,533 Pharmaceutical Systems 629 1,644 2,273 666 1,563 2,229 533 1,468 2,001 Advanced Patient Monitoring 47 27 74 — — — — — — Total segment revenues $ 5,964 $ 4,110 $ 10,074 $ 5,488 $ 4,014 $ 9,502 $ 4,950 $ 3,891 $ 8,841 Life Sciences Integrated Diagnostic Solutions $ 1,733 $ 1,946 $ 3,679 $ 1,774 $ 1,850 $ 3,624 $ 2,190 $ 1,995 $ 4,185 Biosciences 577 935 1,512 603 906 1,509 542 838 1,379 Total segment revenues $ 2,310 $ 2,881 $ 5,191 $ 2,377 $ 2,756 $ 5,133 $ 2,732 $ 2,833 $ 5,564 Interventional Surgery $ 1,130 $ 363 $ 1,492 $ 1,159 $ 338 $ 1,497 $ 1,094 $ 306 $ 1,400 Peripheral Intervention 1,029 904 1,933 1,016 849 1,865 960 799 1,759 Urology and Critical Care 1,236 319 1,554 1,073 301 1,374 986 319 1,305 Total segment revenues $ 3,394 $ 1,586 $ 4,980 $ 3,247 $ 1,489 $ 4,736 $ 3,040 $ 1,424 $ 4,464 Other (a) $ (6) $ (62) $ (67) $ — $ — $ — $ — $ — $ — Total Company revenues from continuing operations $ 11,663 $ 8,515 $ 20,178 $ 11,113 $ 8,258 $ 19,372 $ 10,722 $ 8,148 $ 18,870 (a) Represents the recognition of accruals resulting from recent developments relating to the Italian government medical device pay back legislation, as well as another legal matter, and which substantially relate to years prior to the current fiscal year. Such amounts were not allocated to the Company’s reportable segments and these matters are further discussed in Note 6. The following tables provide a reconciliation of segment operating income to Income from Continuing Operations before Income Taxes and segment information for both capital expenditures and depreciation and amortization. (Millions of dollars) 2024 2023 2022 Income from Continuing Operations Before Income Taxes Medical (a) (b) $ 2,742 $ 1,967 $ 2,215 Life Sciences 1,595 1,585 1,710 Interventional 1,420 1,217 1,081 Total Segment Operating Income 5,758 4,769 5,006 Integration, restructuring and transaction expense (458) (313) (173) Net interest expense (364) (403) (382) Other unallocated items (c) (2,931) (2,391) (2,668) Total Income from Continuing Operations Before Income Taxes $ 2,005 $ 1,662 $ 1,783 Capital Expenditures Medical $ 438 $ 563 $ 602 Life Sciences 114 139 213 Interventional 127 138 130 Corporate and All Other 46 35 28 Total Capital Expenditures $ 725 $ 874 $ 973 Depreciation and Amortization Medical $ 1,216 $ 1,199 $ 1,144 Life Sciences 272 277 283 Interventional 786 799 789 Corporate and All Other 13 13 13 Total Depreciation and Amortization $ 2,286 $ 2,288 $ 2,229 (a) The amounts in 2024, 2023 and 2022 include charges of $38 million, $653 million and $72 million, respectively, recorded to Cost of products sold, to record or adjust future costs estimated for product remediation efforts. (b) The amount in 2022 includes a charge of $54 million, recorded to Cost of products sold, to write down the carrying value of certain fixed assets in the Pharmaceutical Systems unit. (c) Primarily comprised of foreign exchange, certain general and administrative expenses and share-based compensation expense. The amount in 2024 includes a charge of $175 million to accrue an estimated liability for the SEC investigation, which is further discussed in Note 6. The amount in 2023 includes a pre-tax gain recognized on the Company's sale of its Surgical Instrumentation platform of approximately $268 million, which is further discussed in Note 2. Geographic Information The countries in which the Company has local revenue-generating operations have been combined into the following geographic areas: the United States (including Puerto Rico); EMEA (which includes Europe, the Middle East and Africa); Greater Asia (which includes countries in Greater China, Japan, South Asia, Southeast Asia, Korea, and Australia and New Zealand); and Other, which is comprised of Latin America (which includes Mexico, Central America, the Caribbean and South America) and Canada. Revenues to unaffiliated customers are generally based upon the source of the product shipment. Long-lived assets, which include net property, plant and equipment, are based upon physical location. The table below shows revenues from continuing operations and long-lived assets of continuing operations by geographic area: (Millions of dollars) 2024 2023 2022 Revenues United States $ 11,663 $ 11,113 $ 10,722 EMEA 4,402 4,244 4,043 Greater Asia 2,906 2,913 3,047 Other 1,207 1,102 1,058 $ 20,178 $ 19,372 $ 18,870 Long-Lived Assets United States $ 35,526 $ 35,732 $ 36,617 EMEA 6,706 5,317 5,126 Greater Asia 1,580 1,521 1,528 Other 2,548 1,116 1,079 Corporate 459 418 442 $ 46,818 $ 44,104 $ 44,792

Share-Based Compensation

Share-Based Compensation	12 Months Ended
	Sep. 30, 2024
Share-Based Payment Arrangement [Abstract]
Share-Based Compensation	Share-Based Compensation The Company grants share-based awards under the 2004 Employee and Director Equity-Based Compensation Plan ("2004 Plan"), which provides long-term incentive compensation to employees and directors consisting of: stock appreciation rights ("SARs"), performance-based restricted stock units, time-vested restricted stock units and other stock awards. The fair value of share-based payments is recognized as compensation expense in net income. BD estimates forfeitures based on experience at the time of grant and adjusts expense to reflect actual forfeiture s. The amounts and location of compensation cost relating to share-based payments included in the consolidated statements of income is as follows: (Millions of dollars) 2024 2023 2022 Cost of products sold $ 51 $ 50 $ 46 Selling and administrative expense 156 170 156 Research and development expense 42 41 37 Integration, restructuring and transaction expense — — 1 Total share-based compensation cost $ 249 $ 261 $ 240 Tax benefit associated with share-based compensation costs recognized $ 58 $ 58 $ 55 Total share-based compensation expense includes pre-tax compensation expense included in Income from Discontinued Operations, Net of Tax that was not material in 2022. Stock Appreciation Rights SARs represent the right to receive, upon exercise, shares of common stock having a value equal to the difference between the market price of common stock on the date of exercise and the exercise price on the date of grant. SARs generally vest over a period of four years and have a term of ten years. The fair value of awards was estimated on the date of grant using a lattice-based binomial option valuation model and these valuations were largely based upon the following weighted-average assumptions: 2024 2023 2022 Risk-free interest rate 4.51% 3.78% 1.41% Expected volatility 22.0% 21.0% 22.0% Expected dividend yield 1.59% 1.53% 1.42% Expected life 7.0 years 7.0 years 7.3 years Fair value derived $63.05 $57.80 $49.45 Expected volatility is based upon historical volatility for the Company’s common stock and other factors. The expected life of SARs granted is derived from the output of the lattice-based model, using assumed exercise rates based on historical exercise and termination patterns, and represents the period of time that SARs granted are expected to be outstanding. The risk-free interest rate used is based upon the published U.S. Treasury yield curve in effect at the time of grant for instruments with a similar life. The dividend yield is based upon the most recently declared quarterly dividend as of the grant date. The Company issued 0.1 million shares during 2024 to satisfy the SARs exercised. A summary of SARs outstanding as of September 30, 2024 and changes during the year then ended is as follows: SARs (in Weighted Weighted Aggregate Balance at October 1 4,905 $ 211.47 Granted 597 238.89 Exercised (297) 154.25 Forfeited, canceled or expired (210) 237.09 Balance at September 30 4,995 $ 217.07 5.25 $ 125 Vested and expected to vest at September 30 4,863 216.50 5.17 $ 125 Exercisable at September 30 3,669 $ 209.57 4.18 $ 121 A summary of SARs exercised during 2024, 2023 and 2022 is as follows: (Millions of dollars) 2024 2023 2022 Total intrinsic value of SARs exercised $ 25 $ 126 $ 184 Total fair value of SARs vested $ 31 $ 34 $ 36 Performance-Based and Time-Vested Restricted Stock Units Performance-based restricted stock units cliff vest three years after the date of grant. These units are tied to the Company’s performance against pre-established targets over a performance period of three years. The performance measures for fiscal years 2024, 2023 and 2022 were average annual currency-neutral revenue growth and average annual return on invested capital, with the combined factor subject to adjustment based on the Company's relative total shareholder return (measures the Company’s stock performance during the performance period against that of peer companies). Under the Company’s long-term incentive program, the actual payout under these awards may vary from zero to 200% of an employee’s target payout, based on the Company’s actual performance over the performance period of three years. In fiscal year 2021, the Company also issued additional performance-based time-vested units to certain key executives, a portion of which cliff vested in fiscal year 2024 based on the Company’s performance against average annual growth in the Company’s Adjusted EPS over a performance period of three years. The fair value was based on the market price of the Company’s stock on the date of grant, and compensation cost was adjusted for subsequent changes in the expected outcome of performance-related conditions. Time-vested restricted stock unit awards vest on a graded basis over a period of three years, except for certain key executives of the Company, including the executive officers, for which such units generally vest one year following the employee’s retirement. The related share-based compensation expense is recorded over the requisite service period, which is the vesting period or is based on retirement eligibility. The fair value of all time-vested restricted stock units is based on the market value of the Company’s stock on the date of grant. A summary of restricted stock units outstanding as of September 30, 2024 and changes during the year then ended is as follows: Performance-Based Time-Vested Stock Units (in Weighted Stock Units (in Weighted Balance at October 1 963 $ 226.51 1,716 $ 225.33 Granted 387 223.60 922 231.32 Distributed (145) 212.46 (556) 225.13 Forfeited or canceled (213) 219.15 (390) 231.68 Balance at September 30 991 (a) $ 229.02 1,693 $ 227.20 Expected to vest at September 30 465 (b) $ 229.96 1,549 $ 226.80 (a) Based on 200% of target payout for performance based restricted units and 100% of the performance based time-vested units. (b) Net of expected forfeited units and units in excess of the expected performance payout of 71 thousand and 454 thousand shares, respectively. The weighted average grant date fair value of restricted stock units granted during the years 2024, 2023 and 2022 are as follows: Performance-Based Time-Vested 2024 2023 2022 2024 2023 2022 Weighted average grant date fair value of units granted $ 223.60 $ 227.11 $ 242.39 $ 231.32 $ 231.58 $ 239.39 The total fair value of stock units vested during 2024, 2023 and 2022 was as follows: Performance-Based Time-Vested (Millions of dollars) 2024 2023 2022 2024 2023 2022 Total fair value of units vested $ 45 $ 28 $ 14 $ 179 $ 169 $ 169 At September 30, 2024, the weighted average remaining vesting term of performance-based and time vested restricted stock units is 1.24 and 0.87 years, respectively. Unrecognized Compensation Expense and Other Stock Plans The amount of unrecognized compensation expense for all non-vested share-based awards as of September 30, 2024, is approximately $253 million, which is expected to be recognized over a weighted- average remaining life of approximately 1.8 years. At September 30, 2024, 10.0 million shares were authorized for future grants under the 2004 Plan. The Company has a policy of satisfying share-based payments through either open market purchases or shares held in treasury. At September 30, 2024, the Company has sufficient shares held in treasury to satisfy these payments. As of September 30, 2024, 81 thousand shares were held in trust relative to a Director's Deferral plan, which provides a means to defer director compensation, from time to time, on a deferred stock or cash basis. Also as of September 30, 2024, 200 thousand shares were issuable under a Deferred Compensation Plan that allows certain highly-compensated employees, including executive officers, to defer salary, annual incentive awards and certain equity-based compensation.

Benefit Plans

Benefit Plans	12 Months Ended
	Sep. 30, 2024
Retirement Benefits [Abstract]
Benefit Plans	Benefit Plans The Company has defined benefit pension plans covering certain employees in the United States and in certain international locations. Postretirement healthcare and life insurance benefits provided to qualifying domestic retirees as well as other postretirement benefit plans in international countries are not material. The measurement date used for the Company’s employee benefit plans is September 30. In August 2023, the Company announced that effective September 30, 2024, it would freeze the U.S. Plan, and plan participants, which include legacy Bard U.S. pension plan participants as further discussed below, no longer will accrue benefits under the plan subsequent to this date. Both the legacy BD U.S. pension and legacy Bard U.S. pension plans had already been frozen to prevent new participants effective January 1, 2018 and January 1, 2011, respectively. In fiscal year 2022, the transfer of employees to Embecta in connection with the spin-off triggered remeasurements of some of the Company’s benefit plans. The BD U.S. pension plan was also remeasured upon the merging of this plan with the legacy Bard U.S. pension plan effective January 1, 2022. These remeasurements did not materially impact the Company’s benefit obligation and resulted in adjustments to Accumulated other comprehensive loss . Generally, all components of the Company’s net periodic pension and postretirement benefit costs, aside from service cost, are recorded to Other expense, net on its consolidated statements of income. Certain amounts for termination benefits, curtailments and settlements related to the spin-off of Embecta, were recorded in Income from Discontinued Operations, Net of Tax and were not material. Net pension cost for the years ended September 30 included the following components: Pension Plans (Millions of dollars) 2024 2023 2022 Service cost $ 88 $ 91 $ 134 Interest cost 139 129 77 Expected return on plan assets (150) (141) (187) Amortization of prior service credit (4) (7) (15) Amortization of loss 57 58 61 Curtailments/settlement loss 1 44 73 Net pension cost $ 131 $ 174 $ 143 Net pension cost included in the preceding table that is attributable to international plans $ 28 $ 25 $ 20 The amounts provided above for amortization of prior service credit and amortization of loss represent the reclassifications of prior service credits and net actuarial losses that were recognized in Accumulated other comprehensive income (loss) in prior periods. The Company recognizes pension settlements when payments from the plan exceed the sum of service and interest cost components of net periodic pension cost associated with the plan for the fiscal year. The settlement losses recorded in 2023 and 2022 included lump sum benefit payments primarily associated with the Company’s U.S. pension plan. A curtailment gain was recognized in 2023 related the freeze of the U.S. pension plan. The change in benefit obligation, change in fair value of pension plan assets, funded status and amounts recognized in the Consolidated Balance Sheets for these plans were as follows: Pension Plans (Millions of dollars) 2024 2023 Change in benefit obligation: Beginning obligation $ 2,617 $ 2,634 Service cost 88 91 Interest cost 139 129 Benefits paid (201) (67) Actuarial gain 241 (24) Curtailments/settlements (21) (214) Other, includes translation 51 68 Benefit obligation at September 30 $ 2,913 $ 2,617 Change in fair value of plan assets: Beginning fair value $ 2,129 $ 2,242 Actual return on plan assets 395 33 Employer contribution 200 62 Benefits paid (201) (67) Settlements (21) (200) Other, includes translation 54 59 Plan assets at September 30 $ 2,557 $ 2,129 Funded Status at September 30: Unfunded benefit obligation $ (356) $ (488) Amounts recognized in the Consolidated Balance Other Assets $ 99 $ 81 Salaries, wages and related items (12) (15) Long-term Employee Benefit Obligations (443) (554) Net amount recognized $ (356) $ (488) Amounts recognized in Accumulated other Prior service credit $ 2 $ 3 Net actuarial loss (636) (689) Net amount recognized $ (634) $ (686) International pension plan assets at fair value included in the preceding table were $880 million and $748 million at September 30, 2024 and 2023, respectively. The international pension plan projected benefit obligations were $992 million and $833 million at September 30, 2024 and 2023, respectively. The benefit obligation associated with postretirement healthcare and life insurance plans provided to qualifying domestic retirees, which was largely recorded to Long-Term Employee Benefit Obligations, was $94 million and $92 million at September 30, 2024 and 2023, respectively. Pension plans with accumulated benefit obligations in excess of plan assets and plans with projected benefit obligations in excess of plan assets consist of the following at September 30: Accumulated Benefit Projected Benefit (Millions of dollars) 2024 2023 2024 2023 Projected benefit obligation $ 2,382 $ 2,140 $ 2,382 $ 2,159 Accumulated benefit obligation $ 2,318 $ 2,088 Fair value of plan assets $ 1,927 $ 1,575 $ 1,927 $ 1,591 The weighted average assumptions used in determining pension plan information were as follows: 2024 2023 2022 Net Cost Discount rate: U.S. plans (a) 6.01 % 5.62 % 2.89 % International plans 4.52 4.26 1.75 Expected return on plan assets: U.S. plans 7.29 7.25 6.25 International plans 5.30 5.02 4.84 Rate of compensation increase: U.S. plans 4.00 4.51 4.31 International plans 2.81 2.86 2.63 Cash balance plan interest crediting rate: U.S. plans 4.00 4.00 4.00 International plans 2.16 1.98 2.02 Benefit Obligation Discount rate: U.S. plans 4.98 6.01 5.62 International plans 3.88 4.62 4.26 Rate of compensation increase: U.S. plans 4.00 4.00 4.51 International plans 2.81 2.86 2.86 Cash balance plan interest crediting rate: U.S. plans 4.00 4.00 4.00 International plans 2.21 2.21 1.98 (a) The Company calculated the service and interest components utilizing an approach that discounts the individual expected cash flows using the applicable spot rates derived from the yield curve over the projected cash flow period. Expected Rate of Return on Plan Assets The expected rate of return on plan assets is based upon expectations of long-term average rates of return to be achieved by the underlying investment portfolios. In establishing this assumption, the Company considers many factors, including historical assumptions compared with actual results; benchmark data; expected returns on various plan asset classes, as well as current and expected asset allocations. Expected Funding The Company’s funding policy for its defined benefit pension plans is to contribute amounts sufficient to meet legal funding requirements, plus any additional amounts that may be appropriate considering the funded status of the plans, tax consequences, the cash flow generated by the Company and other factors. The Company made a discretionary contribution to its BD U.S. pension plan of $150 million during fiscal year 2024. The Company did not make any required contributions in 2024 and does not anticipate any significant required contributions to its pension plans in fiscal year 2025. Expected benefit payments are as follows: (Millions of dollars) Pension 2025 $ 238 2026 239 2027 221 2028 216 2029 212 2030-2034 1,008 Expected benefit payments associated with postretirement healthcare plans are immaterial to the Company's consolidated financial results. Investments The Company’s primary objective is to achieve returns sufficient to meet future benefit obligations. It seeks to generate above market returns by investing in more volatile asset classes such as equities while at the same time controlling risk through diversification in non-correlated asset classes and through allocations to more stable asset classes like fixed income. U.S. Plans The Company’s U.S. pension plans comprise 66% of total benefit plan investments, based on September 30, 2024 market values, and have a target asset mix of 45% fixed income, 21% diversifying investments and 34% equities. This mix was established based on an analysis of projected benefit payments and estimates of long-term returns, volatilities and correlations for various asset classes. The asset allocations to diversifying investments include high-yield bonds, hedge funds, real estate, infrastructure, leveraged loans and emerging markets bonds. The actual portfolio investment mix may, from time to time, deviate from the established target mix due to various factors such as normal market fluctuations, the reliance on estimates in connection with the determination of allocations and normal portfolio activity such as additions and withdrawals. Rebalancing of the asset portfolio on a quarterly basis is required to address any allocations that deviate from the established target allocations in excess of defined allowable ranges. The target allocations are subject to periodic review, including a review of the asset portfolio’s performance, by the named fiduciary of the plans. Any tactical deviations from the established asset mix require the approval of the named fiduciary. The U.S. plans may enter into both exchange traded and non-exchange traded derivative transactions in order to manage interest rate exposure, volatility, term structure of interest rates, and sector and currency exposures within the fixed income portfolios. The Company has established minimum credit quality standards for counterparties in such transactions. The following table provides the fair value measurements of U.S. plan assets, as well as the measurement techniques and inputs utilized to measure fair value of these assets, at September 30, 2024 and 2023. The categorization of fund investments is based upon the categorization of these funds’ underlying assets. Basis of fair value measurement (See Note 1) (Millions of dollars) Total U.S. Investments Measured at Net Asset Value (a) Level 1 Level 2 Level 3 2024 2023 2024 2023 2024 2023 2024 2023 2024 2023 Fixed Income: Corporate bonds $ 518 $ 443 $ — $ — $ 296 $ 260 $ 222 $ 182 $ — $ — Government and agency-U.S. 159 53 — — 149 43 10 10 — — Government and agency-Foreign 31 17 — — — — 31 17 — — Other fixed income 53 46 — — 25 24 28 22 — — Equity securities 582 469 71 59 512 410 — — — — Cash and cash equivalents 172 202 — — 172 202 — — — — Other 162 151 75 79 87 72 — — — — Fair value of plan assets $ 1,676 $ 1,382 $ 146 $ 138 $ 1,240 $ 1,012 $ 291 $ 231 $ — $ — (a) As per applicable disclosure requirements, certain investments that were measured at net asset value per share or its equivalent have not been categorized within the fair value hierarchy. Values of such assets are based on the corroborated net asset value provided by the fund administrator. Fixed Income Securities U.S. pension plan assets categorized above as fixed income securities include fund investments comprised of corporate and government and agency investments. Investments in corporate bonds are diversified across industry and sector and consist of investment-grade, as well as high-yield debt instruments. U.S. government investments consist of obligations of the U.S. Treasury, other U.S. government agencies, state governments and local municipalities. Assets categorized as foreign government and agency debt securities included investments in developed and emerging markets. The values of fixed income investments classified within Level 1 are based on the closing price reported on the major market on which the investments are traded. A portion of the fixed income instruments classified within Level 2 are valued based upon estimated prices from independent vendors’ pricing models and these prices are derived from market observable sources including: benchmark yields, reported trades, broker/dealer quotes, issuer spreads, benchmark securities, bids, offers and other market-related data. Equity Securities U.S. pension plan assets categorized as equity securities consist of fund investments in publicly-traded U.S. and non-U.S. equity securities. In order to achieve appropriate diversification, these portfolios are invested across market sectors, investment styles, capitalization weights and geographic regions. The values of equity securities classified within Level 1 are based on the closing price reported on the major market on which the investments are traded or have a readily determinable fair value based on published prices obtained from fund managers which represent the price at which the instruments can be redeemed at period end. The U.S. pension plan has no future funding commitments associated with these investments and has the right to redeem them upon one day’s notice, at any time and without restriction. Cash and Cash Equivalents A portion of the U.S. plans’ assets consists of investments in cash and cash equivalents, primarily to accommodate liquidity requirements relating to trade settlement and benefit payment activity, and the values of these assets are based upon quoted market prices. Other Securities Other U.S. pension plan assets include fund investments comprised of hedge funds. The values of such instruments classified within Level 1 are based on the closing price reported on the major market on which the investments are traded. International Plans International plan assets comprise 34% of the Company’s total benefit plan assets, based on market value at September 30, 2024. Such plans have local independent fiduciary committees, with responsibility for development and oversight of investment policy, including asset allocation decisions. In making such decisions, consideration is given to local regulations, investment practices and funding rules. The following table provides the fair value measurements of international plan assets, as well as the measurement techniques and inputs utilized to measure fair value of these assets, at September 30, 2024 and 2023. Basis of fair value measurement (See Note 1) (Millions of dollars) Total International Level 1 Level 2 Level 3 (a) 2024 2023 2024 2023 2024 2023 2024 2023 Fixed Income: Corporate bonds $ 114 $ 122 $ 92 $ 100 $ 9 $ 10 $ 13 $ 12 Government and agency-U.S. 9 9 7 8 2 2 — — Government and agency-Foreign 223 197 188 165 28 26 7 6 Other fixed income 52 43 44 34 9 9 — — Equity securities 196 173 166 147 — 1 30 25 Cash and cash equivalents 13 10 11 8 — — 2 2 Real estate 44 36 1 1 34 26 9 9 Insurance contracts 113 103 — — — — 113 103 Other 117 55 92 35 3 1 22 19 Fair value of plan assets $ 880 $ 748 $ 600 $ 499 $ 85 $ 74 $ 195 $ 175 (a) Changes in the fair value of international pension assets measured using Level 3 inputs for the years ended September 30, 2024 and 2023 were immaterial. Fixed Income Securities Fixed income investments held by international pension plans include corporate, U.S. government and non-U.S. government securities. The values of fixed income securities classified within Level 1 are based on the closing price reported on the major market on which the investments are traded. Values of investments classified within Level 2 are based upon estimated prices from independent vendors’ pricing models and these prices are derived from market observable sources. Equity Securities Equity securities included in the international plan assets consist of publicly-traded U.S. and non-U.S. equity securities. The values of equity securities classified within Level 1 are based on the closing price reported on the major market on which the investments are traded or have a readily determinable fair value based on published prices obtained from fund managers which represent the price at which the instruments can be redeemed at period end. The international plans holding these securities have no future funding commitments associated with these investments and have the right to redeem them upon one day’s notice, at any time and without restriction. Other Securities The international plans hold a portion of assets in cash and cash equivalents, in order to accommodate liquidity requirements and the values are based upon quoted market prices. Real estate investments consist of investments in funds holding an interest in real properties and the corresponding values represent the estimated fair value based on the fair value of the underlying investment value or cost, adjusted for any accumulated earnings or losses. The values of insurance contracts approximately represent cash surrender value. Other investments include fund investments for which values are based upon either quoted market prices or market observable sources. Defined Contribution Plans The cost of voluntary defined contribution plans which provide for a Company match or contribution was $195 million in 2024, $156 million in 2023 and $178 million in 2022.

Acquisitions

Acquisitions	12 Months Ended
	Sep. 30, 2024
Business Combinations [Abstract]
Acquisitions	Acquisitions Edwards Lifesciences’ Critical Care Product Group On September 3, 2024, the Company completed its acquisition of Edwards Lifesciences’ Critical Care product group (“Critical Care”), which was renamed as BD Advanced Patient Monitoring (“Advanced Patient Monitoring”). Since the acquisition date, financial results for Advanced Patient Monitoring’s product offerings are being reported as a separate organizational unit within the Medical segment. Advanced Patient Monitoring is a global leader in advanced monitoring solutions that expands the Company’s portfolio of smart connected care solutions with its growing set of leading monitoring technologies, advanced AI-enabled clinical decision tools and robust innovation pipeline that complement the Company's existing technologies serving operating rooms and intensive care units. The Company funded the transaction with cash on hand, using net proceeds raised through debt issuances in the third quarter of fiscal year 2024, as further discussed in Note 16, and borrowings under its commercial paper program. The acquisition was accounted for under the acquisition method of accounting for business combinations. The Company is in the process of finalizing the allocation of the purchase price to the individual assets acquired and liabilities assumed, related to assessing certain assumptions underlying the valuation of intangible assets. The preliminary allocations of the purchase price provide a reasonable basis for estimating the fair values of assets acquired and liabilities assumed. These provisional estimates may be adjusted upon the availability of further information regarding events or circumstances that existed at the acquisition date. Such adjustments may be significant. The fair value of consideration transferred in connection with the acquisition was $3.911 billion, and the assets acquired and the liabilities assumed resulted in the recognition of developed technology intangible assets of $714 million, customer relationships intangible assets of $650 million and $714 million of other net assets, which are primarily inventory. The goodwill recorded from the excess of the purchase price over the fair value of the acquired net assets was $1.833 billion, which related to synergies expected to be gained from combining operations of the acquiree and acquirer, as well as revenue and cash flow projections associated with future innovative technologies expected to occur. The preliminary estimate of the goodwill that is expected to be deductible for tax purposes is approximately $1.1 billion. The Company included Advanced Patient Monitoring in its consolidated results of operations beginning on September 3, 2024. The Company’s unaudited pro forma Revenues for fiscal years 2024 and 2023, giving effect as if Advanced Patient Monitoring had been acquired as of October 1, 2022, were $21.069 billion and $20.258 billion, respectively. The calculation of pro forma Net Income for fiscal years 2024 and 2023 is not practicable because of complexities associated with its hypothetical calculation. Parata On July 18, 2022, the Company completed the acquisition of Parata Systems (“Parata”), an innovative provider of pharmacy automation solutions. The fair value of consideration transferred was $1.548 billion. Since the acquisition date, financial results for Parata's product offerings are being reported within results for the Medical segment’s Medication Management Solutions unit. The acquisition was accounted for under the acquisition method of accounting for business combinations. The fair value of the assets acquired and the liabilities assumed resulted in the recognition of developed technology intangible assets of $628 million, customer relationships intangible asset of $161 million, and $1 million of other net liabilities. The goodwill recorded from the excess of the purchase price over the fair value of the acquired net assets was $759 million, which related to synergies expected to be gained from leveraging the existing presence of the Company’s sales and marketing teams in pharmacies and acute care facilities, the broader coverage of the Company’s legacy sales and marketing teams, and revenue and cash flow projections associated with future technologies. A portion of the goodwill is deductible for tax purposes. In addition to the Parata acquisition discussed above, the Company completed various other acquisitions during fiscal year 2022 which were not material individually or in the aggregate, including Parata.

Business Restructuring Charges

Business Restructuring Charges	12 Months Ended
	Sep. 30, 2024
Restructuring and Related Activities [Abstract]
Business Restructuring Charges	Business Restructuring Charges The Company incurred restructuring costs, primarily in connection with the Company's simplification and other cost saving initiatives that are part of its strategic objectives, which were largely recorded within Integration, restructuring and transaction expense on its consolidated statements of income. These simplification and other costs saving initiatives are focused on reducing complexity, enhancing product quality, refining customer experience, and improving cost efficiency across all of the Company’s segments. Restructuring liability activity in 2024, 2023 and 2022 was as follows: (Millions of dollars) Employee Termination Other (a) Total Balance at September 30, 2021 $ 14 $ 5 $ 19 Charged to expense 21 103 123 Cash payments (11) (71) (82) Non-cash settlements — (25) (25) Other adjustments — (1) (1) Balance at September 30, 2022 $ 24 $ 11 $ 35 Charged to expense 117 122 239 Cash payments (62) (103) (165) Non-cash settlements — (30) (30) Other adjustments — 1 1 Balance at September 30, 2023 $ 79 $ 1 $ 80 Charged to expense 80 307 387 Cash payments (103) (202) (305) Non-cash settlements — (104) (104) Other adjustments 2 — 2 Balance at September 30, 2024 $ 58 $ 2 $ 60 (a) Other non-employee-related expenses primarily relate to other costs associated with the execution of the Company’s cost efficiency and restructuring programs, such as incremental project management costs, facility exit costs, inventory write-offs and long-lived asset impairments and disposals, which are discussed further in Note 15.

Intangible Assets

Intangible Assets	12 Months Ended
	Sep. 30, 2024
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets	Intangible Assets Intangible assets at September 30 consisted of: 2024 2023 (Millions of dollars) Gross Accumulated Net Carrying Amount Gross Accumulated Net Carrying Amount Amortized intangible assets Developed technology $ 15,827 $ (8,094) $ 7,733 $ 15,080 $ (7,023) $ 8,058 Customer relationships 5,513 (2,878) 2,635 4,859 (2,521) 2,338 Patents, trademarks and other 1,185 (682) 503 1,130 (624) 505 Amortized intangible assets $ 22,525 $ (11,654) $ 10,871 $ 21,069 $ (10,168) $ 10,901 Unamortized intangible assets Acquired in-process research and development $ 44 $ 44 Trademarks 2 2 Unamortized intangible assets $ 46 $ 46 Intangible amortization expense was $1.468 billion, $1.465 billion and $1.430 billion in 2024, 2023 and 2022, respectively. The estimated aggregate amortization expense for the fiscal years ending September 30, 2025 to 2029 are as follows: 2025 — $1.551 billion; 2026 — $1.519 billion; 2027 — $1.450 billion; 2028 — $1.357 billion; 2029 — $1.264 billion. The following is a reconciliation of goodwill by business segment: (Millions of dollars) Medical Life Sciences Interventional Total Goodwill as of September 30, 2022 $ 10,909 $ 888 $ 12,824 $ 24,621 Divestitures and related adjustments (a) — — (218) (218) Purchase price allocation adjustments (b) 13 — — 13 Currency translation 33 9 64 105 Goodwill as of September 30, 2023 $ 10,955 $ 897 $ 12,670 $ 24,522 Acquisitions (c) 1,833 — — 1,833 Currency translation 43 7 59 109 Goodwill as of September 30, 2024 $ 12,832 $ 904 $ 12,729 $ 26,465 (a) Represents goodwill derecognized upon the Company’s sale of its Surgical Instrumentation platform, as further discussed in Note 2. (b) The purchase price allocation adjustments were primarily driven by an adjustment to tax-related balances recorded upon the finalization of the Parata acquisition allocation within one year of the transaction's closing. (c) Represents goodwill recognized in the Medical segment upon the Company's acquisition of Advanced Patient Monitoring, which is further discussed in Note 11.

Derivative Instruments and Hedg

Derivative Instruments and Hedging Activities	12 Months Ended
	Sep. 30, 2024
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative Instruments and Hedging Activities	Derivative Instruments and Hedging Activities The Company uses derivative instruments to mitigate certain exposures. The Company does not enter into derivative financial instruments for trading or speculative purposes. The effects these derivative instruments and hedged items had on the Company’s balance sheets and the fair values of the derivatives outstanding at September 30, 2024 and 2023 were not material. The effects on the Company’s financial performance and cash flows are provided below. Foreign Currency Risks and Related Strategies The Company has foreign currency exposures throughout Europe, Greater Asia, Canada and Latin America. Transactional currency exposures that arise from entering into transactions, generally on an intercompany basis, in non-hyperinflationary countries that are denominated in currencies other than the functional currency are mitigated primarily through the use of forward contracts. In order to mitigate transactional foreign currency exposures resulting from anticipated intercompany purchases and sales denominated in a currency other than local functional currencies, the Company has hedged a portion of this currency risk with certain instruments such as foreign exchange forward and option contracts, which are designated as cash flow hedges. In order to mitigate foreign currency exposure relating to its investments in certain foreign subsidiaries, the Company has hedged the currency risk associated with those investments with certain instruments such as foreign currency-denominated debt and cross-currency swaps, which are designated as net investment hedges, as well as currency exchange contracts. The notional amounts of the Company’s foreign currency-related derivative instruments as of September 30, 2024 and 2023 were as follows: (Millions of dollars) Hedge Designation 2024 2023 Foreign exchange contracts (a) Undesignated $ 4,521 $ 3,146 Foreign exchange contracts (b) Cash flow hedges 543 — Foreign currency-denominated debt (c) Net investment hedges 3,065 1,056 Cross-currency swaps (d) Net investment hedges 1,366 2,119 (a) Represents hedges of transactional foreign exchange exposures resulting primarily from intercompany payables and receivables. Gains and losses on these instruments are recognized immediately in income. These gains and losses are largely offset by gains and losses on the underlying hedged items, as well as the hedging costs associated with the derivative instruments. Net amounts recognized in Other expense, net , during the years ending September 30, 2024, 2023 and 2022 are detailed in Note 19. (b) Represents foreign exchange contracts that the Company entered into in fiscal year 2024 related to anticipated intercompany purchases and sales, described above, which generally have durations of less than eighteen months. (c) Represents foreign currency-denominated long-term notes outstanding, which were effective as economic hedges of net investments in certain of the Company's foreign subsidiaries. (d) Represents cross-currency swaps, which were effective as economic hedges of net investments in certain of the Company's foreign subsidiaries. Net gains or losses resulting from the change in fair value of the foreign exchange contracts designated as cash flow hedges are initially recorded within Other comprehensive income (loss) and reclassified into earnings upon the occurrence of the related underlying third-party transaction. If foreign exchange contracts designated as cash flow hedges are terminated prematurely as a result of the hedged transaction being probable of not occurring, the balance in Accumulated other comprehensive income (loss) attributable to those derivatives is immediately reclassified into Revenues or Cost of products sold (depending on whether the hedged item is an intercompany sale or purchase). Net after tax losses recognized in Other comprehensive income (loss) during 2024 were immaterial and no amounts were reclassified from Accumulated other comprehensive income (loss) relating to these cash flow hedges during 2024. The amounts expected to be reclassified from accumulated other comprehensive income into earnings within the next 12 months, are not material to the Company's consolidated financial results. Net gains or losses relating to the net investment hedges, which are attributable to changes in the foreign currencies to U.S. dollar spot exchange rates, are recorded as accumulated foreign currency translation in Other comprehensive income (loss) . Upon the termination of a net investment hedge, any net gain or loss included in Accumulated other comprehensive income (loss) relative to the investment hedge remains until the foreign subsidiary investment is disposed of or is substantially liquidated. Net (losses) gains recorded to Accumulated other comprehensive income (loss) relating to the Company's net investment hedges as of September 30, 2024, 2023 and 2022 were as follows: (Millions of dollars) 2024 2023 2022 Foreign currency-denominated debt (96) (155) 320 Cross-currency swaps (a) (71) (70) 173 (a) The amounts in 2024, 2023 and 2022 include net of tax gains recognized on terminated cross-currency swaps of $9 million, $13 million and $46 million, respectively . Interest Rate Risks and Related Strategies The Company uses a mix of fixed and variable rate debt, which is further discussed in Note 16, to manage its interest rate exposure, and periodically uses interest rate swaps to manage such exposures. Under these interest rate swaps, the Company exchanges, at specified intervals, the difference between fixed and floating interest amounts calculated by reference to an agreed-upon notional principal amount. These swaps are designated as either cash flow or fair value hedges. Changes in the fair value of the interest rate swaps designated as cash flow hedges (i.e., hedging the exposure to variability in expected future cash flows that is attributable to a particular risk) are recorded in Other comprehensive income (loss) . If interest rate derivatives designated as cash flow hedges are terminated, the balance in Accumulated other comprehensive income (loss) attributable to those derivatives is reclassified into earnings, within Interest expense , over the remaining life of the hedged debt. The amounts reclassified from accumulated other comprehensive income relating to cash flow hedges during 2024, 2023 and 2022, as well as the amounts expected to be reclassified within the next 12 months, are not material to the Company's consolidated financial results. Net after-tax (losses) gains were recorded in Other comprehensive income (loss) relating to interest rate cash flow hedges of $(10) million, $23 million and $92 million in fiscal years 2024, 2023 and 2022, respectively. The amounts recorded during 2024 and 2022 included net after-tax gains of $67 million and $41 million, respectively, that were realized upon the Company’s termination of forward starting interest rate swaps. For interest rate swaps designated as fair value hedges (i.e., hedges against the exposure to changes in the fair value of an asset or a liability or an identified portion thereof that is attributable to a particular risk), changes in the fair value of the interest rate swaps offset changes in the fair value of the fixed rate debt due to changes in market interest rates. Amounts recorded during the years ended September 30, 2024 and 2023 were immaterial to the Company's consolidated financial results. The notional amounts of the Company’s interest rate-related derivative instruments as of September 30, 2024 and 2023 were as follows: (Millions of dollars) Hedge Designation 2024 2023 Interest rate swaps (a) Fair value hedges $ 700 $ 700 Forward starting interest rate swaps (b) Cash flow hedges — 500 (a) Represents fixed-to-floating interest rate swap agreements the Company entered into to convert the interest payments on certain long-term notes from the fixed rate to a floating interest rate based on secured overnight financing rates ("SOFR"). (b) Represents interest rate derivatives entered into to mitigate exposure to interest rate risk related to future debt issuances. Other Risk Exposures The Company purchases resins, which are oil-based components used in the manufacture of certain products. Significant increases in world oil prices that lead to increases in resin purchase costs could impact future operating results. From time to time, the Company has managed price risks associated with these commodity purchases through commodity derivative forward contracts. The Company’s commodity derivative forward contracts at September 30, 2024 and 2023 were immaterial to the Company's consolidated financial results.

Financial Instruments and Fair

Financial Instruments and Fair Value Measurements	12 Months Ended
	Sep. 30, 2024
Fair Value Disclosures [Abstract]
Financial Instruments and Fair Value Measurements	Financial Instruments and Fair Value Measurements The following reconciles cash and equivalents and restricted cash reported within the Company's consolidated balance sheets at September 30, 2024 and 2023 to the total of these amounts shown on the Company's consolidated statements of cash flows: (Millions of dollars) 2024 2023 Cash and equivalents $ 1,717 $ 1,416 Restricted cash 139 65 Cash and equivalents and restricted cash $ 1,856 $ 1,481 The fair values of the Company’s financial instruments are as follows: (Millions of dollars) Basis of fair value measurement (See Note 1) 2024 2023 Institutional money market accounts (a) Level 1 $ 285 $ 373 Current portion of long-term debt (b) Level 2 1,748 1,122 Long-term debt (b) Level 2 17,199 12,850 (a) These financial instruments are recorded within Cash and equivalents on the consolidated balance sheets. The institutional money market accounts permit daily redemption. (b) Long-term debt is recorded at amortized cost. The fair value of long-term debt is measured based upon quoted prices in active markets for similar instruments. Short-term investments are held to their maturities and are carried at cost, which approximates fair value. The short-term investments primarily consist of time deposits with maturities greater than three months and less than one year. All other instruments measured by the Company at fair value, including derivatives, contingent consideration liabilities and available-for-sale debt securities, are immaterial to the Company's consolidated balance sheets. Nonrecurring Fair Value Measurements In fiscal year 2024, the Company recorded non-cash asset impairment charges of $83 million to Integration, restructuring and transaction expense to write down the carrying value of certain fixed assets. In fiscal year 2022, the Company recorded non-cash asset impairment charges of $11 million to Cost of products sold in the Life Sciences segment, $19 million to Integration, restructuring and transaction expense in the Medical segment and $54 million to Cost of products sold in the Medical segment to write down the carrying value of certain fixed assets. The amounts recognized were recorded to adjust the carrying amount of assets to the assets' fair values, which were generally estimated, based upon a market participant's perspective, using Level 3 measurements, including values estimated using the income approach. Concentration of Credit Risk The Company maintains cash deposits in excess of government-provided insurance limits. Such cash deposits are exposed to loss in the event of nonperformance by financial institutions. Substantially all of the Company’s trade receivables are due from public and private entities involved in the healthcare industry. Due to the large size and diversity of the Company’s customer base, concentrations of credit risk with respect to trade receivables are limited. The Company does not normally require collateral. The Company is exposed to credit loss in the event of nonperformance by financial institutions with which it conducts business. However, this loss is limited to the amounts, if any, by which the obligations of the counterparty to the financial instrument contract exceed the obligations of the Company. The Company also minimizes exposure to credit risk by dealing with a diversified group of major financial institutions. The Company continually evaluates its accounts receivables for potential collection risks, particularly those resulting from sales to government-owned or government-supported healthcare facilities in certain countries, as payment may be dependent upon the financial stability and creditworthiness of those countries’ national economies. The Company continually evaluates all governmental receivables for potential collection risks associated with the availability of government funding and reimbursement practices. The Company believes the current reserves related to all governmental receivables are adequate and that this concentration of credit risk will not have a material adverse impact on its financial position or liquidity. Transfers of trade receivables Over the normal course of its business activities, the Company transfers certain trade receivable assets to third parties under factoring agreements. Per the terms of these agreements, the Company surrenders control over its trade receivables upon transfer. Accordingly, the Company accounts for the transfers as sales of trade receivables by recognizing an increase to Cash and equivalents and a decrease to Trade receivables, net when proceeds from the transactions are received. The costs incurred by the Company in connection with factoring activities were not material to its consolidated financial results. The amounts transferred and yet to be remitted under factoring arrangements are provided below. (Millions of dollars) 2024 2023 2022 Trade receivables transferred to third parties under factoring arrangements $ 1,385 $ 2,615 $ 1,215 (Millions of dollars) 2024 2023 Amounts yet to be collected and remitted to the third parties 254 357 Supplier Finance Programs The Company has agreements where participating suppliers are provided the ability to receive early payment of the Company’s obligations at a nominal discount through supplier finance programs entered into with third party financial institutions. The Company is not a party to these arrangements, and these programs do not impact the Company’s obligations or affect the Company’s payment terms, which generally range from 90 to 150 days. The agreements with the financial institutions do not require the Company to provide assets pledged as security or other forms of guarantees for the supplier finance programs. The Company had $112 million and $94 million of outstanding payables related to supplier finance programs as of September 30, 2024 and 2023, respectively, which were recorded within Accounts payable on the Company's consolidated balance sheets.

Debt

Debt	12 Months Ended
	Sep. 30, 2024
Debt Disclosure [Abstract]
Debt	Debt Current debt obligations The carrying value of Current debt obligations , net of unamortized debt issuance costs, at September 30 consisted of: (Millions of dollars) 2024 2023 Commercial paper borrowings $ 400 $ — Current portion of long-term debt 3.875% Notes due May 15, 2024 (a) — 144 3.363% Notes due June 6, 2024 (a) — 997 3.734% Notes due December 15, 2024 875 — 3.020% Notes due May 24, 2025 335 — 0.034% Notes due August 13, 2025 559 — Other 1 — Total current debt obligations $ 2,170 $ 1,141 (a) All of the aggregate principal amount outstanding was retired upon maturity during 2024, as further discussed below. The weighted average interest rates for current debt obligations were 2.91% and 3.43% at September 30, 2024 and 2023, respectively. From time to time, the Company may access the commercial paper market as it manages working capital over the normal course of its business activities. The Company’s U.S. and multicurrency euro commercial paper programs provide for a maximum amount of unsecured borrowings under the two programs, in aggregate, of $2.750 billion. Proceeds from these programs may be used for working capital purposes and general corporate purposes, which may include acquisitions, share repurchases and repayments of debt. The Company utilized commercial paper borrowings in the fourth quarter of fiscal year 2024 to partially fund the Advanced Patient Monitoring acquisition, as further discussed in Note 11. There was $400 million of commercial paper borrowings outstanding as of September 30, 2024 and no such borrowings outstanding as of September 30, 2023. Long-term debt The carrying value of Long-Term Debt , net of unamortized debt issuance costs, at September 30 consisted of: (Millions of dollars) 2024 2023 3.734% Notes due December 15, 2024 $ — $ 874 3.020% Notes due May 24, 2025 — 306 0.034% Notes due August 13, 2025 — 528 1.208% Notes due June 4, 2026 671 634 6.700% Notes due December 1, 2026 158 161 1.900% Notes due December 15, 2026 559 528 3.700% Notes due June 6, 2027 1,721 1,719 7.000% Debentures due August 1, 2027 118 119 4.693% Notes due February 13, 2028 797 796 6.700% Debentures due August 1, 2028 115 115 0.334% Notes due August 13, 2028 1,004 949 4.874% Notes due February 8, 2029 (a) 622 — 5.081% Notes due June 7, 2029 (a) 596 — 3.553% Notes due September 13, 2029 891 842 2.823% Notes due May 20, 2030 746 745 3.519% Notes due February 8, 2031 (a) 835 — 1.957% Notes due February 11, 2031 994 993 3.828% Notes due June 7, 2032 (a) 1,113 — 4.298% Notes due August 22, 2032 496 496 5.110% Notes due February 8, 2034 (a) 545 — 1.213% Notes due February 12, 2036 668 631 4.029% Notes due June 7, 2036 (a) 889 — 6.000% Notes due May 15, 2039 121 121 5.000% Notes due November 12, 2040 90 90 1.336% Notes due August 13, 2041 999 945 4.875% Notes due May 15, 2044 244 245 4.685% Notes due December 15, 2044 934 899 4.669% Notes due June 6, 2047 1,460 1,445 3.794% Notes due May 20, 2050 554 554 Other long-term debt 1 2 Total Long-Term Debt $ 17,940 $ 14,738 (a) Represents notes issued during 2024, as further discussed below. The aggregate annual maturities of Long-Term Debt including interest during the fiscal years ending September 30, 2025 to 2029 are as follows: 2025 — $2.824 billion; 2026 — $1.297 billion; 2027 — $3.136 billion; 2028 — $2.434 billion; 2029 — $2.581 billion. Other current credit facilities In July 2024, the Company extended its five-year senior unsecured revolving credit facility in place by one Debt issuances The Company issued the following U.S. dollar-denominated debt during fiscal years 2024 and 2023: Interest rate and maturity Period issued Amount issued (Millions of dollars) Use of proceeds 5.081% Notes due June 7, 2029 Third quarter 2024 $ 600 Funding of the cash consideration and related fees and expenses for the Advanced Patient Monitoring acquisition and for general corporate purposes 4.874% Notes due February 8, 2029 Second quarter 2024 $ 625 Retirement of 3.363% notes due June 6, 2024 and retirement, upon maturity, of 3.734% notes due December 15, 2024 5.110% Notes due February 8, 2034 Second quarter 2024 $ 550 Retirement of 3.363% notes due June 6, 2024 and retirement, upon maturity, of 3.734% notes due December 15, 2024 4.693% notes due February 13, 2028 Second quarter 2023 $ 800 Retirement of 1.401% notes due May 24, 2023 and 0.000% notes due August 13, 2023 The Company issued the following Euro-denominated debt during fiscal year 2024: Interest rate and maturity Period issued Amount issued (Millions of Euros) Amount issued (millions of dollars) Use of proceeds 3.828% Notes due June 7, 2032 Third quarter 2024 € 1,000 $ 1,087 Funding of the cash consideration and related fees and expenses for the Advanced Patient Monitoring acquisition and for general corporate purposes 3.519% Notes due February 8, 2031 Second quarter 2024 € 750 $ 806 Retirement of 3.875% notes due May 15, 2024 and 3.363% notes due June 6, 2024 Also in fiscal years 2024 and 2023, Becton Finance issued Euro-denominated notes, listed below, which are fully and unconditionally guaranteed on a senior unsecured basis by the Company. No other of the Company's subsidiaries provide any guarantees with respect to these notes. The indenture covenants included a limitation on liens and a restriction on sale and leasebacks, change of control and consolidation, merger and sale of assets covenants. These covenants are subject to a number of exceptions, limitations and qualifications. The indenture does not restrict the Company, Becton Finance, or any other of the Company's subsidiaries from incurring additional debt or other liabilities, including additional senior debt. Additionally, the indenture does not restrict Becton Dickinson Euro Finance S.à r.l. and the Company from granting security interests over its assets. The notes issued by Becton Finance included the following: Interest rate and maturity Period issued Amount issued (Millions of Euros) Amount issued (Millions of dollars) Use of proceeds 4.029% Notes due June 7, 2036 Third quarter 2024 € 800 $ 869 Funding of the cash consideration and related fees and expenses for the Advanced Patient Monitoring acquisition and for general corporate purposes 3.553% notes due September 13, 2029 Second quarter 2023 € 800 $ 868 Retirement of 0.632% notes due June 4, 2023 Debt retirements The Company’s retirements of debt upon maturity in fiscal years 2024 and 2023 included the following: Principal, interest rate and maturity Period of retirement $998 million of 3.363% notes due June 6, 2024 Third quarter 2024 $144 million of 3.875% notes due May 15, 2024 Third quarter 2024 400 million Euros ($439 million) of 0.000% notes due August 13, 2023 Fourth quarter 2023 800 million Euros ($857 million) of 0.632% notes due June 4, 2023 Third quarter 2023 300 million Euros ($325 million) of 1.401% notes due May 24, 2023 Third quarter 2023 500 million Euros ($528 million) of 1.000% notes due December 15, 2022 First quarter 2023 Capitalized interest The Company capitalizes interest costs as a component of the cost of construction in progress. A summary of interest costs and payments for the years ended September 30 is as follows: (Millions of dollars) 2024 2023 2022 Charged to operations $ 528 $ 452 $ 398 Capitalized 57 51 46 Total interest costs $ 584 $ 503 $ 444 Interest paid, net of amounts capitalized $ 473 $ 452 $ 390

Income Taxes

Income Taxes	12 Months Ended
	Sep. 30, 2024
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes Provision for Income Taxes The provision (benefit) for income taxes for the years ended September 30 consisted of: (Millions of dollars) 2024 2023 2022 Current: Federal $ 132 $ 364 $ 17 State and local, including Puerto Rico 17 87 32 Foreign 362 303 228 $ 511 $ 754 $ 277 Deferred: Domestic $ (169) $ (644) $ (96) Foreign (42) 22 (33) (211) (622) (129) Income tax provision $ 300 $ 132 $ 148 The components of Income from Continuing Operations Before Income Taxes for the years ended September 30 consisted of: (Millions of dollars) 2024 2023 2022 Domestic, including Puerto Rico $ 336 $ 358 $ 496 Foreign 1,669 1,304 1,287 Income from Continuing Operations Before Income Taxes $ 2,005 $ 1,662 $ 1,783 Unrecognized Tax Benefits The table below summarizes the gross amounts of unrecognized tax benefits without regard to reduction in tax liabilities or additions to deferred tax assets and liabilities if such unrecognized tax benefits were settled. The Company believes it is reasonably possible that the amount of unrecognized benefits will change during the next twelve months due to one or more of the following events: expiring statutes, audit activity, tax payments, other activity, or final decisions in matters that are the subject of controversy in various taxing jurisdictions in which we operate. However, the Company does not expect changes to have a significant effect on its results of operations, financial condition, or cash flows. (Millions of dollars) 2024 2023 2022 Balance at October 1 $ 269 $ 267 $ 354 Increase due to acquisitions — — 2 Increase due to current year tax positions 22 22 40 Increase due to prior year tax positions — 33 60 Decreases due to prior year tax positions — (29) — Decrease due to settlements with tax authorities (64) (6) (77) Decrease due to lapse of statute of limitations (6) (18) (112) Balance at September 30 $ 221 $ 269 $ 267 Unrecognized tax benefits that would affect the effective tax rate if recognized $ 257 $ 366 $ 348 The following were included for the years ended September 30 as a component of Income tax provision on the consolidated statements of income. (Millions of dollars) 2024 2023 2022 Interest and penalties associated with unrecognized tax benefits $ 42 $ 20 $ (6) The Company conducts business and files tax returns in numerous countries and currently has tax audits in progress in a number of tax jurisdictions. The IRS has completed its audit for the BD legacy fiscal year 2014 and BD combined company fiscal years 2015 and 2017. With regard to legacy CareFusion, which the Company acquired in 2015, and legacy Bard, all pre-acquisition examinations have been completed. The IRS is reviewing BD’s fiscal years 2018 through 2022. For the other major tax jurisdictions where the Company conducts business, tax years are generally open after 2016. Deferred Income Taxes Deferred income taxes at September 30 consisted of: 2024 2023 (Millions of dollars) Assets Liabilities Assets Liabilities Compensation and benefits $ 405 $ — $ 426 $ — Property and equipment — 391 — 405 Intangibles — 1,612 — 1,858 Loss and credit carryforwards 2,946 — 2,352 — Product recall and liability reserves 261 — 362 — Capitalized research and development expenses (a) 364 — 243 — Other 512 64 431 88 4,489 2,067 3,814 2,351 Valuation allowance (2,990) — (2,272) — Net (b) $ 1,498 $ 2,067 $ 1,542 $ 2,351 (a) As required by the 2017 Tax Cuts and Jobs Act, the Company’s research and development expenditures were capitalized and amortized in fiscal year 2024 for income tax purposes. This resulted in an increase in cash tax paid in fiscal year 2024 with a corresponding deferred tax benefit. (b) Net deferred tax assets are included in Other Assets and net deferred tax liabilities are included in Deferred Income Taxes and Other Liabilities on the consolidated balance sheets . Deferred tax assets and liabilities are netted on the balance sheet by separate tax jurisdictions. The Company asserts indefinite reinvestment for all historical unremitted foreign earnings as of September 30, 2024. Deferred taxes have not been provided on undistributed earnings of foreign subsidiaries as of September 30, 2024 since the determination of the total amount of unrecognized deferred tax liability is not practicable. Generally, deferred tax assets have been established as a result of net operating losses and credit carryforwards with expiration dates from 2025 to an unlimited expiration date. Valuation allowances have been established as a result of an evaluation of the uncertainty associated with the realization of certain deferred tax assets on these losses and credit carryforwards. The valuation allowance at September 30, 2024 is primarily the result of foreign losses due to the Company’s global re-organization of its foreign entities and these generally have no expiration date. Valuation allowances are also maintained with respect to deferred tax assets for certain state carryforwards that may not be realized. The net change during the year in the total valuation allowance is attributable to foreign losses and credits. Tax Rate Reconciliation A reconciliation of the federal statutory tax rate to the Company’s effective income tax rate for continuing operations was as follows: 2024 2023 2022 Federal statutory tax rate 21.0 % 21.0 % 21.0 % State and local income taxes, net of federal tax benefit (0.7) (1.0) (1.1) Foreign income tax at rates other than 21% (9.1) (8.2) (7.3) Effect of foreign operations 4.3 (3.9) 5.6 Effect of Research Credits, FDII and Other Credits (a) (22.1) (3.2) (2.2) Effect of share-based compensation (0.3) (0.4) (1.7) Effect of gain on divestitures — 3.2 — Effect of valuation allowance 19.3 — (5.5) Effect of nondeductible costs (b) 2.2 — — Other, net 0.4 0.4 (0.5) Effective income tax rate 15.0 % 7.9 % 8.3 % (a) During fiscal year 2024, the Company was granted non-U.S. tax credits, for which a full valuation allowance was established. (b) Primarily related to the estimated liability recorded as a result of the SEC investigation, as further discussed in Note 6. Tax Holidays and Payments The approximate tax impacts related to tax holidays in various countries in which the Company does business are provided below. The tax holidays expire at various dates through 2039. The Company’s income tax payments, net of refunds are also provided below. (Millions of dollars, except per share amounts) 2024 2023 2022 Tax impact related to tax holidays $ 414 $ 363 $ 284 Impact of tax holiday on diluted earnings per share 1.42 1.26 0.99 Income tax payments, net of refunds 653 629 532

Leases

Leases	12 Months Ended
	Sep. 30, 2024
Leases [Abstract]
Leases	Leases The Company leases real estate, vehicles and other equipment which are used in the Company’s manufacturing, administrative and research and development activities. The Company identifies a contract that contains a lease as one which conveys a right, either explicitly or implicitly, to control the use of an identified asset in exchange for consideration. The Company’s lease arrangements are generally classified as operating leases. These arrangements have remaining terms ranging from less than one year to approximately 25 years and the weighted-average remaining lease term of the Company’s leases is approximately 8.3 years. An option to renew or terminate the current term of a lease arrangement is included in the lease term if the Company is reasonably certain to exercise that option. The Company does not recognize a right-of-use asset and lease liability for short-term leases, which have terms of 12 months or less, on its consolidated balance sheet. For the longer-term lease arrangements that are recognized on the Company’s consolidated balance sheet, the right-of-use asset and lease liability is initially measured at the commencement date based upon the present value of the lease payments due under the lease. These payments represent the combination of the fixed lease and fixed non-lease components that are due under the arrangement. The costs associated with the Company’s short-term leases, as well as variable costs relating to the Company’s lease arrangements, are not material to its consolidated financial results. The implicit interest rates of the Company’s lease arrangements are generally not readily determinable and as such, the Company applies an incremental borrowing rate, which is established based upon the information available at the lease commencement date, to determine the present value of lease payments due under an arrangement. The weighted-average incremental borrowing rate that has been applied to measure the Company’s lease liabilities is 4.4%. The Company’s lease costs recorded in its consolidated statements of income for the years ended September 30, 2024, 2023 and 2022 were $190 million, $145 million and $138 million, respectively. Cash payments arising from the Company’s lease arrangements are reflected on its consolidated statement of cash flows as outflows used for operating activities. The right-of-use assets and lease liabilities recognized on the Company’s consolidated balance sheet as of September 30, 2024 and 2023 were as follows: (Millions of dollars) 2024 2023 Right-of-use assets recorded in Other Assets $ 876 $ 517 Current lease liabilities recorded in Accrued expenses 142 117 Non-current lease liabilities recorded in Deferred Income Taxes and Other Liabilities 667 414 The Company’s payments due under its operating leases are as follows: (Millions of dollars) 2025 $ 174 2026 149 2027 113 2028 86 2029 77 Thereafter 389 Total payments due 988 Less: imputed interest 178 Total $ 809

Supplemental Financial Informat

Supplemental Financial Information	12 Months Ended
	Sep. 30, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Supplemental Financial Information	Supplemental Financial Information Other Expense, Net (Millions of dollars) 2024 2023 2022 Other investment gains (losses), net (a) $ 5 $ (3) $ (35) Deferred compensation 57 32 (46) Net pension and postretirement benefit cost (b) (65) (98) (17) Net foreign exchange losses (c) (47) (36) (28) Impacts of debt extinguishment (d) — — (24) Embecta service agreements income, net (e) 26 59 33 Other (4) — 1 Other expense, net $ (28) $ (46) $ (117) (a) The amounts include gains (losses) recognized relating to certain equity investments. (b) Represents all components of the Company’s net periodic pension and postretirement benefit costs, aside from service cost, including pension settlement expenses of $57 million and $73 million in fiscal years 2023 and 2022, respectively. (c) Represents net gains and losses from transactional foreign exchange exposures, offset by net gains and losses on undesignated foreign exchange derivatives. (d) Represents losses recognized upon the extinguishment of certain senior notes. (e) Consists of net income from transition and logistics service agreements with Embecta following the spin-off of the former diabetes care business in fiscal year 2022, as further discussed in Note 2. Trade Receivables, Net The amounts recognized in 2024, 2023 and 2022 relating to allowances for doubtful accounts and cash discounts, which are netted against trade receivables, are provided in the following table: (Millions of dollars) Allowance for Allowance for Total Balance at September 30, 2021 $ 73 $ 18 $ 91 Additions charged to costs and expenses 4 73 77 Deductions and other (12) (a) (75) (87) Balance at September 30, 2022 $ 65 $ 16 $ 81 Additions charged to costs and expenses 9 100 109 Deductions and other (10) (a) (100) (110) Balance at September 30, 2023 $ 65 $ 16 $ 81 Additions charged to costs and expenses 30 91 121 Deductions and other (30) (a) (93) (124) Balance at September 30, 2024 $ 64 $ 15 $ 79 (a) Accounts written off. Inventories Inventories at September 30 consisted of: (Millions of dollars) 2024 2023 Materials $ 803 $ 714 Work in process 443 381 Finished products 2,597 2,178 $ 3,843 $ 3,273 The Company acquired $666 million of inventories in the Advanced Patient Monditoring transaction, which is further discussed in Note 11. Property, Plant and Equipment, Net Property, Plant and Equipment, Net at September 30 consisted of: (Millions of dollars) 2024 2023 Land $ 129 $ 131 Buildings 3,733 3,537 Machinery, equipment and fixtures 10,197 9,609 Leasehold improvements 320 301 14,378 13,578 Less accumulated depreciation and amortization 7,557 7,021 $ 6,821 $ 6,557

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($) $ in Millions	12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2022
Pay vs Performance Disclosure
Net Income	$ 1,705	$ 1,484	$ 1,779

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended	12 Months Ended
	Sep. 30, 2024 shares	Sep. 30, 2024 shares
Trading Arrangements, by Individual
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false
Michael Garrison [Member]
Trading Arrangements, by Individual
Material Terms of Trading Arrangement	On August 2, 2024, Michael Garrison, Executive Vice President and President, Medical Segment of BD, adopted a trading plan intended to satisfy the conditions under Rule 10b5-1(c) of the Exchange Act. Mr. Garrison’s plan is for (i) the exercise of up to 15,467 stock appreciation rights (“SARs”) at various exercise prices, net of shares withheld to satisfy applicable taxes, (ii) the sale of up to 1,383 shares of BD’s common stock, (iii) the sale of up to 3,640 shares of BD’s common stock upon the vesting of time vested units (“TVUs”), net of shares withheld to satisfy applicable taxes, and (iv) the sale of up to 1,660 shares of BD’s common stock upon the vesting of performance units, subject to the final payout factor and net of shares withheld to satisfy applicable taxes. The foregoing exercises or sales will be made in accordance with the prices and formulas set forth in the plan and such plan terminates on the earlier of the date all the shares under the plan are sold and December 2, 2025.
Name	Michael Garrison
Title	Executive Vice President and President, Medical Segment
Rule 10b5-1 Arrangement Adopted	true
Adoption Date	August 2, 2024
David Shan [Member]
Trading Arrangements, by Individual
Material Terms of Trading Arrangement	On September 5, 2024, David Shan, Executive Vice President and Chief Integrated Supply Chain Officer of BD, adopted a trading plan intended to satisfy the conditions under Rule 10b5-1(c) of the Exchange Act. Mr. Shan’s plan is for (i) the sale of up to 2,000 shares of BD’s common stock and (ii) the sale of up to 2,369 shares of BD’s common stock upon the vesting of TVUs, net of shares withheld to satisfy applicable taxes. The sales will be made in accordance with the prices and formulas set forth in the plan and such plan terminates on the earlier of the date all the shares under the plan are sold and December 5, 2025.
Name	David Shan
Title	Executive Vice President and Chief Integrated Supply Chain Officer
Rule 10b5-1 Arrangement Adopted	true
Adoption Date	September 5, 2024
Shana Neal [Member]
Trading Arrangements, by Individual
Material Terms of Trading Arrangement	On September 6, 2024, Shana Neal, Executive Vice President and Chief People Officer of BD, adopted a trading plan intended to satisfy the conditions under Rule 10b5-1(c) of the Exchange Act. Ms. Neal’s plan is for the sale of up to 2,575 shares of BD’s common stock. The sales will be made in accordance with the prices and formulas set forth in the plan and such plan terminates on the earlier of the date all the shares under the plan are sold and December 6, 2025.
Name	Shana Neal
Title	Executive Vice President and Chief People Officer of BD
Rule 10b5-1 Arrangement Adopted	true
Adoption Date	September 6, 2024
Aggregate Available	2,575	2,575
Roland Goette [Member]
Trading Arrangements, by Individual
Material Terms of Trading Arrangement	On September 6, 2024, Roland Goette, Executive Vice President and President, EMEA of BD, adopted a trading plan intended to satisfy the conditions under Rule 10b5-1(c) of the Exchange Act. Mr. Goette’s plan is for (i) the exercise of up to 13,334 SARs at various exercise prices, net of shares withheld to satisfy applicable taxes and (ii) the sale of up to 1,277 shares of BD’s common stock. The foregoing exercises or sales will be made in accordance with the prices and formulas set forth in the plan and such plan terminates on the earlier of the date all the shares under the plan are sold and December 6, 2025.
Name	Roland Goette
Title	Executive Vice President and President, EMEA
Rule 10b5-1 Arrangement Adopted	true
Adoption Date	September 6, 2024
Michael Garrison Trading Arrangement, Stock Appreciation Rights [Member] | Michael Garrison [Member]
Trading Arrangements, by Individual
Aggregate Available	15,467	15,467
Michael Garrison, Trading Arrangement, Common Stock [Member] | Michael Garrison [Member]
Trading Arrangements, by Individual
Aggregate Available	1,383	1,383
Michael Garrison, Trading Arrangement, Common Stock Upon The Vesting Of Time Vested Units [Member] | Michael Garrison [Member]
Trading Arrangements, by Individual
Aggregate Available	3,640	3,640
Michael Garrison, Trading Arrangement, Common Stock Upon The Vesting Of Performance Units [Member] | Michael Garrison [Member]
Trading Arrangements, by Individual
Aggregate Available	1,660	1,660
David Shan, Trading Arrangement, Common Stock [Member] | David Shan [Member]
Trading Arrangements, by Individual
Aggregate Available	2,000	2,000
David Shan, Trading Arrangement, Common Stock Upon The Vesting Of Time Vested Units [Member] | David Shan [Member]
Trading Arrangements, by Individual
Aggregate Available	2,369	2,369
Roland Goette, Trading Arrangement, Stock Appreciation Rights [Member] | Roland Goette [Member]
Trading Arrangements, by Individual
Aggregate Available	13,334	13,334
Roland Goette, Trading Arrangement, Common Stock [Member] | Roland Goette [Member]
Trading Arrangements, by Individual
Aggregate Available	1,277	1,277
Officer Trading Arrangement [Member] | Michael Garrison [Member]
Trading Arrangements, by Individual
Arrangement Duration		487 days
Officer Trading Arrangement [Member] | David Shan [Member]
Trading Arrangements, by Individual
Arrangement Duration		456 days
Officer Trading Arrangement [Member] | Shana Neal [Member]
Trading Arrangements, by Individual
Arrangement Duration		456 days
Officer Trading Arrangement [Member] | Roland Goette [Member]
Trading Arrangements, by Individual
Arrangement Duration		456 days

Insider Trading Policies and Pr

Insider Trading Policies and Procedures	12 Months Ended
	Sep. 30, 2024
Insider Trading Policies and Procedures [Line Items]
Insider Trading Policies and Procedures Adopted	true

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Sep. 30, 2024
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying Consolidated Financial Statements and Notes to Consolidated Financial Statements of Becton, Dickinson and Company (the "Company" or "BD") have been prepared in accordance with U.S. generally accepted accounting principles ("U.S. GAAP"). Within the financial statements and tables presented, certain columns and rows may not add due to the use of rounded numbers for disclosure purposes. Percentages and earnings per share amounts presented are calculated from the underlying amounts. Our fiscal year ends on September 30. On April 1, 2022, the Company completed the spin-off of its Diabetes Care business as a separate publicly traded company. The historical results of the Diabetes Care business (previously included in BD’s Medical segment) that was contributed to Embecta Corp ("Embecta") in the spin-off were reflected as discontinued operations in the Company’s consolidated financial statements. Additional disclosures regarding the spin-off are provided in Note 2.
Principles of Consolidation	Principles of Consolidation The consolidated financial statements include the Company’s accounts and those of its majority-owned subsidiaries after the elimination of intercompany transactions. The Company has no material interests in variable interest entities.
Cash Equivalents	Cash Equivalents Cash equivalents consist of all highly liquid investments with a maturity of three months or less at time of purchase.
Restricted Cash	Restricted Cash Restricted cash consists of cash restricted from withdrawal and usage and largely represents funds that are restricted for certain product liability matters, which are further discussed in Note 6.
Trade Receivables	Trade Receivables The Company grants credit to customers in the normal course of business and the resulting trade receivables are stated at their net realizable value. The allowance for doubtful accounts represents the Company’s estimate of expected credit losses relating to trade receivables and is determined based on historical experience, current conditions, reasonable and supportable forecasts and other specific account data. Amounts are written off against the allowances for doubtful accounts when the Company determines that a customer account is not collectable.
Inventories	Inventories Inventories are stated at the lower of approximate cost or net realizable value determined on the first-in, first-out basis.
Property, Plant and Equipment	Property, Plant and Equipment Property, plant and equipment are stated at cost, less accumulated depreciation and amortization. Depreciation and amortization are principally provided on the straight-line basis over estimated useful lives, which range from 20 to 45 years for buildings, four one
Goodwill and Other Intangible Assets	Goodwill and Other Intangible Assets The Company’s unamortized intangible assets include goodwill that arises from acquisitions of businesses. The Company reviews goodwill for impairment using quantitative models. Goodwill is reviewed at least annually for impairment at the reporting unit level, which is defined as an operating segment or one level below an operating segment, referred to as a component. The Company’s reporting units represent one level below reporting segments. The Company reviews goodwill for each reporting unit by comparing the fair value of the reporting unit, estimated using an income approach, with its carrying value. The annual impairment review performed on July 1, 2024 indicated that all identified reporting units’ fair values exceeded their respective carrying values. Amortized intangible assets include developed technology assets which arise from acquisitions. These assets represent acquired intellectual property that is already technologically feasible upon the acquisition date or acquired in-process research and development assets that are completed subsequent to acquisition. Developed technology assets are generally amortized over periods ranging from 15 to 20 years, using the straight-line method. Customer relationship assets are generally amortized over periods ranging from 10 to 15 years, using the straight-line method. Other intangibles with finite useful lives, which include patents, are amortized over periods principally ranging from one
Foreign Currency Translation	Foreign Currency Translation Generally, foreign subsidiaries’ functional currency is the local currency of operations and the net assets of foreign operations are translated into U.S. dollars using current exchange rates. The U.S. dollar results that arise from such translation, as well as exchange gains and losses on intercompany balances of a long-term investment nature, are included in the foreign currency translation adjustments in Accumulated other comprehensive income (loss).
Revenue Recognition	Revenue Recognition The Company recognizes revenue from product sales when the customer obtains control of the product, which is generally upon shipment or delivery, depending on the delivery terms specified in the sales agreement. Revenues associated with certain instruments and equipment for which installation is complex, and therefore significantly affects the customer’s ability to use and benefit from the product, are recognized upon customer acceptance of these installed products. Revenue for certain service arrangements, including extended warranty and software maintenance contracts, is recognized ratably over the contract term. When arrangements include multiple performance obligations, the total transaction price of the contract is allocated to each performance obligation based on the estimated relative standalone selling prices of the promised goods or services underlying each performance obligation. Variable consideration such as rebates, sales discounts and sales returns are estimated and treated as a reduction of revenue in the same period the related revenue is recognized. These estimates are based on contractual terms, historical practices, and current trends, and are adjusted as new information becomes available. Revenues exclude any taxes that the Company collects from customers and remits to tax authorities. Equipment lease transactions with customers are evaluated and classified as either operating or sales-type leases. Generally, these arrangements are accounted for as operating leases and therefore, revenue is recognized at the contracted rate over the rental period defined within the customer agreement.
Contingencies	Contingencies In accordance with U.S. GAAP, the Company establishes accruals to the extent future losses are probable and reasonably estimable. With respect to putative class action lawsuits and certain tort actions in the United States and certain of the Canadian lawsuits described below or in our other SEC filings, the Company may not be able to determine if a probable loss exists for the following reasons: (i) all or certain of the proceedings are in early stages; (ii) the Company has not received and reviewed complete information regarding all or certain of the plaintiffs and their medical conditions; and/or (iii) there are significant factual issues to be resolved. In addition, there is uncertainty as to the likelihood of a class being certified or the ultimate size of any class. With respect to certain of the civil investigative demands (“CIDs”) served by the Department of Justice which are discussed below, the Company may not be able to determine if a probable loss exists, unless otherwise noted, for the following reasons: (i) all or certain of the proceedings are in early stages; and/or (ii) there are significant factual and legal issues to be resolved. In view of the uncertainties discussed above, the Company could incur charges in excess of any currently established accruals and, to the extent available, liability insurance. In the opinion of management, any such future charges, individually or in the aggregate, could have a material adverse effect on the Company’s consolidated results of operations, financial condition, and/or consolidated cash flows.
Derivative Financial Instruments	Derivative Financial Instruments
Income Taxes	Income Taxes The Company has reviewed its needs in the United States for possible repatriation of undistributed earnings of its foreign subsidiaries and continues to invest foreign subsidiaries earnings outside of the United States to fund foreign investments or meet foreign working capital and property, plant and equipment expenditure needs. As a result, the Company is permanently reinvested with respect to all of its historical foreign earnings as of September 30, 2024. Deferred taxes are not provided on undistributed earnings of foreign subsidiaries that are indefinitely reinvested. The determination of the amount of the unrecognized deferred tax liability related to the undistributed earnings is not practicable because of the complexities associated with its hypothetical calculation. The Company conducts business and files tax returns in numerous countries and currently has tax audits in progress in a number of tax jurisdictions. In evaluating the exposure associated with various tax filing positions, the Company records accruals for uncertain tax positions based on the technical support for the positions, past audit experience with similar situations, and the potential interest and penalties related to the matters. The Company maintains valuation allowances where it is more likely than not that all or a portion of a deferred tax asset will not be realized. Changes in valuation allowances are included in the tax provision in the period of change. In determining whether a valuation allowance is warranted, management evaluates factors such as prior earnings history, expected future earnings, carryback and carryforward periods and tax strategies that could potentially enhance the likelihood of the realization of a deferred tax asset. Additional disclosures regarding the Company's accounting for income taxes are provided in Note 17. The Tax Cuts and Jobs Act was enacted on December 22, 2017 and subjects a U.S. shareholder to tax on global intangible low-taxed income ("GILTI") earned by certain foreign subsidiaries. The Company has elected to account for its GILTI tax due as a period expense in the year the tax is incurred.
Earnings per Share	Earnings per Share Basic earnings per share are computed by dividing income available to common stockholders by the weighted average number of common shares outstanding. Diluted earnings per share reflect the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock. In computing diluted earnings per share, only potential common shares that are dilutive (i.e., those that reduce earnings per share or increase loss per share) are included in the calculation.
Fair Value Measurements	Fair Value Measurements A fair value hierarchy is applied to prioritize inputs used in measuring fair value. The three levels of inputs used to measure fair value are detailed below. Additional disclosures regarding the Company’s fair value measurements are provided in Notes 10 and 15. Level 1 — Inputs to the valuation methodology which represent unadjusted quoted prices in active markets for identical assets and liabilities. Level 2 — Inputs to the valuation methodology which include: quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; inputs other than quoted prices that are observable for the asset or liability. Level 3 — Inputs to the valuation methodology which are unobservable and significant to the fair value measurement.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions. These estimates or assumptions affect reported assets, liabilities, revenues and expenses as reflected in the consolidated financial statements. Actual results could differ from these estimates.
New Accounting Principle Adopted and New Accounting Principles Not Yet Adopted	Accounting Changes New Accounting Principles Adopted In September 2022, the Financial Accounting Standards Board ("FASB") issued an accounting standard update that requires additional qualitative and quantitative disclosures regarding supplier finance programs. The new disclosure requirements are intended to help investors better consider the effect of these programs on a company's working capital, liquidity, and cash flows. The Company adopted this accounting standard on October 1, 2023, and disclosures regarding the Company’s supplier finance programs are provided in Note 15. On July 1, 2022, the Company early-adopted an accounting standard update issued by the FASB, which requires an entity to apply the provisions of Accounting Standard Codification Topic 606, "Revenue from Contracts with Customers," ("ASC 606") when recognizing and measuring contract assets and contract liabilities acquired in a business combination. The Company’s adoption of this accounting standard update for business combinations that occurred during fiscal year 2022 did not have a material impact on its consolidated financial statements. New Accounting Principles Not Yet Adopted In November 2024, the FASB issued an accounting standard update that requires the Company to disclose more detailed information about the types of expenses (including purchases of inventory, employee compensation, depreciation, amortization, and depletion) included in each relevant income statement expense caption. The update is effective for the Company beginning with its fiscal year 2028 reporting and for interim reporting beginning with its fiscal year 2029. Early adoption is permitted. The Company is currently evaluating the impact that this update will have on its disclosures. In December 2023, the FASB issued an accounting standard update that requires more disaggregated information to be included in the income tax rate reconciliation and income taxes paid annual disclosures. This update is effective for the Company beginning in its fiscal year 2026 and the Company is currently evaluating the impact that this update will have on its disclosures.
Revenue from Contract with Customer	Timing of Revenue Recognition The Company's revenues are primarily recognized when the customer obtains control of the product sold, which is generally upon shipment or delivery, depending on the delivery terms specified in the sales agreement. Revenues associated with certain instruments and equipment for which installation is complex, and therefore significantly affects the customer’s ability to use and benefit from the product, are recognized when customer acceptance of these installed products has been confirmed. For certain service arrangements, including extended warranty and software maintenance contracts, revenue is recognized ratably over the contract term. The majority of revenues relating to extended warranty contracts associated with certain instruments and equipment is generally recognized within a few years whereas deferred revenue relating to software maintenance contracts is generally recognized over a longer period. Measurement of Revenues The Company acts as the principal in substantially all of its customer arrangements and as such, generally records revenues on a gross basis. Revenues exclude any taxes that the Company collects from customers and remits to tax authorities. The Company considers its shipping and handling costs to be costs of contract fulfillment and has made the accounting policy election to record these costs within Selling and administrative expense . Payment terms extended to the Company's customers are based upon commercially reasonable terms for the markets in which the Company's products are sold. Because the Company generally expects to receive payment within one year or less from when control of a product is transferred to the customer, the Company does not generally adjust its revenues for the effects of a financing component. The Company’s allowance for doubtful accounts reflects the current estimate of credit losses expected to be incurred over the life of its trade receivables. Such estimated credit losses are determined based on historical loss experiences, customer-specific credit risk, and reasonable and supportable forward-looking information, such as country or regional risks that are not captured in the historical loss information. Amounts are written off against the allowances for doubtful accounts when the Company determines that a customer account is uncollectable. The allowance for doubtful accounts for trade receivables is not material to the Company's consolidated financial results. The Company's gross revenues are subject to a variety of deductions which are recorded in the same period that the underlying revenues are recognized. Such variable consideration includes rebates, sales discounts and sales returns. Because these deductions represent estimates of the related obligations, judgment is required when determining the impact of these revenue deductions on gross revenues for a reporting period. Rebates provided by the Company are based upon prices determined under the Company's agreements with its end-user customers. Additional factors considered in the estimate of the Company's rebate liability include the quantification of inventory that is either in stock at or in transit to the Company's distributors, as well as the estimated lag time between the sale of product and the payment of corresponding rebates. The Company’s rebate liabilities are classified as an offset to Trade receivables, net , or as Accounts payable or Accrued expenses , depending on the form of settlement and were $749 million and $669 million at September 30, 2024 and 2023, respectively. The impact of other forms of variable consideration, including sales discounts and sales returns, is not material to the Company's revenues. Additional disclosures relating to sales discounts and sales returns are provided in Note 19. The Company's agreements with customers within certain organizational units including Medication Management Solutions, Integrated Diagnostic Solutions and Biosciences, contain multiple performance obligations including both products and certain services noted above. The transaction price for these agreements
Fair Value of Financial Instruments, Policy	Long-term debt is recorded at amortized cost. The fair value of long-term debt is measured based upon quoted prices in active markets for similar instruments.
Concentration of Credit Risk	Concentration of Credit Risk The Company maintains cash deposits in excess of government-provided insurance limits. Such cash deposits are exposed to loss in the event of nonperformance by financial institutions. Substantially all of the Company’s trade receivables are due from public and private entities involved in the healthcare industry. Due to the large size and diversity of the Company’s customer base, concentrations of credit risk with respect to trade receivables are limited. The Company does not normally require collateral. The Company is exposed to credit loss in the event of nonperformance by financial institutions with which it conducts business. However, this loss is limited to the amounts, if any, by which the obligations of the counterparty to the financial instrument contract exceed the obligations of the Company. The Company also minimizes exposure to credit risk by dealing with a diversified group of major financial institutions. The Company continually evaluates its accounts receivables for potential collection risks, particularly those resulting from sales to government-owned or government-supported healthcare facilities in certain countries, as payment may be dependent upon the financial stability and creditworthiness of those countries’ national economies. The Company continually evaluates all governmental receivables for potential collection risks associated with the availability of government funding and reimbursement practices. The Company believes the current reserves related to all governmental receivables are adequate and that this concentration of credit risk will not have a material adverse impact on its financial position or liquidity.
Lessee, Leases	The Company identifies a contract that contains a lease as one which conveys a right, either explicitly or implicitly, to control the use of an identified asset in exchange for consideration. The Company’s lease arrangements are generally classified as operating leases. These arrangements have remaining terms ranging from less than one year to approximately 25 years and the weighted-average remaining lease term of the Company’s leases is approximately 8.3 years. An option to renew or terminate the current term of a lease arrangement is included in the lease term if the Company is reasonably certain to exercise that option.The Company does not recognize a right-of-use asset and lease liability for short-term leases, which have terms of 12 months or less, on its consolidated balance sheet. For the longer-term lease arrangements that are recognized on the Company’s consolidated balance sheet, the right-of-use asset and lease liability is initially measured at the commencement date based upon the present value of the lease payments due under the lease. These payments represent the combination of the fixed lease and fixed non-lease components that are due under the arrangement.
Short-term Leases	The Company does not recognize a right-of-use asset and lease liability for short-term leases, which have terms of 12 months or less, on its consolidated balance sheet.

Divestitures (Tables)

Divestitures (Tables)	12 Months Ended
	Sep. 30, 2024
Discontinued Operations and Disposal Groups [Abstract]
Disposal Groups, Including Discontinued Operations	Details of (Loss) Income from Discontinued Operations, Net of Tax , which represent the historical results of the Diabetes Care business prior to the spin-off date of April 1, 2022, are as follows: Millions of dollars 2022 Revenues $ 538 Cost of products sold 143 Selling and administrative expense 78 Research and development expense 32 Other operating expense, net 95 Total Operating Costs and Expenses 348 Operating Income 190 Interest expense (4) Income from Discontinued Operations Before Income Taxes 186 Income tax provision 42 Income from Discontinued Operations, Net of Tax $ 144

Shareholders' Equity (Tables)

Shareholders' Equity (Tables)	12 Months Ended
	Sep. 30, 2024
Stockholders' Equity Note [Abstract]
Changes in Certain Components of Shareholders' Equity	Changes in certain components of shareholders’ equity were as follows: Common Capital in Retained Deferred Treasury Stock (Millions of dollars) Shares (in Amount Balance at September 30, 2021 $ 365 $ 19,272 $ 13,826 $ 23 (80,164) $ (7,723) Net income — — 1,779 — — — Cash dividends: Common ($3.48 per share) — — (992) — — — Preferred — — (90) — — — Issuance of shares under employee and other plans, net — (108) (1) — 1,271 44 Share-based compensation — 239 — — — — Common stock held in trusts, net (a) — — — — 25 — Repurchase of common stock — 150 — — (2,415) (650) Spin-off of Embecta (See Note 2) — — 634 — — — Balance at September 30, 2022 $ 365 $ 19,553 $ 15,157 $ 23 (81,283) $ (8,330) Net income — — 1,484 — — — Cash dividends: Common ($3.64 per share) — — (1,046) — — — Preferred — — (60) — — — Issuance of shares for preferred shares converted to common shares (b) 6 (4) — — — — Issuance of shares under employee and other plans, net — (88) — 1 1,056 24 Share-based compensation — 259 — — — — Common stock held in trusts, net (a) — — — — 24 — Balance at September 30, 2023 $ 371 $ 19,720 $ 15,535 $ 24 (80,203) $ (8,305) Net income — — 1,705 — — — Cash dividends: Common ($3.80 per share) — — (1,100) — — — Issuance of shares under employee and other plans, net — (73) — 1 801 2 Share-based compensation — 247 — — — — Common stock held in trusts, net (a) — — — — 27 — Repurchase of common stock — — — — (2,118) (503) Balance at September 30, 2024 $ 371 $ 19,893 $ 16,139 $ 25 (81,493) $ (8,807) (a) Common stock held in trusts consists of the Company’s shares held in rabbi trusts in connection with deferred compensation under the Company’s employee salary and bonus deferral plan and directors’ deferral plan. (b) Represents the conversion, in accordance with their terms, of 1.500 million mandatory convertible preferred shares that were issued in May 2020 were converted into 5.955 million shares of BD common stock on the mandatory conversion date of June 1, 2023.
Accumulated Other Comprehensive (Loss) Income	The components and changes of Accumulated other comprehensive income (loss) were as follows: (Millions of dollars) Total Foreign Benefit Plans Cash Flow Available-for-Sale Debt Securities Balance at September 30, 2021 $ (2,088) $ (1,292) $ (784) $ (10) $ — Other comprehensive income before reclassifications, net of taxes 306 54 169 83 — Amounts reclassified into income, net of 43 — 41 2 — Spin-off of Embecta (See Note 2) 251 251 — — — Balance at September 30, 2022 $ (1,488) $ (987) $ (574) $ 75 $ — Other comprehensive (loss) income before reclassifications, net of taxes (106) (91) (37) 21 — Amounts reclassified into income, net of 46 — 41 6 — Balance at September 30, 2023 $ (1,548) $ (1,078) $ (571) $ 103 $ — Other comprehensive loss before reclassifications, net of taxes (227) (166) (32) (28) (1) Amounts reclassified into income, net of 42 — 46 (4) — Balance at September 30, 2024 $ (1,732) $ (1,244) $ (557) $ 70 $ (1)

Earnings per Share (Tables)

Earnings per Share (Tables)	12 Months Ended
	Sep. 30, 2024
Earnings Per Share [Abstract]
Weighted Average Common Shares Used in Computations of Basic and Diluted Earnings Per Share	The weighted average common shares used in the computations of basic and diluted earnings per share (shares in thousands) for the years ended September 30 were as follows: 2024 2023 2022 Average common shares outstanding 289,763 286,282 285,005 Dilutive share equivalents from share-based plans (a) (b) 1,246 2,110 2,333 Dilutive share equivalents from Series C preferred shares (c) — — 26 Average common and common equivalent shares outstanding — assuming dilution 291,009 288,392 287,364 (a) In 2023 and 2022, dilutive share equivalents associated with mandatory convertible preferred stock of 4 million and 6 million, respectively, were excluded from the diluted shares outstanding calculation because the result would have been antidilutive. All of the mandatory convertible preferred shares outstanding were converted during fiscal year 2023, as further discussed in Note 4. (b) In 2024, 1 million of certain share-based compensation awards were excluded from the diluted earnings per share calculation as the exercise prices of these awards were greater than the average market price of the Company’s common shares. In 2023 and 2022, no such awards were excluded from the diluted earnings per share calculation. Additional disclosures regarding the Company’s share-based compensation are provided in Note 9. (c) Represents dilutive share equivalents from Series C preferred shares that temporarily replaced shares of common stock held in trusts to adhere to trust requirements until the Company’s spin-off of its Diabetes Care business on April 1, 2022 was completed.

Segment Data (Tables)

Segment Data (Tables)	12 Months Ended
	Sep. 30, 2024
Segment Reporting [Abstract]
Revenue from External Customers by Geographic Areas	Financial information for the Company’s segments is detailed below. The Company has no material intersegment revenues. (Millions of dollars) 2024 2023 2022 United States International Total United States International Total United States International Total Medical Medication Delivery Solutions $ 2,661 $ 1,768 $ 4,429 $ 2,519 $ 1,774 $ 4,293 $ 2,483 $ 1,825 $ 4,308 Medication Management Solutions 2,627 670 3,297 2,303 677 2,980 1,935 598 2,533 Pharmaceutical Systems 629 1,644 2,273 666 1,563 2,229 533 1,468 2,001 Advanced Patient Monitoring 47 27 74 — — — — — — Total segment revenues $ 5,964 $ 4,110 $ 10,074 $ 5,488 $ 4,014 $ 9,502 $ 4,950 $ 3,891 $ 8,841 Life Sciences Integrated Diagnostic Solutions $ 1,733 $ 1,946 $ 3,679 $ 1,774 $ 1,850 $ 3,624 $ 2,190 $ 1,995 $ 4,185 Biosciences 577 935 1,512 603 906 1,509 542 838 1,379 Total segment revenues $ 2,310 $ 2,881 $ 5,191 $ 2,377 $ 2,756 $ 5,133 $ 2,732 $ 2,833 $ 5,564 Interventional Surgery $ 1,130 $ 363 $ 1,492 $ 1,159 $ 338 $ 1,497 $ 1,094 $ 306 $ 1,400 Peripheral Intervention 1,029 904 1,933 1,016 849 1,865 960 799 1,759 Urology and Critical Care 1,236 319 1,554 1,073 301 1,374 986 319 1,305 Total segment revenues $ 3,394 $ 1,586 $ 4,980 $ 3,247 $ 1,489 $ 4,736 $ 3,040 $ 1,424 $ 4,464 Other (a) $ (6) $ (62) $ (67) $ — $ — $ — $ — $ — $ — Total Company revenues from continuing operations $ 11,663 $ 8,515 $ 20,178 $ 11,113 $ 8,258 $ 19,372 $ 10,722 $ 8,148 $ 18,870 (a) Represents the recognition of accruals resulting from recent developments relating to the Italian government medical device pay back legislation, as well as another legal matter, and which substantially relate to years prior to the current fiscal year. Such amounts were not allocated to the Company’s reportable segments and these matters are further discussed in Note 6.
Financial Information for Company's Segments	The following tables provide a reconciliation of segment operating income to Income from Continuing Operations before Income Taxes and segment information for both capital expenditures and depreciation and amortization. (Millions of dollars) 2024 2023 2022 Income from Continuing Operations Before Income Taxes Medical (a) (b) $ 2,742 $ 1,967 $ 2,215 Life Sciences 1,595 1,585 1,710 Interventional 1,420 1,217 1,081 Total Segment Operating Income 5,758 4,769 5,006 Integration, restructuring and transaction expense (458) (313) (173) Net interest expense (364) (403) (382) Other unallocated items (c) (2,931) (2,391) (2,668) Total Income from Continuing Operations Before Income Taxes $ 2,005 $ 1,662 $ 1,783 Capital Expenditures Medical $ 438 $ 563 $ 602 Life Sciences 114 139 213 Interventional 127 138 130 Corporate and All Other 46 35 28 Total Capital Expenditures $ 725 $ 874 $ 973 Depreciation and Amortization Medical $ 1,216 $ 1,199 $ 1,144 Life Sciences 272 277 283 Interventional 786 799 789 Corporate and All Other 13 13 13 Total Depreciation and Amortization $ 2,286 $ 2,288 $ 2,229 (a) The amounts in 2024, 2023 and 2022 include charges of $38 million, $653 million and $72 million, respectively, recorded to Cost of products sold, to record or adjust future costs estimated for product remediation efforts. (b) The amount in 2022 includes a charge of $54 million, recorded to Cost of products sold, to write down the carrying value of certain fixed assets in the Pharmaceutical Systems unit. (c)
Revenues to Unaffiliated Customers and Long-lived Assets Including Property, Plant and Equipment	The table below shows revenues from continuing operations and long-lived assets of continuing operations by geographic area: (Millions of dollars) 2024 2023 2022 Revenues United States $ 11,663 $ 11,113 $ 10,722 EMEA 4,402 4,244 4,043 Greater Asia 2,906 2,913 3,047 Other 1,207 1,102 1,058 $ 20,178 $ 19,372 $ 18,870 Long-Lived Assets United States $ 35,526 $ 35,732 $ 36,617 EMEA 6,706 5,317 5,126 Greater Asia 1,580 1,521 1,528 Other 2,548 1,116 1,079 Corporate 459 418 442 $ 46,818 $ 44,104 $ 44,792

Share-Based Compensation (Table

Share-Based Compensation (Tables)	12 Months Ended
	Sep. 30, 2024
Share-Based Payment Arrangement [Abstract]
Compensation Cost Relating to Share-Based Payments	The amounts and location of compensation cost relating to share-based payments included in the consolidated statements of income is as follows: (Millions of dollars) 2024 2023 2022 Cost of products sold $ 51 $ 50 $ 46 Selling and administrative expense 156 170 156 Research and development expense 42 41 37 Integration, restructuring and transaction expense — — 1 Total share-based compensation cost $ 249 $ 261 $ 240 Tax benefit associated with share-based compensation costs recognized $ 58 $ 58 $ 55
Assumptions for Estimation of Fair Values of Stock Appreciation Rights Granted During Reporting Periods	The fair value of awards was estimated on the date of grant using a lattice-based binomial option valuation model and these valuations were largely based upon the following weighted-average assumptions: 2024 2023 2022 Risk-free interest rate 4.51% 3.78% 1.41% Expected volatility 22.0% 21.0% 22.0% Expected dividend yield 1.59% 1.53% 1.42% Expected life 7.0 years 7.0 years 7.3 years Fair value derived $63.05 $57.80 $49.45
Summary of SARs Outstanding	A summary of SARs outstanding as of September 30, 2024 and changes during the year then ended is as follows: SARs (in Weighted Weighted Aggregate Balance at October 1 4,905 $ 211.47 Granted 597 238.89 Exercised (297) 154.25 Forfeited, canceled or expired (210) 237.09 Balance at September 30 4,995 $ 217.07 5.25 $ 125 Vested and expected to vest at September 30 4,863 216.50 5.17 $ 125 Exercisable at September 30 3,669 $ 209.57 4.18 $ 121
Schedule Of Share Based Compensation, Summary of Stock Appreciation Rights Exercised	A summary of SARs exercised during 2024, 2023 and 2022 is as follows: (Millions of dollars) 2024 2023 2022 Total intrinsic value of SARs exercised $ 25 $ 126 $ 184 Total fair value of SARs vested $ 31 $ 34 $ 36
Summary of Performance-Based Restricted Stock Units Outstanding	A summary of restricted stock units outstanding as of September 30, 2024 and changes during the year then ended is as follows: Performance-Based Time-Vested Stock Units (in Weighted Stock Units (in Weighted Balance at October 1 963 $ 226.51 1,716 $ 225.33 Granted 387 223.60 922 231.32 Distributed (145) 212.46 (556) 225.13 Forfeited or canceled (213) 219.15 (390) 231.68 Balance at September 30 991 (a) $ 229.02 1,693 $ 227.20 Expected to vest at September 30 465 (b) $ 229.96 1,549 $ 226.80 (a) Based on 200% of target payout for performance based restricted units and 100% of the performance based time-vested units. (b) Net of expected forfeited units and units in excess of the expected performance payout of 71 thousand and 454 thousand shares, respectively.
Schedule Of Share Based Compensation, Restricted Stock Units, Grant Date Fair Value of Units Granted	The weighted average grant date fair value of restricted stock units granted during the years 2024, 2023 and 2022 are as follows: Performance-Based Time-Vested 2024 2023 2022 2024 2023 2022 Weighted average grant date fair value of units granted $ 223.60 $ 227.11 $ 242.39 $ 231.32 $ 231.58 $ 239.39
Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity	The total fair value of stock units vested during 2024, 2023 and 2022 was as follows: Performance-Based Time-Vested (Millions of dollars) 2024 2023 2022 2024 2023 2022 Total fair value of units vested $ 45 $ 28 $ 14 $ 179 $ 169 $ 169

Benefit Plans (Tables)

Benefit Plans (Tables)	12 Months Ended
	Sep. 30, 2024
Retirement Benefits [Abstract]
Net Pension and Other Postretirement Cost	Net pension cost for the years ended September 30 included the following components: Pension Plans (Millions of dollars) 2024 2023 2022 Service cost $ 88 $ 91 $ 134 Interest cost 139 129 77 Expected return on plan assets (150) (141) (187) Amortization of prior service credit (4) (7) (15) Amortization of loss 57 58 61 Curtailments/settlement loss 1 44 73 Net pension cost $ 131 $ 174 $ 143 Net pension cost included in the preceding table that is attributable to international plans $ 28 $ 25 $ 20
Change in Benefit Obligation, Change in Fair Value of Plan Assets	The change in benefit obligation, change in fair value of pension plan assets, funded status and amounts recognized in the Consolidated Balance Sheets for these plans were as follows: Pension Plans (Millions of dollars) 2024 2023 Change in benefit obligation: Beginning obligation $ 2,617 $ 2,634 Service cost 88 91 Interest cost 139 129 Benefits paid (201) (67) Actuarial gain 241 (24) Curtailments/settlements (21) (214) Other, includes translation 51 68 Benefit obligation at September 30 $ 2,913 $ 2,617 Change in fair value of plan assets: Beginning fair value $ 2,129 $ 2,242 Actual return on plan assets 395 33 Employer contribution 200 62 Benefits paid (201) (67) Settlements (21) (200) Other, includes translation 54 59 Plan assets at September 30 $ 2,557 $ 2,129 Funded Status at September 30: Unfunded benefit obligation $ (356) $ (488) Amounts recognized in the Consolidated Balance Other Assets $ 99 $ 81 Salaries, wages and related items (12) (15) Long-term Employee Benefit Obligations (443) (554) Net amount recognized $ (356) $ (488) Amounts recognized in Accumulated other Prior service credit $ 2 $ 3 Net actuarial loss (636) (689) Net amount recognized $ (634) $ (686)
Pension Plans with Accumulated Benefit Obligations	Pension plans with accumulated benefit obligations in excess of plan assets and plans with projected benefit obligations in excess of plan assets consist of the following at September 30: Accumulated Benefit Projected Benefit (Millions of dollars) 2024 2023 2024 2023 Projected benefit obligation $ 2,382 $ 2,140 $ 2,382 $ 2,159 Accumulated benefit obligation $ 2,318 $ 2,088 Fair value of plan assets $ 1,927 $ 1,575 $ 1,927 $ 1,591
Weighted Average Assumptions Determining Pension Plan	The weighted average assumptions used in determining pension plan information were as follows: 2024 2023 2022 Net Cost Discount rate: U.S. plans (a) 6.01 % 5.62 % 2.89 % International plans 4.52 4.26 1.75 Expected return on plan assets: U.S. plans 7.29 7.25 6.25 International plans 5.30 5.02 4.84 Rate of compensation increase: U.S. plans 4.00 4.51 4.31 International plans 2.81 2.86 2.63 Cash balance plan interest crediting rate: U.S. plans 4.00 4.00 4.00 International plans 2.16 1.98 2.02 Benefit Obligation Discount rate: U.S. plans 4.98 6.01 5.62 International plans 3.88 4.62 4.26 Rate of compensation increase: U.S. plans 4.00 4.00 4.51 International plans 2.81 2.86 2.86 Cash balance plan interest crediting rate: U.S. plans 4.00 4.00 4.00 International plans 2.21 2.21 1.98 (a) The Company calculated the service and interest components utilizing an approach that discounts the individual expected cash flows using the applicable spot rates derived from the yield curve over the projected cash flow period.
Expected Benefit Payments	Expected benefit payments are as follows: (Millions of dollars) Pension 2025 $ 238 2026 239 2027 221 2028 216 2029 212 2030-2034 1,008
Fair Value Measurements of U.S. Plan Assets	The following table provides the fair value measurements of U.S. plan assets, as well as the measurement techniques and inputs utilized to measure fair value of these assets, at September 30, 2024 and 2023. The categorization of fund investments is based upon the categorization of these funds’ underlying assets. Basis of fair value measurement (See Note 1) (Millions of dollars) Total U.S. Investments Measured at Net Asset Value (a) Level 1 Level 2 Level 3 2024 2023 2024 2023 2024 2023 2024 2023 2024 2023 Fixed Income: Corporate bonds $ 518 $ 443 $ — $ — $ 296 $ 260 $ 222 $ 182 $ — $ — Government and agency-U.S. 159 53 — — 149 43 10 10 — — Government and agency-Foreign 31 17 — — — — 31 17 — — Other fixed income 53 46 — — 25 24 28 22 — — Equity securities 582 469 71 59 512 410 — — — — Cash and cash equivalents 172 202 — — 172 202 — — — — Other 162 151 75 79 87 72 — — — — Fair value of plan assets $ 1,676 $ 1,382 $ 146 $ 138 $ 1,240 $ 1,012 $ 291 $ 231 $ — $ — (a) As per applicable disclosure requirements, certain investments that were measured at net asset value per share or its equivalent have not been categorized within the fair value hierarchy. Values of such assets are based on the corroborated net asset value provided by the fund administrator.
Fair Value Measurements of Foreign Plan Assets	The following table provides the fair value measurements of international plan assets, as well as the measurement techniques and inputs utilized to measure fair value of these assets, at September 30, 2024 and 2023. Basis of fair value measurement (See Note 1) (Millions of dollars) Total International Level 1 Level 2 Level 3 (a) 2024 2023 2024 2023 2024 2023 2024 2023 Fixed Income: Corporate bonds $ 114 $ 122 $ 92 $ 100 $ 9 $ 10 $ 13 $ 12 Government and agency-U.S. 9 9 7 8 2 2 — — Government and agency-Foreign 223 197 188 165 28 26 7 6 Other fixed income 52 43 44 34 9 9 — — Equity securities 196 173 166 147 — 1 30 25 Cash and cash equivalents 13 10 11 8 — — 2 2 Real estate 44 36 1 1 34 26 9 9 Insurance contracts 113 103 — — — — 113 103 Other 117 55 92 35 3 1 22 19 Fair value of plan assets $ 880 $ 748 $ 600 $ 499 $ 85 $ 74 $ 195 $ 175 (a) Changes in the fair value of international pension assets measured using Level 3 inputs for the years ended September 30, 2024 and 2023 were immaterial.

Business Restructuring Charges

Business Restructuring Charges (Tables)	12 Months Ended
	Sep. 30, 2024
Restructuring and Related Activities [Abstract]
Summary of Restructuring Accrual Activity	Restructuring liability activity in 2024, 2023 and 2022 was as follows: (Millions of dollars) Employee Termination Other (a) Total Balance at September 30, 2021 $ 14 $ 5 $ 19 Charged to expense 21 103 123 Cash payments (11) (71) (82) Non-cash settlements — (25) (25) Other adjustments — (1) (1) Balance at September 30, 2022 $ 24 $ 11 $ 35 Charged to expense 117 122 239 Cash payments (62) (103) (165) Non-cash settlements — (30) (30) Other adjustments — 1 1 Balance at September 30, 2023 $ 79 $ 1 $ 80 Charged to expense 80 307 387 Cash payments (103) (202) (305) Non-cash settlements — (104) (104) Other adjustments 2 — 2 Balance at September 30, 2024 $ 58 $ 2 $ 60 (a) Other non-employee-related expenses primarily relate to other costs associated with the execution of the Company’s cost efficiency and restructuring programs, such as incremental project management costs, facility exit costs, inventory write-offs and long-lived asset impairments and disposals, which are discussed further in Note 15.

Intangible Assets (Tables)

Intangible Assets (Tables)	12 Months Ended
	Sep. 30, 2024
Goodwill and Intangible Assets Disclosure [Abstract]
Components of Intangible Assets	Intangible assets at September 30 consisted of: 2024 2023 (Millions of dollars) Gross Accumulated Net Carrying Amount Gross Accumulated Net Carrying Amount Amortized intangible assets Developed technology $ 15,827 $ (8,094) $ 7,733 $ 15,080 $ (7,023) $ 8,058 Customer relationships 5,513 (2,878) 2,635 4,859 (2,521) 2,338 Patents, trademarks and other 1,185 (682) 503 1,130 (624) 505 Amortized intangible assets $ 22,525 $ (11,654) $ 10,871 $ 21,069 $ (10,168) $ 10,901 Unamortized intangible assets Acquired in-process research and development $ 44 $ 44 Trademarks 2 2 Unamortized intangible assets $ 46 $ 46
Reconciliation of Goodwill by Business Segment	The following is a reconciliation of goodwill by business segment: (Millions of dollars) Medical Life Sciences Interventional Total Goodwill as of September 30, 2022 $ 10,909 $ 888 $ 12,824 $ 24,621 Divestitures and related adjustments (a) — — (218) (218) Purchase price allocation adjustments (b) 13 — — 13 Currency translation 33 9 64 105 Goodwill as of September 30, 2023 $ 10,955 $ 897 $ 12,670 $ 24,522 Acquisitions (c) 1,833 — — 1,833 Currency translation 43 7 59 109 Goodwill as of September 30, 2024 $ 12,832 $ 904 $ 12,729 $ 26,465 (a) Represents goodwill derecognized upon the Company’s sale of its Surgical Instrumentation platform, as further discussed in Note 2. (b) The purchase price allocation adjustments were primarily driven by an adjustment to tax-related balances recorded upon the finalization of the Parata acquisition allocation within one year of the transaction's closing. (c) Represents goodwill recognized in the Medical segment upon the Company's acquisition of Advanced Patient Monitoring, which is further discussed in Note 11.

Derivative Instruments and He_2

Derivative Instruments and Hedging Activities (Tables)	12 Months Ended
	Sep. 30, 2024
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Schedule of Notional Amounts of Outstanding Derivative Positions	The notional amounts of the Company’s foreign currency-related derivative instruments as of September 30, 2024 and 2023 were as follows: (Millions of dollars) Hedge Designation 2024 2023 Foreign exchange contracts (a) Undesignated $ 4,521 $ 3,146 Foreign exchange contracts (b) Cash flow hedges 543 — Foreign currency-denominated debt (c) Net investment hedges 3,065 1,056 Cross-currency swaps (d) Net investment hedges 1,366 2,119 (a) Represents hedges of transactional foreign exchange exposures resulting primarily from intercompany payables and receivables. Gains and losses on these instruments are recognized immediately in income. These gains and losses are largely offset by gains and losses on the underlying hedged items, as well as the hedging costs associated with the derivative instruments. Net amounts recognized in Other expense, net , during the years ending September 30, 2024, 2023 and 2022 are detailed in Note 19. (b) Represents foreign exchange contracts that the Company entered into in fiscal year 2024 related to anticipated intercompany purchases and sales, described above, which generally have durations of less than eighteen months. (c) Represents foreign currency-denominated long-term notes outstanding, which were effective as economic hedges of net investments in certain of the Company's foreign subsidiaries. (d) Represents cross-currency swaps, which were effective as economic hedges of net investments in certain of the Company's foreign subsidiaries. The notional amounts of the Company’s interest rate-related derivative instruments as of September 30, 2024 and 2023 were as follows: (Millions of dollars) Hedge Designation 2024 2023 Interest rate swaps (a) Fair value hedges $ 700 $ 700 Forward starting interest rate swaps (b) Cash flow hedges — 500 (a) Represents fixed-to-floating interest rate swap agreements the Company entered into to convert the interest payments on certain long-term notes from the fixed rate to a floating interest rate based on secured overnight financing rates ("SOFR"). (b)
Schedule of Net Investment Hedges in Accumulated Other Comprehensive Income (Loss)	Net (losses) gains recorded to Accumulated other comprehensive income (loss) relating to the Company's net investment hedges as of September 30, 2024, 2023 and 2022 were as follows: (Millions of dollars) 2024 2023 2022 Foreign currency-denominated debt (96) (155) 320 Cross-currency swaps (a) (71) (70) 173 (a) The amounts in 2024, 2023 and 2022 include net of tax gains recognized on terminated cross-currency swaps of $9 million, $13 million and $46 million, respectively .

Financial Instruments and Fai_2

Financial Instruments and Fair Value Measurements (Tables)	12 Months Ended
	Sep. 30, 2024
Fair Value Disclosures [Abstract]
Schedule of Cash and Cash Equivalents	The following reconciles cash and equivalents and restricted cash reported within the Company's consolidated balance sheets at September 30, 2024 and 2023 to the total of these amounts shown on the Company's consolidated statements of cash flows: (Millions of dollars) 2024 2023 Cash and equivalents $ 1,717 $ 1,416 Restricted cash 139 65 Cash and equivalents and restricted cash $ 1,856 $ 1,481
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis	The fair values of the Company’s financial instruments are as follows: (Millions of dollars) Basis of fair value measurement (See Note 1) 2024 2023 Institutional money market accounts (a) Level 1 $ 285 $ 373 Current portion of long-term debt (b) Level 2 1,748 1,122 Long-term debt (b) Level 2 17,199 12,850 (a) These financial instruments are recorded within Cash and equivalents on the consolidated balance sheets. The institutional money market accounts permit daily redemption. (b) Long-term debt is recorded at amortized cost. The fair value of long-term debt is measured based upon quoted prices in active markets for similar instruments.
Transfer of Financial Assets Accounted for as Sales	The amounts transferred and yet to be remitted under factoring arrangements are provided below. (Millions of dollars) 2024 2023 2022 Trade receivables transferred to third parties under factoring arrangements $ 1,385 $ 2,615 $ 1,215 (Millions of dollars) 2024 2023 Amounts yet to be collected and remitted to the third parties 254 357

Debt (Tables)

Debt (Tables)	12 Months Ended
	Sep. 30, 2024
Debt Disclosure [Abstract]
Summary of Short-Term Debt	The carrying value of Current debt obligations , net of unamortized debt issuance costs, at September 30 consisted of: (Millions of dollars) 2024 2023 Commercial paper borrowings $ 400 $ — Current portion of long-term debt 3.875% Notes due May 15, 2024 (a) — 144 3.363% Notes due June 6, 2024 (a) — 997 3.734% Notes due December 15, 2024 875 — 3.020% Notes due May 24, 2025 335 — 0.034% Notes due August 13, 2025 559 — Other 1 — Total current debt obligations $ 2,170 $ 1,141 (a) All of the aggregate principal amount outstanding was retired upon maturity during 2024, as further discussed below.
Summary of Long-Term Debt	The carrying value of Long-Term Debt , net of unamortized debt issuance costs, at September 30 consisted of: (Millions of dollars) 2024 2023 3.734% Notes due December 15, 2024 $ — $ 874 3.020% Notes due May 24, 2025 — 306 0.034% Notes due August 13, 2025 — 528 1.208% Notes due June 4, 2026 671 634 6.700% Notes due December 1, 2026 158 161 1.900% Notes due December 15, 2026 559 528 3.700% Notes due June 6, 2027 1,721 1,719 7.000% Debentures due August 1, 2027 118 119 4.693% Notes due February 13, 2028 797 796 6.700% Debentures due August 1, 2028 115 115 0.334% Notes due August 13, 2028 1,004 949 4.874% Notes due February 8, 2029 (a) 622 — 5.081% Notes due June 7, 2029 (a) 596 — 3.553% Notes due September 13, 2029 891 842 2.823% Notes due May 20, 2030 746 745 3.519% Notes due February 8, 2031 (a) 835 — 1.957% Notes due February 11, 2031 994 993 3.828% Notes due June 7, 2032 (a) 1,113 — 4.298% Notes due August 22, 2032 496 496 5.110% Notes due February 8, 2034 (a) 545 — 1.213% Notes due February 12, 2036 668 631 4.029% Notes due June 7, 2036 (a) 889 — 6.000% Notes due May 15, 2039 121 121 5.000% Notes due November 12, 2040 90 90 1.336% Notes due August 13, 2041 999 945 4.875% Notes due May 15, 2044 244 245 4.685% Notes due December 15, 2044 934 899 4.669% Notes due June 6, 2047 1,460 1,445 3.794% Notes due May 20, 2050 554 554 Other long-term debt 1 2 Total Long-Term Debt $ 17,940 $ 14,738 (a) Represents notes issued during 2024, as further discussed below.
Schedule of Debt Issuances	The Company issued the following U.S. dollar-denominated debt during fiscal years 2024 and 2023: Interest rate and maturity Period issued Amount issued (Millions of dollars) Use of proceeds 5.081% Notes due June 7, 2029 Third quarter 2024 $ 600 Funding of the cash consideration and related fees and expenses for the Advanced Patient Monitoring acquisition and for general corporate purposes 4.874% Notes due February 8, 2029 Second quarter 2024 $ 625 Retirement of 3.363% notes due June 6, 2024 and retirement, upon maturity, of 3.734% notes due December 15, 2024 5.110% Notes due February 8, 2034 Second quarter 2024 $ 550 Retirement of 3.363% notes due June 6, 2024 and retirement, upon maturity, of 3.734% notes due December 15, 2024 4.693% notes due February 13, 2028 Second quarter 2023 $ 800 Retirement of 1.401% notes due May 24, 2023 and 0.000% notes due August 13, 2023 The Company issued the following Euro-denominated debt during fiscal year 2024: Interest rate and maturity Period issued Amount issued (Millions of Euros) Amount issued (millions of dollars) Use of proceeds 3.828% Notes due June 7, 2032 Third quarter 2024 € 1,000 $ 1,087 Funding of the cash consideration and related fees and expenses for the Advanced Patient Monitoring acquisition and for general corporate purposes 3.519% Notes due February 8, 2031 Second quarter 2024 € 750 $ 806 Retirement of 3.875% notes due May 15, 2024 and 3.363% notes due June 6, 2024 Interest rate and maturity Period issued Amount issued (Millions of Euros) Amount issued (Millions of dollars) Use of proceeds 4.029% Notes due June 7, 2036 Third quarter 2024 € 800 $ 869 Funding of the cash consideration and related fees and expenses for the Advanced Patient Monitoring acquisition and for general corporate purposes 3.553% notes due September 13, 2029 Second quarter 2023 € 800 $ 868 Retirement of 0.632% notes due June 4, 2023
Schedule of Extinguishment of Debt	The Company’s retirements of debt upon maturity in fiscal years 2024 and 2023 included the following: Principal, interest rate and maturity Period of retirement $998 million of 3.363% notes due June 6, 2024 Third quarter 2024 $144 million of 3.875% notes due May 15, 2024 Third quarter 2024 400 million Euros ($439 million) of 0.000% notes due August 13, 2023 Fourth quarter 2023 800 million Euros ($857 million) of 0.632% notes due June 4, 2023 Third quarter 2023 300 million Euros ($325 million) of 1.401% notes due May 24, 2023 Third quarter 2023 500 million Euros ($528 million) of 1.000% notes due December 15, 2022 First quarter 2023
Summary of Interest Costs and Payments	A summary of interest costs and payments for the years ended September 30 is as follows: (Millions of dollars) 2024 2023 2022 Charged to operations $ 528 $ 452 $ 398 Capitalized 57 51 46 Total interest costs $ 584 $ 503 $ 444 Interest paid, net of amounts capitalized $ 473 $ 452 $ 390

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Sep. 30, 2024
Income Tax Disclosure [Abstract]
Provision for Income Taxes from Continuing Operations	The provision (benefit) for income taxes for the years ended September 30 consisted of: (Millions of dollars) 2024 2023 2022 Current: Federal $ 132 $ 364 $ 17 State and local, including Puerto Rico 17 87 32 Foreign 362 303 228 $ 511 $ 754 $ 277 Deferred: Domestic $ (169) $ (644) $ (96) Foreign (42) 22 (33) (211) (622) (129) Income tax provision $ 300 $ 132 $ 148 The following were included for the years ended September 30 as a component of Income tax provision on the consolidated statements of income. (Millions of dollars) 2024 2023 2022 Interest and penalties associated with unrecognized tax benefits $ 42 $ 20 $ (6)
Components of Income from Continuing Operations Before Income Taxes	The components of Income from Continuing Operations Before Income Taxes for the years ended September 30 consisted of: (Millions of dollars) 2024 2023 2022 Domestic, including Puerto Rico $ 336 $ 358 $ 496 Foreign 1,669 1,304 1,287 Income from Continuing Operations Before Income Taxes $ 2,005 $ 1,662 $ 1,783
Summary of Gross Amounts of Unrecognized Tax Benefits	The table below summarizes the gross amounts of unrecognized tax benefits without regard to reduction in tax liabilities or additions to deferred tax assets and liabilities if such unrecognized tax benefits were settled. The Company believes it is reasonably possible that the amount of unrecognized benefits will change during the next twelve months due to one or more of the following events: expiring statutes, audit activity, tax payments, other activity, or final decisions in matters that are the subject of controversy in various taxing jurisdictions in which we operate. However, the Company does not expect changes to have a significant effect on its results of operations, financial condition, or cash flows. (Millions of dollars) 2024 2023 2022 Balance at October 1 $ 269 $ 267 $ 354 Increase due to acquisitions — — 2 Increase due to current year tax positions 22 22 40 Increase due to prior year tax positions — 33 60 Decreases due to prior year tax positions — (29) — Decrease due to settlements with tax authorities (64) (6) (77) Decrease due to lapse of statute of limitations (6) (18) (112) Balance at September 30 $ 221 $ 269 $ 267 Unrecognized tax benefits that would affect the effective tax rate if recognized $ 257 $ 366 $ 348
Deferred Income Taxes	Deferred income taxes at September 30 consisted of: 2024 2023 (Millions of dollars) Assets Liabilities Assets Liabilities Compensation and benefits $ 405 $ — $ 426 $ — Property and equipment — 391 — 405 Intangibles — 1,612 — 1,858 Loss and credit carryforwards 2,946 — 2,352 — Product recall and liability reserves 261 — 362 — Capitalized research and development expenses (a) 364 — 243 — Other 512 64 431 88 4,489 2,067 3,814 2,351 Valuation allowance (2,990) — (2,272) — Net (b) $ 1,498 $ 2,067 $ 1,542 $ 2,351 (a) As required by the 2017 Tax Cuts and Jobs Act, the Company’s research and development expenditures were capitalized and amortized in fiscal year 2024 for income tax purposes. This resulted in an increase in cash tax paid in fiscal year 2024 with a corresponding deferred tax benefit. (b) Net deferred tax assets are included in Other Assets and net deferred tax liabilities are included in Deferred Income Taxes and Other Liabilities on the consolidated balance sheets .
Reconciliation of Federal Statutory Tax Rate to Company's Effective Tax Rate	A reconciliation of the federal statutory tax rate to the Company’s effective income tax rate for continuing operations was as follows: 2024 2023 2022 Federal statutory tax rate 21.0 % 21.0 % 21.0 % State and local income taxes, net of federal tax benefit (0.7) (1.0) (1.1) Foreign income tax at rates other than 21% (9.1) (8.2) (7.3) Effect of foreign operations 4.3 (3.9) 5.6 Effect of Research Credits, FDII and Other Credits (a) (22.1) (3.2) (2.2) Effect of share-based compensation (0.3) (0.4) (1.7) Effect of gain on divestitures — 3.2 — Effect of valuation allowance 19.3 — (5.5) Effect of nondeductible costs (b) 2.2 — — Other, net 0.4 0.4 (0.5) Effective income tax rate 15.0 % 7.9 % 8.3 % (a) During fiscal year 2024, the Company was granted non-U.S. tax credits, for which a full valuation allowance was established. (b) Primarily related to the estimated liability recorded as a result of the SEC investigation, as further discussed in Note 6.
Summary of Income Tax Holiday	The approximate tax impacts related to tax holidays in various countries in which the Company does business are provided below. The tax holidays expire at various dates through 2039. The Company’s income tax payments, net of refunds are also provided below. (Millions of dollars, except per share amounts) 2024 2023 2022 Tax impact related to tax holidays $ 414 $ 363 $ 284 Impact of tax holiday on diluted earnings per share 1.42 1.26 0.99 Income tax payments, net of refunds 653 629 532

Leases (Tables)

Leases (Tables)	12 Months Ended
	Sep. 30, 2024
Leases [Abstract]
Supplemental Balance Sheet Information Related to Leases	The right-of-use assets and lease liabilities recognized on the Company’s consolidated balance sheet as of September 30, 2024 and 2023 were as follows: (Millions of dollars) 2024 2023 Right-of-use assets recorded in Other Assets $ 876 $ 517 Current lease liabilities recorded in Accrued expenses 142 117 Non-current lease liabilities recorded in Deferred Income Taxes and Other Liabilities 667 414
Lessee, Operating Lease, Liability, Maturity	The Company’s payments due under its operating leases are as follows: (Millions of dollars) 2025 $ 174 2026 149 2027 113 2028 86 2029 77 Thereafter 389 Total payments due 988 Less: imputed interest 178 Total $ 809

Supplemental Financial Inform_2

Supplemental Financial Information (Tables)	12 Months Ended
	Sep. 30, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of Other Nonoperating Income (Expense)	Other Expense, Net (Millions of dollars) 2024 2023 2022 Other investment gains (losses), net (a) $ 5 $ (3) $ (35) Deferred compensation 57 32 (46) Net pension and postretirement benefit cost (b) (65) (98) (17) Net foreign exchange losses (c) (47) (36) (28) Impacts of debt extinguishment (d) — — (24) Embecta service agreements income, net (e) 26 59 33 Other (4) — 1 Other expense, net $ (28) $ (46) $ (117) (a) The amounts include gains (losses) recognized relating to certain equity investments. (b) Represents all components of the Company’s net periodic pension and postretirement benefit costs, aside from service cost, including pension settlement expenses of $57 million and $73 million in fiscal years 2023 and 2022, respectively. (c) Represents net gains and losses from transactional foreign exchange exposures, offset by net gains and losses on undesignated foreign exchange derivatives. (d) Represents losses recognized upon the extinguishment of certain senior notes. (e) Consists of net income from transition and logistics service agreements with Embecta following the spin-off of the former diabetes care business in fiscal year 2022, as further discussed in Note 2.
Trade Receivables, Allowances for Doubtful Accounts and Cash Discounts	The amounts recognized in 2024, 2023 and 2022 relating to allowances for doubtful accounts and cash discounts, which are netted against trade receivables, are provided in the following table: (Millions of dollars) Allowance for Allowance for Total Balance at September 30, 2021 $ 73 $ 18 $ 91 Additions charged to costs and expenses 4 73 77 Deductions and other (12) (a) (75) (87) Balance at September 30, 2022 $ 65 $ 16 $ 81 Additions charged to costs and expenses 9 100 109 Deductions and other (10) (a) (100) (110) Balance at September 30, 2023 $ 65 $ 16 $ 81 Additions charged to costs and expenses 30 91 121 Deductions and other (30) (a) (93) (124) Balance at September 30, 2024 $ 64 $ 15 $ 79 (a) Accounts written off.
Inventories	Inventories at September 30 consisted of: (Millions of dollars) 2024 2023 Materials $ 803 $ 714 Work in process 443 381 Finished products 2,597 2,178 $ 3,843 $ 3,273 The Company acquired $666 million of inventories in the Advanced Patient Monditoring transaction, which is further discussed in Note 11.
Property, Plant and Equipment, Net	Property, Plant and Equipment, Net at September 30 consisted of: (Millions of dollars) 2024 2023 Land $ 129 $ 131 Buildings 3,733 3,537 Machinery, equipment and fixtures 10,197 9,609 Leasehold improvements 320 301 14,378 13,578 Less accumulated depreciation and amortization 7,557 7,021 $ 6,821 $ 6,557

Summary of Significant Accoun_3

Summary of Significant Accounting Policies - Additional Information (Detail) - USD ($) $ in Millions	12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2022
Summary of Significant Accounting Policies [Line Items]
Depreciation and amortization expense	$ 676	$ 696	$ 672
Selling and administrative expense	4,857	4,719	4,709
Shipping and Handling
Summary of Significant Accounting Policies [Line Items]
Selling and administrative expense	$ 702	$ 733	$ 751
Minimum | Core and Developed Technology
Summary of Significant Accounting Policies [Line Items]
Finite-lived intangible assets, useful life	15 years
Minimum | Customer relationships
Summary of Significant Accounting Policies [Line Items]
Finite-lived intangible assets, useful life	10 years
Minimum | Patents, Trademarks, and Other
Summary of Significant Accounting Policies [Line Items]
Finite-lived intangible assets, useful life	1 year
Minimum | Buildings
Summary of Significant Accounting Policies [Line Items]
Property, plant and equipment, useful life	20 years
Minimum | Machinery and Equipment
Summary of Significant Accounting Policies [Line Items]
Property, plant and equipment, useful life	4 years
Minimum | Leasehold Improvements
Summary of Significant Accounting Policies [Line Items]
Property, plant and equipment, useful life	1 year
Maximum | Core and Developed Technology
Summary of Significant Accounting Policies [Line Items]
Finite-lived intangible assets, useful life	20 years
Maximum | Customer relationships
Summary of Significant Accounting Policies [Line Items]
Finite-lived intangible assets, useful life	15 years
Maximum | Patents, Trademarks, and Other
Summary of Significant Accounting Policies [Line Items]
Finite-lived intangible assets, useful life	40 years
Maximum | Buildings
Summary of Significant Accounting Policies [Line Items]
Property, plant and equipment, useful life	45 years
Maximum | Machinery and Equipment
Summary of Significant Accounting Policies [Line Items]
Property, plant and equipment, useful life	20 years
Maximum | Leasehold Improvements
Summary of Significant Accounting Policies [Line Items]
Property, plant and equipment, useful life	20 years

Divestitures - Additional Infor

Divestitures - Additional Information (Details) - USD ($) $ in Millions	3 Months Ended	6 Months Ended	12 Months Ended
	Jun. 30, 2022	Mar. 31, 2022	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2022
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Gain (loss) on disposition of business			$ 0	$ 268	$ 0
Surgical Instrumentation
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Gain (loss) on disposition of business				268
Discontinued Operations, Disposed of by Means Other than Sale, Spinoff
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Disposal groups, including discontinued operation, consideration, cash		$ 1,266
Disposal group, including discontinued operation, other expense	$ 30	$ 78		$ 46

Divestitures - Details of (Loss

Divestitures - Details of (Loss) Income from Discontinued Operations, Net of Tax (Details) - USD ($) $ in Millions	12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2022
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
(Loss) Income from Discontinued Operations, Net of Tax	$ 0	$ (46)	$ 144
Discontinued Operations, Disposed of by Means Other than Sale, Spinoff
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Revenues			538
Cost of products sold			143
Selling and administrative expense			78
Research and development expense			32
Other operating expense, net			95
Total Operating Costs and Expenses			348
Operating Income			190
Interest expense			(4)
Income from Discontinued Operations Before Income Taxes			186
Income tax provision			42
(Loss) Income from Discontinued Operations, Net of Tax			$ 144

Shareholders' Equity - Changes

Shareholders' Equity - Changes in Certain Components of Shareholders' Equity (Detail) - USD ($) $ / shares in Units, $ in Millions	12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2022	Jun. 01, 2023
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning balance	$ 25,796
Beginning balance (shares)	(80,202,608)
Net Income	$ 1,705	$ 1,484	$ 1,779
Stockholders' equity note, spinoff transaction			$ 251
Ending balance	$ 25,890	$ 25,796
Ending balance (shares)	(81,493,082)	(80,202,608)
Common stock dividend per share (USD per share)	$ 3.80	$ 3.64	$ 3.48
Convertible Preferred Stock
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Preferred stock, shares outstanding				1,500,000
Common Stock  Issued at Par Value
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Convertible preferred stock, shares issued upon conversion				5,955,000
Common Stock  Issued at Par Value
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning balance	$ 371	$ 365	$ 365
Stock issued during period, conversion of convertible securities		6
Ending balance	371	371	365
Capital in Excess of Par Value
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning balance	19,720	19,553	19,272
Stock issued during period, conversion of convertible securities		(4)
Issuance of shares under employee and other plans, net	(73)	(88)	(108)
Share-based compensation	247	259	239
Treasury stock, value, acquired, cost method			150
Ending balance	19,893	19,720	19,553
Retained Earnings
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning balance	15,535	15,157	13,826
Net Income	1,705	1,484	1,779
Dividends, common stock	(1,100)	(1,046)	(992)
Dividends, preferred stock		(60)	(90)
Issuance of shares under employee and other plans, net			(1)
Stockholders' equity note, spinoff transaction			634
Ending balance	16,139	15,535	15,157
Deferred Compensation
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning balance	24	23	23
Issuance of shares under employee and other plans, net	1	1
Ending balance	25	24	23
Treasury Stock
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning balance	$ (8,305)	$ (8,330)	$ (7,723)
Beginning balance (shares)	(80,203,000)	(81,283,000)	(80,164,000)
Issuance of shares under employee and other plans, net	$ 2	$ 24	$ 44
Share-based compensation plans, net (shares)	801,000	1,056,000	1,271,000
Common stock held in trusts, net (shares)	27,000	24,000	25,000
Treasury stock, value, acquired, cost method	$ (503)		$ (650)
Treasury stock, shares, acquired	(2,118,000)		(2,415,000)
Ending balance	$ (8,807)	$ (8,305)	$ (8,330)
Ending balance (shares)	(81,493,000)	(80,203,000)	(81,283,000)

Shareholders' Equity - Addition

Shareholders' Equity - Additional Information (Detail) - USD ($) shares in Thousands, $ in Millions	12 Months Ended
	Sep. 30, 2024	Sep. 30, 2022	Nov. 30, 2021	Sep. 24, 2013
Class of Stock [Line Items]
Share repurchase program, authorized, number of shares				10,000
Share repurchase program, number of additional shares authorized to be repurchased			10,000
Accelerated Share Repurchase Program
Class of Stock [Line Items]
Treasury stock, shares, acquired	2,118
Share repurchase program, authorized, amount	$ 500	$ 500
Share repurchase program, excise tax, percentage	1%
Share repurchase program, excise tax, amount	$ 3
Total shares to be delivered under accelerated share repurchase program		1,953
Accelerated Share Repurchase Program, Agreement One
Class of Stock [Line Items]
Treasury stock, shares, acquired		462
Treasury Stock
Class of Stock [Line Items]
Treasury stock, shares, acquired	2,118	2,415
Treasury stock, value, acquired, cost method	$ 503	$ 650
Treasury Stock | Accelerated Share Repurchase Program
Class of Stock [Line Items]
Treasury stock, value, acquired, cost method		$ 150

Shareholders' Equity - Accumula

Shareholders' Equity - Accumulated Other Comprehensive (Loss) Income (Detail) - USD ($) $ in Millions	12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2022
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Accumulated other comprehensive (loss) income, beginning balance	$ (1,548)	$ (1,488)	$ (2,088)
Other comprehensive income before reclassifications, net of taxes	(227)	(106)	306
Amounts reclassified into income, net of taxes	42	46	43
Stockholders' equity note, spinoff transaction			251
Accumulated other comprehensive (loss) income, ending balance	(1,732)	(1,548)	(1,488)
Foreign Currency Translation
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Accumulated other comprehensive (loss) income, beginning balance	(1,078)	(987)	(1,292)
Other comprehensive income before reclassifications, net of taxes	(166)	(91)	54
Amounts reclassified into income, net of taxes	0	0	0
Stockholders' equity note, spinoff transaction			251
Accumulated other comprehensive (loss) income, ending balance	(1,244)	(1,078)	(987)
Benefit Plans
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Accumulated other comprehensive (loss) income, beginning balance	(571)	(574)	(784)
Other comprehensive income before reclassifications, net of taxes	(32)	(37)	169
Amounts reclassified into income, net of taxes	46	41	41
Stockholders' equity note, spinoff transaction			0
Accumulated other comprehensive (loss) income, ending balance	(557)	(571)	(574)
Cash Flow Hedges
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Accumulated other comprehensive (loss) income, beginning balance	103	75	(10)
Other comprehensive income before reclassifications, net of taxes	(28)	21	83
Amounts reclassified into income, net of taxes	(4)	6	2
Stockholders' equity note, spinoff transaction			0
Accumulated other comprehensive (loss) income, ending balance	70	103	75
Available-for-Sale Debt Securities
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Accumulated other comprehensive (loss) income, beginning balance	0	0	0
Other comprehensive income before reclassifications, net of taxes	(1)	0	0
Amounts reclassified into income, net of taxes	0	0	0
Stockholders' equity note, spinoff transaction			0
Accumulated other comprehensive (loss) income, ending balance	$ (1)	$ 0	$ 0

Earnings per Share - Weighted A

Earnings per Share - Weighted Average Common Shares Used in Computations of Basic and Diluted Earnings Per Share (Details) - shares shares in Thousands	12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2022
Earnings Per Share [Abstract]
Average common shares outstanding (shares)	289,763	286,282	285,005
Dilutive share equivalents from share-based plans (shares)	1,246	2,110	2,333
Dilutive share equivalents from Series C preferred shares (in shares)	0	0	26
Average common and common equivalent shares outstanding - assuming dilution (shares)	291,009	288,392	287,364

Earnings per Share - Weighted_2

Earnings per Share - Weighted Average Common Shares Used in Computations of Basic and Diluted Earnings Per Share Footnotes (Details) - shares shares in Millions	12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2022
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount (shares)	1	0	0
Convertible Preferred Stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount (shares)		4	6

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Detail) $ in Thousands	3 Months Ended		12 Months Ended
	Sep. 30, 2024 USD ($) claim	Jun. 30, 2024 USD ($)	Sep. 30, 2024 USD ($) lawsuit plaintiff claim	Sep. 30, 2023 USD ($) claim	Sep. 30, 2022 USD ($)
Loss Contingencies [Line Items]
Aggregate future purchase commitments			$ 1,831,000
Product liability, accrual, period expense			36,000
Pyxis
Loss Contingencies [Line Items]
Loss Contingency Accrual, Product Liability, Net	$ 28,000		28,000
Products Within Mass Tort Litigation
Loss Contingencies [Line Items]
Loss Contingency Accrual, Product Liability, Net	$ 1,700,000		$ 1,700,000	$ 1,900,000
GEORGIA
Loss Contingencies [Line Items]
Number of EtO sterilization lawsuits | lawsuit			350
Number of plaintiffs | plaintiff			360
Number of lawsuits, allege injury from unrelated defendants | lawsuit			50
GEORGIA | Maximum
Loss Contingencies [Line Items]
Loss contingency, damages sought, value			$ 250
Other Operating Income (Expense)
Loss Contingencies [Line Items]
Product liability, accrual, period expense			$ 36,000	$ (26,000)	$ (21,000)
HerniaProductClaims
Loss Contingencies [Line Items]
Loss contingency, pending claims, number | claim	6,610		6,610	34,845
SEC Matter
Loss Contingencies [Line Items]
Loss contingency, loss in period	$ 125,000	$ 50,000
Loss contingency accrual	$ 175,000		$ 175,000
Italian Medical Device Payback Legislation Matter
Loss Contingencies [Line Items]
Loss contingency, loss in period			$ 62,000

Revenues (Details)

Revenues (Details) - USD ($) $ in Millions	Sep. 30, 2024	Sep. 30, 2023
Disaggregation of Revenue [Line Items]
Rebate liability	$ 749	$ 669
Contract with Customer, Liability	$ 482	$ 412
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-10-01
Disaggregation of Revenue [Line Items]
Revenue, remaining performance obligation, expected timing of satisfaction, period	3 years
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-10-01 | Products and/or Services
Disaggregation of Revenue [Line Items]
Revenue, remaining performance obligation, amount	$ 2,300
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-10-01 | Consumables
Disaggregation of Revenue [Line Items]
Revenue, remaining performance obligation, amount	$ 2,100

Segment Data - Additional Infor

Segment Data - Additional Information (Details) $ in Millions	12 Months Ended
	Sep. 30, 2024 USD ($) segment customer	Sep. 30, 2023 USD ($) customer	Sep. 30, 2022 USD ($) customer
Segment Reporting Information [Line Items]
Number of principal business segments (segments) | segment	3
Number of customers accounted for 10% or more of revenues (customers) | customer	0	0	0
Product remediation-related charges	$ 38	$ 653	$ 72
Gain (loss) on disposition of business	0	268	0
Surgical Instrumentation
Segment Reporting Information [Line Items]
Gain (loss) on disposition of business		268
SEC Matter
Segment Reporting Information [Line Items]
Loss contingency accrual	175
Cost of products sold | Medical
Segment Reporting Information [Line Items]
Product remediation-related charges	$ 38	$ 653	72
Asset impairment charges			$ 54

Segment Data - Revenues by Geog

Segment Data - Revenues by Geographic Areas (Details) - USD ($) $ in Millions	12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2022
Segment Reporting Information [Line Items]
Revenues	$ 20,178	$ 19,372	$ 18,870
Operating Segments | Medical
Segment Reporting Information [Line Items]
Revenues	10,074	9,502	8,841
Operating Segments | Life Sciences
Segment Reporting Information [Line Items]
Revenues	5,191	5,133	5,564
Operating Segments | Interventional
Segment Reporting Information [Line Items]
Revenues	4,980	4,736	4,464
Corporate and All Other
Segment Reporting Information [Line Items]
Revenues	(67)	0	0
United States
Segment Reporting Information [Line Items]
Revenues	11,663	11,113	10,722
United States | Operating Segments | Medical
Segment Reporting Information [Line Items]
Revenues	5,964	5,488	4,950
United States | Operating Segments | Life Sciences
Segment Reporting Information [Line Items]
Revenues	2,310	2,377	2,732
United States | Operating Segments | Interventional
Segment Reporting Information [Line Items]
Revenues	3,394	3,247	3,040
United States | Corporate and All Other
Segment Reporting Information [Line Items]
Revenues	(6)	0	0
International
Segment Reporting Information [Line Items]
Revenues	8,515	8,258	8,148
International | Operating Segments | Medical
Segment Reporting Information [Line Items]
Revenues	4,110	4,014	3,891
International | Operating Segments | Life Sciences
Segment Reporting Information [Line Items]
Revenues	2,881	2,756	2,833
International | Operating Segments | Interventional
Segment Reporting Information [Line Items]
Revenues	1,586	1,489	1,424
International | Corporate and All Other
Segment Reporting Information [Line Items]
Revenues	(62)	0	0
Medication Delivery Solutions | Operating Segments | Medical
Segment Reporting Information [Line Items]
Revenues	4,429	4,293	4,308
Medication Delivery Solutions | United States | Operating Segments | Medical
Segment Reporting Information [Line Items]
Revenues	2,661	2,519	2,483
Medication Delivery Solutions | International | Operating Segments | Medical
Segment Reporting Information [Line Items]
Revenues	1,768	1,774	1,825
Medication Management Solutions | Operating Segments | Medical
Segment Reporting Information [Line Items]
Revenues	3,297	2,980	2,533
Medication Management Solutions | United States | Operating Segments | Medical
Segment Reporting Information [Line Items]
Revenues	2,627	2,303	1,935
Medication Management Solutions | International | Operating Segments | Medical
Segment Reporting Information [Line Items]
Revenues	670	677	598
Pharmaceutical Systems | Operating Segments | Medical
Segment Reporting Information [Line Items]
Revenues	2,273	2,229	2,001
Pharmaceutical Systems | United States | Operating Segments | Medical
Segment Reporting Information [Line Items]
Revenues	629	666	533
Pharmaceutical Systems | International | Operating Segments | Medical
Segment Reporting Information [Line Items]
Revenues	1,644	1,563	1,468
Advanced Patient Monitoring | Operating Segments | Medical
Segment Reporting Information [Line Items]
Revenues	74	0	0
Advanced Patient Monitoring | United States | Operating Segments | Medical
Segment Reporting Information [Line Items]
Revenues	47	0	0
Advanced Patient Monitoring | International | Operating Segments | Medical
Segment Reporting Information [Line Items]
Revenues	27	0	0
Integrated Diagnostic Solutions | Operating Segments | Life Sciences
Segment Reporting Information [Line Items]
Revenues	3,679	3,624	4,185
Integrated Diagnostic Solutions | United States | Operating Segments | Life Sciences
Segment Reporting Information [Line Items]
Revenues	1,733	1,774	2,190
Integrated Diagnostic Solutions | International | Operating Segments | Life Sciences
Segment Reporting Information [Line Items]
Revenues	1,946	1,850	1,995
Biosciences | Operating Segments | Life Sciences
Segment Reporting Information [Line Items]
Revenues	1,512	1,509	1,379
Biosciences | United States | Operating Segments | Life Sciences
Segment Reporting Information [Line Items]
Revenues	577	603	542
Biosciences | International | Operating Segments | Life Sciences
Segment Reporting Information [Line Items]
Revenues	935	906	838
Surgery | Operating Segments | Interventional
Segment Reporting Information [Line Items]
Revenues	1,492	1,497	1,400
Surgery | United States | Operating Segments | Interventional
Segment Reporting Information [Line Items]
Revenues	1,130	1,159	1,094
Surgery | International | Operating Segments | Interventional
Segment Reporting Information [Line Items]
Revenues	363	338	306
Peripheral Intervention | Operating Segments | Interventional
Segment Reporting Information [Line Items]
Revenues	1,933	1,865	1,759
Peripheral Intervention | United States | Operating Segments | Interventional
Segment Reporting Information [Line Items]
Revenues	1,029	1,016	960
Peripheral Intervention | International | Operating Segments | Interventional
Segment Reporting Information [Line Items]
Revenues	904	849	799
Urology and Critical Care | Operating Segments | Interventional
Segment Reporting Information [Line Items]
Revenues	1,554	1,374	1,305
Urology and Critical Care | United States | Operating Segments | Interventional
Segment Reporting Information [Line Items]
Revenues	1,236	1,073	986
Urology and Critical Care | International | Operating Segments | Interventional
Segment Reporting Information [Line Items]
Revenues	$ 319	$ 301	$ 319

Segment Data - Financial Inform

Segment Data - Financial Information for Company's Segments (Details) - USD ($) $ in Millions	12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2022
Segment Reporting Information [Line Items]
Integration, restructuring and transaction expense	$ (458)	$ (313)	$ (192)
Income from Continuing Operations Before Income Taxes	2,005	1,662	1,783
Total Capital Expenditures	725	874	973
Total Depreciation and Amortization	2,286	2,288	2,229
Operating Segments
Segment Reporting Information [Line Items]
Income from Continuing Operations Before Income Taxes	5,758	4,769	5,006
Operating Segments | Medical
Segment Reporting Information [Line Items]
Income from Continuing Operations Before Income Taxes	2,742	1,967	2,215
Total Capital Expenditures	438	563	602
Total Depreciation and Amortization	1,216	1,199	1,144
Operating Segments | Life Sciences
Segment Reporting Information [Line Items]
Income from Continuing Operations Before Income Taxes	1,595	1,585	1,710
Total Capital Expenditures	114	139	213
Total Depreciation and Amortization	272	277	283
Operating Segments | Interventional
Segment Reporting Information [Line Items]
Income from Continuing Operations Before Income Taxes	1,420	1,217	1,081
Total Capital Expenditures	127	138	130
Total Depreciation and Amortization	786	799	789
Segment Reporting, Reconciling Item, Excluding Corporate Nonsegment
Segment Reporting Information [Line Items]
Integration, restructuring and transaction expense	(458)	(313)	(173)
Net interest expense	(364)	(403)	(382)
Corporate and All Other
Segment Reporting Information [Line Items]
Income from Continuing Operations Before Income Taxes	(2,931)	(2,391)	(2,668)
Total Capital Expenditures	46	35	28
Total Depreciation and Amortization	$ 13	$ 13	$ 13

Segment Data - Revenues to Unaf

Segment Data - Revenues to Unaffiliated Customers and Long-lived Assets Including Property, Plant and Equipment (Detail) - USD ($) $ in Millions	12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2022
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	$ 20,178	$ 19,372	$ 18,870
Long-Lived Assets	46,818	44,104	44,792
Corporate
Revenues from External Customers and Long-Lived Assets [Line Items]
Long-Lived Assets	459	418	442
United States
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	11,663	11,113	10,722
Long-Lived Assets	35,526	35,732	36,617
EMEA
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	4,402	4,244	4,043
Long-Lived Assets	6,706	5,317	5,126
Greater Asia
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	2,906	2,913	3,047
Long-Lived Assets	1,580	1,521	1,528
Other
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	1,207	1,102	1,058
Long-Lived Assets	$ 2,548	$ 1,116	$ 1,079

Share-Based Compensation - Comp

Share-Based Compensation - Compensation Cost Relating to Share-Based Payments (Details) - USD ($) $ in Millions	12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2022
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total share-based compensation cost	$ 249	$ 261	$ 240
Tax benefit associated with share-based compensation costs recognized	58	58	55
Cost of products sold
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total share-based compensation cost	51	50	46
Selling and administrative expense
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total share-based compensation cost	156	170	156
Research and development expense
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total share-based compensation cost	42	41	37
Integration, restructuring and transaction expense
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total share-based compensation cost	$ 0	$ 0	$ 1

Share-Based Compensation - Addi

Share-Based Compensation - Additional Information (Details) shares in Thousands, $ in Millions	12 Months Ended
	Sep. 30, 2024 USD ($) shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
SARs vesting period (in years)	4 years
SARs terms of award (in years)	10 years
Stock issued under SARs exercised (in shares)	100
Percentage of target payout on which performance based restricted stock units are based	200%
Percentage of target payout on which performance based time-vested restricted stock units are based	100%
Expected forfeited performance-based restricted stock units (shares)	71
Units in excess of expected performance payout (in shares)	454
Unrecognized compensation expense for all non-vested share-based awards | $	$ 253
Weighted-average remaining life non-vested share-based awards (in years)	1 year 9 months 18 days
Shares authorized for future grants	10,000
Shares issuable under deferred compensation plan	200
Director
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Deferral plan, shares held in trust	81
Performance-Based
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock units vesting period (in years)	3 years
Performance period (in years)	3 years
Weighted average remaining vesting term (in years)	1 year 2 months 26 days
Performance-Based | Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Performance payout, percent	0%
Performance-Based | Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Performance payout, percent	200%
Time-Vested
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock units vesting period (in years)	3 years
Weighted average remaining vesting term (in years)	10 months 13 days
Time-Vested | Executive Officer
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock units vesting period (in years)	1 year

Share-Based Compensation - Assu

Share-Based Compensation - Assumptions for Estimation of Fair Values of Stock Appreciation Rights Granted During Reporting Periods (Details) - Stock Appreciation Rights (SARs) - $ / shares	12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2022
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk-free interest rate	4.51%	3.78%	1.41%
Expected volatility	22%	21%	22%
Expected dividend yield	1.59%	1.53%	1.42%
Expected life	7 years	7 years	7 years 3 months 18 days
Fair value derived (in USD per share)	$ 63.05	$ 57.80	$ 49.45

Share-Based Compensation - Summ

Share-Based Compensation - Summary of SARs Outstanding (Details) $ / shares in Units, shares in Thousands, $ in Millions	12 Months Ended
	Sep. 30, 2024 USD ($) $ / shares shares
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
SARs, beginning balance (shares) | shares	4,905
SARs, granted (shares) | shares	597
SARs, exercised (shares) | shares	(297)
SARs, forfeited, canceled or expired (shares) | shares	(210)
SARs, ending balance (shares) | shares	4,995
SARs, Vested and expected to vest at ending balance (shares) | shares	4,863
SARs, Exercisable at ending balance (shares) | shares	3,669
Weighted Average Grant Date Fair Value
SARs, weighted average exercise price, beginning balance (in USD per share) | $ / shares	$ 211.47
SARs, weighted average exercise price, granted (in USD per share) | $ / shares	238.89
SARs, weighted average exercise price, exercised (in USD per share) | $ / shares	154.25
SARs, weighted average exercise price, forfeited, canceled or expired (in USD per share) | $ / shares	237.09
SARs, weighted average exercise price, ending balance (in USD per share) | $ / shares	217.07
SARs, weighted average exercise price, vested and expected to vest (in USD per share) | $ / shares	216.50
SARs, weighted average exercise price, exercisable (in USD per share) | $ / shares	$ 209.57
SARs, weighted average remaining contractual term (in years)	5 years 3 months
SARs, weighted average remaining contractual term, vested and expected to vest (in years)	5 years 2 months 1 day
SARs, weighted average remaining contractual term, exercisable (in years)	4 years 2 months 4 days
SARs, aggregate intrinsic value | $	$ 125
SARs, aggregate intrinsic value, vested and expected to vest | $	125
SARs, aggregate intrinsic value, exercisable | $	$ 121

Share-Based Compensation - Su_2

Share-Based Compensation - Summary of SARs Exercised (Details) - USD ($) $ in Millions	12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2022
Share-Based Payment Arrangement [Abstract]
Total intrinsic value of SARs exercised	$ 25	$ 126	$ 184
Total fair value of SARs vested	$ 31	$ 34	$ 36

Share-Based Compensation - Su_3

Share-Based Compensation - Summary of Performance-Based Restricted Stock Units Outstanding (Details) - $ / shares shares in Thousands	12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2022
Performance-Based
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Stock units, beginning balance (shares)	963
Granted, stock units (shares)	387
Distributed, stock units (shares)	(145)
Forfeited, canceled or expired, stock units (shares)	(213)
Stock units, ending balance (shares)	991	963
Stock units, vested and expected to vest at ending balance (shares)	465
Weighted Average Grant Date Fair Value
Stock units exercise price, beginning balance (in USD per share)	$ 226.51
Granted, stock units weighted average grant date fair value (in USD per share)	223.60	$ 227.11	$ 242.39
Distributed, stock units exercise price (USD per share)	212.46
Forfeited, canceled or expired, stock units exercise price (USD per share)	219.15
Stock units exercise price, ending balance (in USD per share)	229.02	$ 226.51
Stock units, vested and expected to vest at ending balance, exercise price (in USD per share)	$ 229.96
Time-Vested
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Stock units, beginning balance (shares)	1,716
Granted, stock units (shares)	922
Distributed, stock units (shares)	(556)
Forfeited, canceled or expired, stock units (shares)	(390)
Stock units, ending balance (shares)	1,693	1,716
Stock units, vested and expected to vest at ending balance (shares)	1,549
Weighted Average Grant Date Fair Value
Stock units exercise price, beginning balance (in USD per share)	$ 225.33
Granted, stock units weighted average grant date fair value (in USD per share)	231.32	$ 231.58	$ 239.39
Distributed, stock units exercise price (USD per share)	225.13
Forfeited, canceled or expired, stock units exercise price (USD per share)	231.68
Stock units exercise price, ending balance (in USD per share)	227.20	$ 225.33
Stock units, vested and expected to vest at ending balance, exercise price (in USD per share)	$ 226.80

Share-Based Compensation - Weig

Share-Based Compensation - Weighted Average Grant Date Fair Value of Restricted Stock Units (Details) - $ / shares	12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2022
Performance-Based
Schedule Of Share Based Compensation, Restricted Stock Units Award, Grant Date Fair Value of Units Granted [Line Items]
Granted, stock units weighted average grant date fair value (in USD per share)	$ 223.60	$ 227.11	$ 242.39
Time-Vested
Schedule Of Share Based Compensation, Restricted Stock Units Award, Grant Date Fair Value of Units Granted [Line Items]
Granted, stock units weighted average grant date fair value (in USD per share)	$ 231.32	$ 231.58	$ 239.39

Share-Based Compensation - Fair

Share-Based Compensation - Fair Value of Stock Units Vested (Details) - USD ($) $ in Millions	12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2022
Performance-Based
Schedule Of Share Based Compensation, Restricted Stock Units, Fair Value of Stock Units Vested [Line Items]
Total fair value of units vested	$ 45	$ 28	$ 14
Time-Vested
Schedule Of Share Based Compensation, Restricted Stock Units, Fair Value of Stock Units Vested [Line Items]
Total fair value of units vested	$ 179	$ 169	$ 169

Benefit Plans - Net Pension and

Benefit Plans - Net Pension and Other Postretirement Cost (Details) - USD ($) $ in Millions	12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2022
Defined Benefit Plan Disclosure [Line Items]
Net pension cost	$ 65	$ 98	$ 17
Pension Plans
Defined Benefit Plan Disclosure [Line Items]
Service cost	88	91	134
Interest cost	139	129	77
Expected return on plan assets	(150)	(141)	(187)
Amortization of prior service credit	(4)	(7)	(15)
Amortization of loss	57	58	61
Curtailments/settlement loss	1	44	73
Net pension cost	131	174	143
International plans | Pension Plans
Defined Benefit Plan Disclosure [Line Items]
Net pension cost	$ 28	$ 25	$ 20

Benefit Plans - Change in Benef

Benefit Plans - Change in Benefit Obligation, Change in Fair Value of Plan Assets (Details) - USD ($) $ in Millions	12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2022
Amounts recognized in the Consolidated Balance Sheets at September 30:
Long-term Employee Benefit Obligations	$ (942)	$ (1,023)
Pension Plans
Defined Benefit Plan, Change in Benefit Obligation [Roll Forward]
Beginning obligation	2,617	2,634
Service cost	88	91	$ 134
Interest cost	139	129	77
Benefits paid	(201)	(67)
Actuarial gain	241	(24)
Curtailments/settlements	(21)	(214)
Other, includes translation	51	68
Ending obligation	2,913	2,617	2,634
Change in fair value of plan assets:
Beginning fair value	2,129	2,242
Actual return on plan assets	395	33
Employer contribution	200	62
Benefits paid	(201)	(67)
Settlements	(21)	(200)
Other, includes translation	54	59
Ending fair value	2,557	2,129	$ 2,242
Funded Status at September 30:
Unfunded benefit obligation	(356)	(488)
Amounts recognized in the Consolidated Balance Sheets at September 30:
Other Assets	99	81
Salaries, wages and related items	(12)	(15)
Long-term Employee Benefit Obligations	(443)	(554)
Net amount recognized	(356)	(488)
Amounts recognized in Accumulated other comprehensive income (loss) before income taxes at September 30:
Prior service credit	2	3
Net actuarial loss	(636)	(689)
Net amount recognized	$ (634)	$ (686)

Benefit Plans - Additional Info

Benefit Plans - Additional Information (Details) - USD ($) $ in Millions	12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2022
Defined Benefit Plan Disclosure [Line Items]
Percent of total assets domestic plans	66%
Cost of the savings incentive plan	$ 195	$ 156	$ 178
Fixed Income Funds
Defined Benefit Plan Disclosure [Line Items]
Company's target allocation percentage for asset mix	45%
Diversified
Defined Benefit Plan Disclosure [Line Items]
Company's target allocation percentage for asset mix	21%
Equity securities
Defined Benefit Plan Disclosure [Line Items]
Company's target allocation percentage for asset mix	34%
Pension Plans
Defined Benefit Plan Disclosure [Line Items]
Pension plan assets at fair value	$ 2,557	2,129	2,242
Pension plan projected benefit obligations	2,913	2,617	$ 2,634
Employer contribution	200	62
International plans | Pension Plans
Defined Benefit Plan Disclosure [Line Items]
Pension plan assets at fair value	880	748
Pension plan projected benefit obligations	$ 992	833
Percent of total plan assets foreign plans	34%
International plans | Pension Plans | Equity securities
Defined Benefit Plan Disclosure [Line Items]
Pension plan assets at fair value	$ 196	173
United States | Pension Plans
Defined Benefit Plan Disclosure [Line Items]
Pension plan assets at fair value	1,676	1,382
Employer contribution	150
United States | Pension Plans | Equity securities
Defined Benefit Plan Disclosure [Line Items]
Pension plan assets at fair value	582	469
United States | Other Postretirement Benefits
Defined Benefit Plan Disclosure [Line Items]
Pension plan projected benefit obligations	$ 94	$ 92

Benefit Plans - Pension Plans w

Benefit Plans - Pension Plans with Accumulated Benefit Obligations (Details) - USD ($) $ in Millions	Sep. 30, 2024	Sep. 30, 2023
Retirement Benefits [Abstract]
Accumulated benefit obligation exceeds the fair value of plan assets, projected benefit obligation	$ 2,382	$ 2,140
Projected benefit obligation exceeds the fair value of plan assets, projected benefit obligation	2,382	2,159
Accumulated benefit obligation exceeds the fair value of plan assets, accumulated benefit obligation	2,318	2,088
Accumulated benefit obligation exceeds the fair value of plan assets, fair value of plan assets	1,927	1,575
Projected benefit obligation exceeds the fair value of plan assets, fair value of plan assets	$ 1,927	$ 1,591

Benefit Plans - Weighted Averag

Benefit Plans - Weighted Average Assumptions Determining Pension Plan (Details) - Pension Plans	12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2022
United States
Net Cost
Discount rate:	6.01%	5.62%	2.89%
Expected return on plan assets:	7.29%	7.25%	6.25%
Rate of compensation increase:	4%	4.51%	4.31%
Cash balance plan interest crediting rate:	4%	4%	4%
Benefit Obligation
Discount rate:	4.98%	6.01%	5.62%
Rate of compensation increase:	4%	4%	4.51%
Cash balance plan interest crediting rate:	4%	4%	4%
International plans
Net Cost
Discount rate:	4.52%	4.26%	1.75%
Expected return on plan assets:	5.30%	5.02%	4.84%
Rate of compensation increase:	2.81%	2.86%	2.63%
Cash balance plan interest crediting rate:	2.16%	1.98%	2.02%
Benefit Obligation
Discount rate:	3.88%	4.62%	4.26%
Rate of compensation increase:	2.81%	2.86%	2.86%
Cash balance plan interest crediting rate:	2.21%	2.21%	1.98%

Benefit Plans - Expected Benefi

Benefit Plans - Expected Benefit Payments (Details) - Pension Plans $ in Millions	Sep. 30, 2024 USD ($)
Defined Benefit Plan Disclosure [Line Items]
2025	$ 238
2026	239
2027	221
2028	216
2029	212
2030-2034	$ 1,008

Benefit Plans - Fair Value Meas

Benefit Plans - Fair Value Measurements of Plan Assets (Details) - Pension Plans - USD ($) $ in Millions	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2022
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	$ 2,557	$ 2,129	$ 2,242
United States
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	1,676	1,382
United States | Corporate bonds
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	518	443
United States | Government and agency-U.S.
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	159	53
United States | Government and agency-Foreign
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	31	17
United States | Other fixed income
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	53	46
United States | Equity securities
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	582	469
United States | Cash and cash equivalents
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	172	202
United States | Other
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	162	151
International plans
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	880	748
International plans | Corporate bonds
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	114	122
International plans | Government and agency-U.S.
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	9	9
International plans | Government and agency-Foreign
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	223	197
International plans | Other fixed income
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	52	43
International plans | Equity securities
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	196	173
International plans | Cash and cash equivalents
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	13	10
International plans | Other
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	117	55
International plans | Real estate
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	44	36
International plans | Insurance contracts
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	113	103
Net Asset Value | United States
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	146	138
Net Asset Value | United States | Corporate bonds
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Net Asset Value | United States | Government and agency-U.S.
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Net Asset Value | United States | Government and agency-Foreign
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Net Asset Value | United States | Other fixed income
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Net Asset Value | United States | Equity securities
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	71	59
Net Asset Value | United States | Cash and cash equivalents
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Net Asset Value | United States | Other
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	75	79
Level 1 | United States
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	1,240	1,012
Level 1 | United States | Corporate bonds
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	296	260
Level 1 | United States | Government and agency-U.S.
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	149	43
Level 1 | United States | Government and agency-Foreign
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Level 1 | United States | Other fixed income
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	25	24
Level 1 | United States | Equity securities
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	512	410
Level 1 | United States | Cash and cash equivalents
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	172	202
Level 1 | United States | Other
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	87	72
Level 1 | International plans
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	600	499
Level 1 | International plans | Corporate bonds
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	92	100
Level 1 | International plans | Government and agency-U.S.
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	7	8
Level 1 | International plans | Government and agency-Foreign
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	188	165
Level 1 | International plans | Other fixed income
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	44	34
Level 1 | International plans | Equity securities
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	166	147
Level 1 | International plans | Cash and cash equivalents
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	11	8
Level 1 | International plans | Other
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	92	35
Level 1 | International plans | Real estate
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	1	1
Level 1 | International plans | Insurance contracts
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Level 2 | United States
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	291	231
Level 2 | United States | Corporate bonds
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	222	182
Level 2 | United States | Government and agency-U.S.
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	10	10
Level 2 | United States | Government and agency-Foreign
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	31	17
Level 2 | United States | Other fixed income
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	28	22
Level 2 | United States | Equity securities
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Level 2 | United States | Cash and cash equivalents
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Level 2 | United States | Other
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Level 2 | International plans
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	85	74
Level 2 | International plans | Corporate bonds
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	9	10
Level 2 | International plans | Government and agency-U.S.
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	2	2
Level 2 | International plans | Government and agency-Foreign
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	28	26
Level 2 | International plans | Other fixed income
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	9	9
Level 2 | International plans | Equity securities
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	1
Level 2 | International plans | Cash and cash equivalents
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Level 2 | International plans | Other
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	3	1
Level 2 | International plans | Real estate
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	34	26
Level 2 | International plans | Insurance contracts
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Level 3 | United States
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Level 3 | United States | Corporate bonds
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Level 3 | United States | Government and agency-U.S.
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Level 3 | United States | Government and agency-Foreign
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Level 3 | United States | Other fixed income
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Level 3 | United States | Equity securities
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Level 3 | United States | Cash and cash equivalents
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Level 3 | United States | Other
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Level 3 | International plans
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	195	175
Level 3 | International plans | Corporate bonds
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	13	12
Level 3 | International plans | Government and agency-U.S.
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Level 3 | International plans | Government and agency-Foreign
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	7	6
Level 3 | International plans | Other fixed income
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Level 3 | International plans | Equity securities
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	30	25
Level 3 | International plans | Cash and cash equivalents
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	2	2
Level 3 | International plans | Other
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	22	19
Level 3 | International plans | Real estate
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	9	9
Level 3 | International plans | Insurance contracts
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	$ 113	$ 103

Acquisitions (Details)

Acquisitions (Details) - USD ($) $ in Millions			12 Months Ended
	Sep. 03, 2024	Jul. 18, 2022	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2022
Business Acquisition [Line Items]
Goodwill			$ 26,465	$ 24,522	$ 24,621
Advanced Patient Monitoring
Business Acquisition [Line Items]
Business combination. consideration transferred	$ 3,911
Business combination, recognized identifiable assets acquired and liabilities assumed, other net assets	(714)
Goodwill	1,833
Business Acquisition, Goodwill, Expected Tax Deductible Amount			1,100
Revenues			$ 21,069	$ 20,258
Advanced Patient Monitoring | Developed technology
Business Acquisition [Line Items]
Business combination, recognized identifiable assets acquired and liabilities assumed, finite-lived intangibles	714
Advanced Patient Monitoring | Customer relationships
Business Acquisition [Line Items]
Business combination, recognized identifiable assets acquired and liabilities assumed, finite-lived intangibles	$ 650
Parata Systems
Business Acquisition [Line Items]
Business combination. consideration transferred		$ 1,548
Business combination, recognized identifiable assets acquired and liabilities assumed, other net assets		(1)
Goodwill		759
Parata Systems | Developed technology
Business Acquisition [Line Items]
Business combination, recognized identifiable assets acquired and liabilities assumed, finite-lived intangibles		628
Parata Systems | Customer relationships
Business Acquisition [Line Items]
Business combination, recognized identifiable assets acquired and liabilities assumed, finite-lived intangibles		$ 161

Business Restructuring Charge_2

Business Restructuring Charges - Changes in Restructuring Balance (Details) - USD ($) $ in Millions	12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2022
Restructuring Cost and Reserve [Line Items]
Restructuring Charges, Statement of Income or Comprehensive Income [Extensible Enumeration]	Integration, restructuring and transaction expense	Integration, restructuring and transaction expense	Integration, restructuring and transaction expense
Restructuring Reserve [Roll Forward]
Beginning balance	$ 80	$ 35	$ 19
Charged to expense	387	239	123
Cash payments	(305)	(165)	(82)
Non-cash settlements	(104)	(30)	(25)
Other adjustments	2	1	1
Ending balance	60	80	35
Employee Termination
Restructuring Reserve [Roll Forward]
Beginning balance	79	24	14
Charged to expense	80	117	21
Cash payments	(103)	(62)	(11)
Non-cash settlements	0	0	0
Other adjustments	2	0	0
Ending balance	58	79	24
Other
Restructuring Reserve [Roll Forward]
Beginning balance	1	11	5
Charged to expense	307	122	103
Cash payments	(202)	(103)	(71)
Non-cash settlements	(104)	(30)	(25)
Other adjustments	0	1	1
Ending balance	$ 2	$ 1	$ 11

Intangible Assets - Components

Intangible Assets - Components of Intangible Assets (Details) - USD ($) $ in Millions	Sep. 30, 2024	Sep. 30, 2023
Finite And Indefinite Lived Intangible Assets [Line Items]
Gross Carrying Amount	$ 22,525	$ 21,069
Accumulated Amortization	(11,654)	(10,168)
Finite-Lived Intangible Assets, Net	10,871	10,901
Unamortized intangible assets	46	46
Acquired in-process research and development
Finite And Indefinite Lived Intangible Assets [Line Items]
Unamortized intangible assets	44	44
Trademarks
Finite And Indefinite Lived Intangible Assets [Line Items]
Unamortized intangible assets	2	2
Developed technology
Finite And Indefinite Lived Intangible Assets [Line Items]
Gross Carrying Amount	15,827	15,080
Accumulated Amortization	(8,094)	(7,023)
Finite-Lived Intangible Assets, Net	7,733	8,058
Customer relationships
Finite And Indefinite Lived Intangible Assets [Line Items]
Gross Carrying Amount	5,513	4,859
Accumulated Amortization	(2,878)	(2,521)
Finite-Lived Intangible Assets, Net	2,635	2,338
Patents, trademarks and other
Finite And Indefinite Lived Intangible Assets [Line Items]
Gross Carrying Amount	1,185	1,130
Accumulated Amortization	(682)	(624)
Finite-Lived Intangible Assets, Net	$ 503	$ 505

Intangible Assets - Additional

Intangible Assets - Additional Information (Details) - USD ($) $ in Millions	12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible amortization expense	$ 1,468	$ 1,465	$ 1,430
Estimated aggregate amortization expense in 2025	1,551
Estimated aggregate amortization expense in 2026	1,519
Estimated aggregate amortization expense in 2027	1,450
Estimated aggregate amortization expense in 2028	1,357
Estimated aggregate amortization expense in 2029	$ 1,264

Intangible Assets - Reconciliat

Intangible Assets - Reconciliation of Goodwill by Business Segment (Details) - USD ($) $ in Millions	12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Goodwill [Roll Forward]
Goodwill, beginning balance	$ 24,522	$ 24,621
Goodwill, written off related to sale of business unit		(218)
Goodwill, measurement period adjustment		13
Goodwill, foreign currency translation gain (loss)	109	105
Goodwill, acquired during period	1,833
Goodwill, ending balance	26,465	24,522
Medical
Goodwill [Roll Forward]
Goodwill, beginning balance	10,955	10,909
Goodwill, written off related to sale of business unit		0
Goodwill, measurement period adjustment		13
Goodwill, foreign currency translation gain (loss)	43	33
Goodwill, acquired during period	1,833
Goodwill, ending balance	12,832	10,955
Life Sciences
Goodwill [Roll Forward]
Goodwill, beginning balance	897	888
Goodwill, written off related to sale of business unit		0
Goodwill, measurement period adjustment		0
Goodwill, foreign currency translation gain (loss)	7	9
Goodwill, acquired during period	0
Goodwill, ending balance	904	897
Interventional
Goodwill [Roll Forward]
Goodwill, beginning balance	12,670	12,824
Goodwill, written off related to sale of business unit		(218)
Goodwill, measurement period adjustment		0
Goodwill, foreign currency translation gain (loss)	59	64
Goodwill, acquired during period	0
Goodwill, ending balance	$ 12,729	$ 12,670

Derivative Instruments and He_3

Derivative Instruments and Hedging Activities - Schedule of Notional Amounts of Outstanding Derivative Positions (Detail) - USD ($) $ in Millions	Sep. 30, 2024	Sep. 30, 2023
Debt | Net investment hedges
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Derivative, Notional Amount	$ 3,065	$ 1,056
Foreign currency-denominated debt
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Derivative, Notional Amount	4,521	3,146
Foreign currency-denominated debt | Cash flow hedges
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Derivative, Notional Amount	543	0
Currency Swap | Net investment hedges
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Derivative, Notional Amount	1,366	2,119
Fixed To Floating | Fair value hedges
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Derivative, Notional Amount	700	700
Interest Rate Swap [Member] | Cash flow hedges
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Derivative, Notional Amount	$ 0	$ 500

Derivative Instruments and He_4

Derivative Instruments and Hedging Activities Disclosure - Gains (Losses) on Net Investment Hedges (Details) - USD ($) $ in Millions	12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2022
Derivative Instruments, Gain (Loss) [Line Items]
Foreign currency translation adjustments	$ (166)	$ (91)	$ 305
Foreign currency-denominated debt
Derivative Instruments, Gain (Loss) [Line Items]
Foreign currency translation adjustments	(96)	(155)	320
Currency Swap
Derivative Instruments, Gain (Loss) [Line Items]
Foreign currency translation adjustments	(71)	(70)	173
Terminated Currency Swap
Derivative Instruments, Gain (Loss) [Line Items]
Foreign currency translation adjustments	$ 9	$ 13	$ 46

Derivative Instruments and He_5

Derivative Instruments and Hedging Activities - Additional Information (Detail) - Cash flow hedges - USD ($) $ in Millions	12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2022
Interest Rate Swap [Member]
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Other comprehensive income (loss), cash flow hedge, gain (loss), before reclassification and tax	$ (10)	$ 23	$ 92
Net after-tax gain upon termination of contract	67		$ 41
Foreign currency-denominated debt
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Other comprehensive income (loss), cash flow hedge, gain (loss), after reclassification and tax	$ 0

Financial Instruments and Fai_3

Financial Instruments and Fair Value Measurement - Cash and Equivalents and Restricted Cash (Details) - USD ($) $ in Millions	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2021
Fair Value Disclosures [Abstract]
Cash and equivalents	$ 1,717	$ 1,416
Restricted cash	139	65
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents	$ 1,856	$ 1,481	$ 1,159	$ 2,392

Financial Instruments and Fai_4

Financial Instruments and Fair Value Measurements - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details) - USD ($) $ in Millions	Sep. 30, 2024	Sep. 30, 2023
Fair Value Disclosures [Abstract]
Institutional money market investments	$ 285	$ 373
Fair value of debt classified from long term to short term	1,748	1,122
Fair value of long-term debt	$ 17,199	$ 12,850

Financial Instruments and Fai_5

Financial Instruments and Fair Value Measurements - Additional Information (Details) - USD ($) $ in Millions	12 Months Ended
	Sep. 30, 2024	Sep. 30, 2022	Sep. 30, 2023
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Supplier finance program, obligation	$ 112		$ 94
Supplier Finance Program, Obligation, Statement of Financial Position [Extensible Enumeration]	Accounts payable		Accounts payable
Integration and Restructuring Expense
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Asset impairment charges	$ 83
Minimum
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Maturity period of short-term investments at the time of purchase	3 months
Supplier finance program, payment timing, period	90 days
Maximum
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Maturity period of short-term investments at the time of purchase	1 year
Supplier finance program, payment timing, period	150 days
Life Sciences | Cost of products sold
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Asset impairment charges		$ 11
Medical | Cost of products sold
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Asset impairment charges		54
Medical | Integration, restructuring and transaction expense
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Asset impairment charges		$ 19

Financial Instruments and Fai_6

Financial Instruments and Fair Value Measurements - Transfer of Financial Assets Accounted for as Sales (Details) - USD ($) $ in Millions	12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2022
Fair Value Disclosures [Abstract]
Trade receivables transferred to third parties under factoring arrangements	$ 1,385	$ 2,615	$ 1,215
Amounts yet to be collected and remitted to the third parties	$ 254	$ 357

Debt - Summary of Short-Term De

Debt - Summary of Short-Term Debt (Details) - USD ($) $ in Millions	Sep. 30, 2024	Sep. 30, 2023
Short-term Debt [Line Items]
Other short-term borrowings	$ 1	$ 0
Current debt obligations	2,170	1,141
Commercial Paper
Short-term Debt [Line Items]
Short-term debt	$ 400	0
3.875% Notes due May 15, 2024
Short-term Debt [Line Items]
Interest rate (percent)	3.875%
Current portion of long-term debt	$ 0	144
3.363% Notes due June 6, 2024
Short-term Debt [Line Items]
Interest rate (percent)	3.363%
Current portion of long-term debt	$ 0	997
3.734% Notes due December 15, 2024
Short-term Debt [Line Items]
Interest rate (percent)	3.734%
Current portion of long-term debt	$ 875	0
3.020% Notes due May 24, 2025
Short-term Debt [Line Items]
Interest rate (percent)	3.02%
Current portion of long-term debt	$ 335	0
0.034% Notes due August 13, 2025
Short-term Debt [Line Items]
Interest rate (percent)	0.034%
Current portion of long-term debt	$ 559	$ 0

Debt - Additional Information (

Debt - Additional Information (Details) - USD ($) $ in Millions	1 Months Ended
	Jul. 31, 2024	Sep. 30, 2024	Sep. 30, 2023
Debt Instrument [Line Items]
Short-term debt, weighted average interest rate (percent)		2.91%	3.43%
Line of credit facility, maximum borrowing capacity		$ 3,250
Aggregate annual maturities of long-term debt, 2025		2,824
Aggregate annual maturities of long-term debt, 2026		1,297
Aggregate annual maturities of long-term debt, 2027		3,136
Aggregate annual maturities of long-term debt, 2028		2,434
Aggregate annual maturities of long-term debt, 2029		2,581
Letters of credit issuable under credit facility		100
Swingline loans issuable under credit facility		194
Line of credit facility, maximum additional principal amount commitments		500
Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Debt instrument, term (in years)	5 years
Debt instrument, term extension (in years)	1 year
Borrowings under credit facility		0	$ 0
Revolving Credit Facility [Member] | Maximum
Debt Instrument [Line Items]
Line of credit facility, current borrowing capacity		2,750
Commercial Paper
Debt Instrument [Line Items]
Line of credit facility, maximum borrowing capacity		2,750
Short-term debt		$ 400	$ 0

Debt - Summary of Long-Term Deb

Debt - Summary of Long-Term Debt (Details) - USD ($) $ in Millions	Sep. 30, 2024	Sep. 30, 2023
Debt Instrument [Line Items]
Long-Term Debt	$ 17,940	$ 14,738
3.734% Notes due December 15, 2024
Debt Instrument [Line Items]
Interest rate (percent)	3.734%
Long-Term Debt	$ 0	874
3.020% Notes due May 24, 2025
Debt Instrument [Line Items]
Interest rate (percent)	3.02%
Long-Term Debt	$ 0	306
0.034% Notes due August 13, 2025
Debt Instrument [Line Items]
Interest rate (percent)	0.034%
Long-Term Debt	$ 0	528
1.208% Notes due June 4, 2026
Debt Instrument [Line Items]
Interest rate (percent)	1.208%
Long-Term Debt	$ 671	634
6.700% Notes due December 1, 2026
Debt Instrument [Line Items]
Interest rate (percent)	6.70%
Long-Term Debt	$ 158	161
1.900% Notes due December 15, 2026
Debt Instrument [Line Items]
Interest rate (percent)	1.90%
Long-Term Debt	$ 559	528
3.700% Notes due June 6, 2027
Debt Instrument [Line Items]
Interest rate (percent)	3.70%
Long-Term Debt	$ 1,721	1,719
7.000% Debentures due August 1, 2027
Debt Instrument [Line Items]
Interest rate (percent)	7%
Long-Term Debt	$ 118	119
4.693% Notes due February 13, 2028
Debt Instrument [Line Items]
Interest rate (percent)	4.693%
Long-Term Debt	$ 797	796
6.700% Debentures due August 1, 2028
Debt Instrument [Line Items]
Interest rate (percent)	6.70%
Long-Term Debt	$ 115	115
0.334% Notes due August 13, 2028
Debt Instrument [Line Items]
Interest rate (percent)	0.334%
Long-Term Debt	$ 1,004	949
4.874% Notes due February 8, 2029
Debt Instrument [Line Items]
Interest rate (percent)	4.874%
Long-Term Debt	$ 622	0
5.081% Notes due June 7, 2029
Debt Instrument [Line Items]
Interest rate (percent)	5.081%
Long-Term Debt	$ 596	0
3.553% Notes due September 13, 2029
Debt Instrument [Line Items]
Interest rate (percent)	3.553%
Long-Term Debt	$ 891	842
2.823% Notes due May 20, 2030
Debt Instrument [Line Items]
Interest rate (percent)	2.823%
Long-Term Debt	$ 746	745
3.519% Notes due February 8, 2031
Debt Instrument [Line Items]
Interest rate (percent)	3.519%
Long-Term Debt	$ 835	0
1.957% Notes due February 11, 2031
Debt Instrument [Line Items]
Interest rate (percent)	1.957%
Long-Term Debt	$ 994	993
3.828% Notes due June 7, 2032
Debt Instrument [Line Items]
Interest rate (percent)	3.828%
Long-Term Debt	$ 1,113	0
4.298% Notes due August 22, 2032
Debt Instrument [Line Items]
Interest rate (percent)	4.298%
Long-Term Debt	$ 496	496
5.110% Notes due February 8, 2034
Debt Instrument [Line Items]
Interest rate (percent)	5.11%
Long-Term Debt	$ 545	0
1.213% Notes due February 12, 2036
Debt Instrument [Line Items]
Interest rate (percent)	1.213%
Long-Term Debt	$ 668	631
4.029% Notes due June 7, 2036
Debt Instrument [Line Items]
Interest rate (percent)	4.029%
Long-Term Debt	$ 889	0
6.000% Notes due May 15, 2039
Debt Instrument [Line Items]
Interest rate (percent)	6%
Long-Term Debt	$ 121	121
5.000% Notes due November 12, 2040
Debt Instrument [Line Items]
Interest rate (percent)	5%
Long-Term Debt	$ 90	90
1.336% Notes due August 13, 2041
Debt Instrument [Line Items]
Interest rate (percent)	1.336%
Long-Term Debt	$ 999	945
4.875% Notes due May 15, 2044
Debt Instrument [Line Items]
Interest rate (percent)	4.875%
Long-Term Debt	$ 244	245
4.685% Notes due December 15, 2044
Debt Instrument [Line Items]
Interest rate (percent)	4.685%
Long-Term Debt	$ 934	899
4.669% Notes due June 6, 2047
Debt Instrument [Line Items]
Interest rate (percent)	4.669%
Long-Term Debt	$ 1,460	1,445
3.794% Notes due May 20, 2050
Debt Instrument [Line Items]
Interest rate (percent)	3.794%
Long-Term Debt	$ 554	554
Other long-term debt
Debt Instrument [Line Items]
Long-Term Debt	$ 1	$ 2

Debt - Schedule of Debt Issuanc

Debt - Schedule of Debt Issuances (Details) € in Millions, $ in Millions	Sep. 30, 2024 USD ($)	Sep. 30, 2024 EUR (€)	Sep. 30, 2023 USD ($)	Sep. 30, 2023 EUR (€)
5.081% Notes due June 7, 2029
Debt Instrument [Line Items]
Interest rate (percent)	5.081%	5.081%
Debt instrument, face amount	$ 600
4.874% Notes due February 8, 2029
Debt Instrument [Line Items]
Interest rate (percent)	4.874%	4.874%
Debt instrument, face amount	$ 625
3.363% Notes due June 6, 2024
Debt Instrument [Line Items]
Interest rate (percent)	3.363%	3.363%
3.734% Notes due December 15, 2024
Debt Instrument [Line Items]
Interest rate (percent)	3.734%	3.734%
5.110% Notes due February 8, 2034
Debt Instrument [Line Items]
Interest rate (percent)	5.11%	5.11%
Debt instrument, face amount	$ 550
4.693% Notes due February 13, 2028
Debt Instrument [Line Items]
Interest rate (percent)	4.693%	4.693%
Debt instrument, face amount			$ 800
1.401% Notes due May 24, 2023
Debt Instrument [Line Items]
Interest rate (percent)	1.401%	1.401%
0.000% Notes due August 13, 2023
Debt Instrument [Line Items]
Interest rate (percent)	0%	0%
3.828% Notes due June 7, 2032
Debt Instrument [Line Items]
Interest rate (percent)	3.828%	3.828%
3.828% Notes due June 7, 2032 | Euro Member Countries, Euro
Debt Instrument [Line Items]
Debt instrument, face amount | €		€ 1,000
3.828% Notes due June 7, 2032 | United States of America, Dollars
Debt Instrument [Line Items]
Debt instrument, face amount	$ 1,087
3.519% Notes due February 8, 2031
Debt Instrument [Line Items]
Interest rate (percent)	3.519%	3.519%
3.519% Notes due February 8, 2031 | Euro Member Countries, Euro
Debt Instrument [Line Items]
Debt instrument, face amount | €		€ 750
3.519% Notes due February 8, 2031 | United States of America, Dollars
Debt Instrument [Line Items]
Debt instrument, face amount	$ 806
3.875% Notes due May 15, 2024
Debt Instrument [Line Items]
Interest rate (percent)	3.875%	3.875%
4.029% Notes due June 7, 2036
Debt Instrument [Line Items]
Interest rate (percent)	4.029%	4.029%
4.029% Notes due June 7, 2036 | Euro Member Countries, Euro
Debt Instrument [Line Items]
Debt instrument, face amount | €		€ 800
4.029% Notes due June 7, 2036 | United States of America, Dollars
Debt Instrument [Line Items]
Debt instrument, face amount	$ 869
3.553% Notes due September 13, 2029
Debt Instrument [Line Items]
Interest rate (percent)	3.553%	3.553%
3.553% Notes due September 13, 2029 | Euro Member Countries, Euro
Debt Instrument [Line Items]
Debt instrument, face amount | €				€ 800
3.553% Notes due September 13, 2029 | United States of America, Dollars
Debt Instrument [Line Items]
Debt instrument, face amount			$ 868
0.632% Notes due June 4, 2023
Debt Instrument [Line Items]
Interest rate (percent)	0.632%	0.632%

Debt - Extinguishments of Debt

Debt - Extinguishments of Debt (Details) € in Millions, $ in Millions	Sep. 30, 2024 USD ($)	Sep. 30, 2024 EUR (€)
3.363% Notes due June 6, 2024
Extinguishment of Debt [Line Items]
Debt instrument, repurchased face amount	$ 998
Interest rate (percent)	3.363%	3.363%
3.875% Notes due May 15, 2024
Extinguishment of Debt [Line Items]
Debt instrument, repurchased face amount	$ 144
Interest rate (percent)	3.875%	3.875%
0.000% Notes due August 13, 2023
Extinguishment of Debt [Line Items]
Interest rate (percent)	0%	0%
0.000% Notes due August 13, 2023 | Euro Member Countries, Euro
Extinguishment of Debt [Line Items]
Debt instrument, repurchased face amount | €		€ 400
0.000% Notes due August 13, 2023 | United States of America, Dollars
Extinguishment of Debt [Line Items]
Debt instrument, repurchased face amount	$ 439
0.632% Notes due June 4, 2023
Extinguishment of Debt [Line Items]
Interest rate (percent)	0.632%	0.632%
0.632% Notes due June 4, 2023 | Euro Member Countries, Euro
Extinguishment of Debt [Line Items]
Debt instrument, repurchased face amount | €		€ 800
0.632% Notes due June 4, 2023 | United States of America, Dollars
Extinguishment of Debt [Line Items]
Debt instrument, repurchased face amount	$ 857
1.401% Notes due May 24, 2023
Extinguishment of Debt [Line Items]
Interest rate (percent)	1.401%	1.401%
1.401% Notes due May 24, 2023 | Euro Member Countries, Euro
Extinguishment of Debt [Line Items]
Debt instrument, repurchased face amount | €		€ 300
1.401% Notes due May 24, 2023 | United States of America, Dollars
Extinguishment of Debt [Line Items]
Debt instrument, repurchased face amount	$ 325
1.000% Notes due December 15, 2022
Extinguishment of Debt [Line Items]
Interest rate (percent)	1%	1%
1.000% Notes due December 15, 2022 | Euro Member Countries, Euro
Extinguishment of Debt [Line Items]
Debt instrument, repurchased face amount | €		€ 500
1.000% Notes due December 15, 2022 | United States of America, Dollars
Extinguishment of Debt [Line Items]
Debt instrument, repurchased face amount	$ 528

Debt - Summary of Interest Cost

Debt - Summary of Interest Costs and Payments (Details) - USD ($) $ in Millions	12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2022
Debt Disclosure [Abstract]
Charged to operations	$ 528	$ 452	$ 398
Capitalized	57	51	46
Total interest costs	584	503	444
Interest paid, net of amounts capitalized	$ 473	$ 452	$ 390

Income Taxes - Provision for In

Income Taxes - Provision for Income Taxes from Continuing Operations (Details) - USD ($) $ in Millions	12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2022
Income Tax Disclosure [Abstract]
Federal	$ 132	$ 364	$ 17
State and local, including Puerto Rico	17	87	32
Foreign	362	303	228
Total, current	511	754	277
Domestic	(169)	(644)	(96)
Foreign	(42)	22	(33)
Total, Deferred	(211)	(622)	(129)
Income tax provision	300	132	148
Interest and penalties associated with unrecognized tax benefits	$ 42	$ 20	$ (6)

Income Taxes - Components of In

Income Taxes - Components of Income from Continuing Operations Before Income Taxes (Details) - USD ($) $ in Millions	12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2022
Income Tax Disclosure [Abstract]
Domestic, including Puerto Rico	$ 336	$ 358	$ 496
Foreign	1,669	1,304	1,287
Income from Continuing Operations Before Income Taxes	$ 2,005	$ 1,662	$ 1,783

Income Taxes - Summary of Gross

Income Taxes - Summary of Gross Amounts of Unrecognized Tax Benefits (Details) - USD ($) $ in Millions	12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2022
Unrecognized Tax Benefits [Roll Forward]
Balance at October 1	$ 269	$ 267	$ 354
Increase due to acquisitions	0	0	2
Increase due to current year tax positions	22	22	40
Increase due to prior year tax positions	0	33	60
Decreases due to prior year tax positions	0	(29)	0
Decrease due to settlements with tax authorities	(64)	(6)	(77)
Decrease due to lapse of statute of limitations	(6)	(18)	(112)
Balance at September 30	221	269	267
Unrecognized tax benefits that would affect the effective tax rate if recognized	$ 257	$ 366	$ 348

Income Taxes - Deferred Income

Income Taxes - Deferred Income Taxes (Details) - USD ($) $ in Millions	Sep. 30, 2024	Sep. 30, 2023
Income Tax Disclosure [Abstract]
Compensation and benefits, assets	$ 405	$ 426
Property and equipment, liabilities	391	405
Intangibles, liabilities	1,612	1,858
Loss and credit carryforwards, assets	2,946	2,352
Product recall and liability reserves, assets	261	362
Capitalized research and development expenses, assets	364	243
Other, assets	512	431
Other, liabilities	64	88
Deferred income taxes, assets, gross	4,489	3,814
Deferred income taxes, liabilities, gross	2,067	2,351
Valuation allowance, assets	(2,990)	(2,272)
Deferred income taxes, assets	1,498	1,542
Deferred income taxes, liabilities	$ 2,067	$ 2,351

Income Taxes - Reconciliation o

Income Taxes - Reconciliation of Federal Statutory Tax Rate to Company's Effective Tax Rate (Details)	12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2022
Income Tax Disclosure [Abstract]
Federal statutory tax rate	21%	21%	21%
State and local income taxes, net of federal tax benefit	(0.70%)	(1.00%)	(1.10%)
Foreign income tax at rates other than 21%	(9.10%)	(8.20%)	(7.30%)
Effect of foreign operations	4.30%	(3.90%)	5.60%
Effect of Research Credits, FDII and Other Credits (a)	(22.10%)	(3.20%)	(2.20%)
Effect of share-based compensation	(0.30%)	(0.40%)	(1.70%)
Effect of gain on divestitures	0%	3.20%	0%
Effect of valuation allowance	19.30%	0%	(5.50%)
Effect of nondeductible costs	2.20%	0%	0%
Other, net	0.40%	0.40%	(0.50%)
Total	15%	7.90%	8.30%

Income Taxes - Summary of Incom

Income Taxes - Summary of Income Tax Holiday (Details) - USD ($) $ / shares in Units, $ in Millions	12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2022
Income Tax Disclosure [Abstract]
Tax impact related to tax holidays	$ 414	$ 363	$ 284
Impact of tax holiday on diluted earnings per share (in USD per share)	$ 1.42	$ 1.26	$ 0.99
Income tax payments, net of refunds	$ 653	$ 629	$ 532

Leases - Additional Information

Leases - Additional Information (Details) - USD ($) $ in Millions	12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2022
Lessee, Lease, Description [Line Items]
Operating lease, weighted average remaining lease term (in years)	8 years 3 months 18 days
Operating lease, weighted average discount rate, percent	4.40%
Operating lease, cost	$ 190	$ 145	$ 138
Minimum
Lessee, Lease, Description [Line Items]
Lessee, operating lease, term of contract (in years)	1 year
Maximum
Lessee, Lease, Description [Line Items]
Lessee, operating lease, term of contract (in years)	25 years

Leases - Supplemental Balance S

Leases - Supplemental Balance Sheet Information Related to Leases (Details) - USD ($) $ in Millions	Sep. 30, 2024	Sep. 30, 2023
Leases [Abstract]
Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]	Other Assets	Other Assets
Right-of-use assets recorded in Other Assets	$ 876	$ 517
Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]	Accrued expenses	Accrued expenses
Current lease liabilities recorded in Accrued expenses	$ 142	$ 117
Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]	Deferred Income Taxes and Other Liabilities	Deferred Income Taxes and Other Liabilities
Non-current lease liabilities recorded in Deferred Income Taxes and Other Liabilities	$ 667	$ 414

Leases - Lessee, Operating Leas

Leases - Lessee, Operating Lease, Liability, Maturity (Details) $ in Millions	Sep. 30, 2024 USD ($)
Leases [Abstract]
Lessee, operating lease, liability, to be paid, year one	$ 174
Lessee, operating lease, liability, to be paid, year two	149
Lessee, operating lease, liability, to be paid, year three	113
Lessee, operating lease, liability, to be paid, year four	86
Lessee, operating lease, liability, to be paid, year five	77
Lessee, operating lease, liability, to be paid, after year five	389
Total payments due	988
Less: imputed interest	178
Total	$ 809

Supplemental Financial Inform_3

Supplemental Financial Information - Other Income (Expense), Net (Details) - USD ($) $ in Millions	12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2022
Equity securities, FV-NI, unrealized gain (loss)	$ 5	$ (3)	$ (35)
Deferred compensation investment income (expense)	57	32	(46)
Net pension cost (credit)	(65)	(98)	(17)
Foreign currency transaction gain (loss), realized	(47)	(36)	(28)
Losses on debt extinguishment	0	0	(24)
Embecta services agreement income, net	26	59	33
Other	(4)	0	1
Other expense, net	$ (28)	(46)	(117)
United States
Pension settlement expense		$ 57	$ 73

Supplemental Financial Inform_4

Supplemental Financial Information - Trade Receivables, Allowances for Doubtful Accounts and Cash Discounts (Details) - USD ($) $ in Millions	12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2022
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]
Beginning Balance	$ 81	$ 81	$ 91
Additions charged to costs and expenses	121	109	77
Deductions and other	(124)	(110)	(87)
Ending Balance	79	81	81
Allowance for Doubtful Accounts
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]
Beginning Balance	65	65	73
Additions charged to costs and expenses	30	9	4
Deductions and other	(30)	(10)	(12)
Ending Balance	64	65	65
Allowance for Cash Discounts
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]
Beginning Balance	16	16	18
Additions charged to costs and expenses	91	100	73
Deductions and other	(93)	(100)	(75)
Ending Balance	$ 15	$ 16	$ 16

Supplemental Financial Inform_5

Supplemental Financial Information - Inventories (Details) - USD ($) $ in Millions	Sep. 30, 2024	Sep. 30, 2023
Inventory [Line Items]
Materials	$ 803	$ 714
Work in process	443	381
Finished products	2,597	2,178
Inventories	3,843	$ 3,273
Advanced Patient Monitoring
Inventory [Line Items]
Inventories acquired	$ 666

Supplemental Financial Inform_6

Supplemental Financial Information - Property, Plant and Equipment, Net (Details) - USD ($) $ in Millions	Sep. 30, 2024	Sep. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Land	$ 129	$ 131
Buildings	3,733	3,537
Machinery, equipment and fixtures	10,197	9,609
Leasehold improvements	320	301
Property, plant and equipment, gross	14,378	13,578
Less accumulated depreciation and amortization	7,557	7,021
Property, plant and equipment, net	$ 6,821	$ 6,557